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ABSTRACT
Angiotensin-II (Ang-II), a peptide hormone, is a potent vasoconstrictor and cell mitogen. It has
been implicated in the development of hypertension as well as atherosclerosis. Recent work has
shown that sclerotic aortic valves possess expression of angiotensin type I receptor (AT-1R) and
angiotensin converting enzyme (ACE), suggesting altered angiotensin signaling during disease.
The role of altered angiotensin signaling on aortic valve mechanics, however, is not clearly
understood. We seek to understand the direct effects of the renin angiotensin signaling (RAS)
system on the biological and biomechanical properties of aortic valve tissue and develop a finite
constitutive model that mimics the effects of RAS on aortic valves. Our results showed that the
mechanical properties such as stiffness were altered by RAS mediators. Three phenomenological
constitutive models were utilize to characterize the biomechanical changes that occur due to
RAS mediators on aortic valves, and the Fung-type model was shown to be the best fit model for
the experimental data. Tissue maintained in anisotropy behavior, but the cross-coupling of the
fibers was affected. Immunohistochemistry (IHC) showed that RAS affects the phenotypic
properties of the cells in the aortic valve tissues. Picrosirius red (PSR) staining suggests that RAS
mediators affect the production of collagen fibers, and quantitative polarized light imaging
(QPLI) demonstrated that RAS mediators affect the orientation of collagen fibers. We concluded
that RAS mediators affected the biological and mechanical functions of the aortic valve leaflet.
The activation of VICS and increased production and disorganization of collagen fibers
correlated to the stiffness of the tissue. These are all hallmarks of early disease progression, and
in the future, we will further investigate the effects of RAS mediators in mechanics of the valve
leaflet at the cellular level.
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CHAPTER 1 INTRODUCTION
Cardiovascular disease (CVD) is one of the most prevalent diseases worldwide and
accounts for almost one third of deaths globally (1). Heart valve disease is the most common
cardiovascular disease on the left side of the heart due to the higher pressure the valves
experience (2). Aortic stenosis (AS) is the second most prevalent adult valve disease in the
United States, accounting for approximately 4% of patient 45 years or older (3). If left untreated,
AS can become fatal. Calcific aortic valve disease (CAVD) is the most common form of stenotic
aortic valve disease. CAVD accounts for the majority of severe aortic stenosis in cases in which
the patient is 70 years or older (4). Valve leaflets become thicker, fibrosed, and calcified as the
disease progresses making them stiffer and narrowing the orifice of the valve. The number of
valve replacements has doubled in the United States in the past decade, and surgery is the only
option as there is currently no effective medical treatments for CAVD (5). There is a need to
understand the pathophysiology of AS, and research is needed to understand the mechanisms of
valve disease in order to develop new treatments/therapeutic strategies for CAVD. Angiotensin
converting enzyme (ACE), angiotensin II (ang-II), and type 1 ang-II receptor (AT-1R) are
present in stenotic aortic valves, strongly implying that the renin angiotensin system (RAS)
signaling pathway is a factor in the disease progression (6). The fibrotic process is thought to be
modified by RAS. Ang-II increases the amount of collagen present in the leaflet and in turn
affects its mechanical properties. Ang-II has also shown to increase the stiffness of aortic valve
leaflets and decreases their extensibility (7).
Biaxial testing has been shown to be the ideal method to mechanically-characterize soft
incompressible materials such as biological tissues. Biaxial testing is where a material is
subjected to load in both the x and y direction in contrast to uniaxial testing which only subjects
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the material to load in one direction. In biaxial testing, Green strain (E) is calculated taking into
account the deformation the tissue experiences in contrast to the engineering strain which only
calculates the change in length the tissue undergoes. There are three stresses that take into
account the orientations, force and area, that arise due to the tensorial nature of stress: Cauchy
stress, 1st Piola-Kirchoff (P-K) stress, and 2nd P-K stress. Stress and strain information can be
used to develop phenomenological constitutive models. These constitutive models can provide
additional information on the mechanical responses of material. There are various constitutive
forms that exist for soft biological tissues, and these are explored in this thesis.
To evaluate the potential for targeting RAS as a therapeutic strategy against valve
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling
pathway affects the acute biological and biomechanical function of the aortic valve by
investigating the role of angiotensin receptors (AT-1R and AT-2R) to which ang-II binds to, and
the enzymes (ACE and chymase) that convert ang-I to ang-II. The first aim focuses on
quantifying the biomechanical effects of RAS via biaxial mechanical testing of porcine aortic
valve tissues pretreated with mediators of RAS signaling. Tissue tangent modulus, extensibility,
areal strain, and anisotropy index are quantified to assess if RAS inhibition altered tissue
mechanical properties. In the second aim, three non-linear phenomenological constitutive
models were used to characterize the mechanical behavior of aortic valve tissues pretreated with
RAS mediators. The third aim focuses on investigating the acute biological effects that RAS
inhibition had on aortic valve tissue. The phenotypic changes the cells undergo on the tissue due
to RAS were investigated via immunohistochemistry. The changes in collagen fibers undergo
were investigated with quantitative polarized light microscopy and picrosirius red staining.
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CHAPTER 2 BACKGROUND AND SIGNIFICANCE
2.1 The Heart
2.1.1 Anatomy
The heart is an important organ that acts as a pump and provides blood to the body. In a
human, it is located in the center of the chest between the lungs and behind the sternum (Figure
2-1), but in other animals, location can vary slightly. The apex is the conical tip at the bottom of
the heart that lies on the diaphragm that points to the left side of the body (8). The heart is
separated into two sides by the intraventricular septum. The right side of the heart pumps
deoxygenated blood from the body to the lungs and the left side pumps oxygenated blood from
the lungs to the rest of the body. The heart is comprised of four chambers: the right and left
ventricles and the right and left atria. The atria collects the blood, similar to a reservoir, and the
ventricles pump the blood either to the lungs or the rest of the body (9). There are two coronary
arteries, the left and the right, that provide blood to the heart itself (Figure 2-1). The superior and
inferior vena cava are venous blood vessels that bring deoxygenated blood from the body to the
right atrium. The superior vena cava carries the deoxygenated blood from the upper half of the
body, and the inferior vena cava carries deoxygenated blood from the lower half of the body. The
pulmonary artery carries the deoxygenated blood from the right ventricle to the lung to become
oxygenated. The pulmonary veins then carry the oxygenated blood from the lungs into the left
atrium. The aorta then delivers the oxygenated blood from the left ventricle to the rest of the
body (8).
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Figure 2-1. A view of the heart location in the thoracic cavity, anterior external view, and
anterior cross-sectional view (8)
The heart contains four valves (Figure 2-2) which open and close to allow blood to flow
in one direction. There are the atrioventricular valves (AV-valves) located between the atria and
ventricles: the tricuspid valve (right side) and the mitral valve (left side). Then there are two
semilunar valves that will allow the blood to leave the heart: the pulmonary valve (right side) and
the aortic valve (left side) (10).

Figure 2-2. The four valves of the heart (8)
2.1.2 Physiology
Deoxygenated blood from the body is received by the right atria. Blood from the lower
body enters the right atrium through the inferior vena cava and blood from the upper body enters
through the superior vena cava. The deoxygenated blood then flows from the right atrium into
the right ventricle through the tricuspid valve. Once the right ventricle has been filled, the
tricuspid valve closes and the pulmonary valve opens to allow the right ventricle to pump blood
4

through the pulmonary valve into the pulmonary artery to the lungs. The lung then oxygenates
the blood. The oxygenated blood then flows from the lungs to the right atrium by the four
pulmonary veins. Similar to the right side, the blood flows from the left atrium into the left
ventricle. The blood flows through the mitral valve, also known as the tricuspid valve, into the
ventricle, and closes once the left ventricle has been filled with oxygenated blood. The left
ventricle, the strongest chamber, then pumps the blood into the aorta when the aortic valve
opens. The aorta then disperses the oxygenated blood to the rest of the body (11). When the
aortic valve closes, oxygenated blood also flows through the coronary arteries. The left coronary
artery provides oxygenated blood to the posterior area of the heart, and the right coronary artery
provides oxygenated blood to the anterior area of the heart (Figure 2-3) (12).

Figure 2-3. The physiology of the heart (8) and the cardiovascular system and organ blood
supply (11)
The circulation of blood through the heart is due to the contraction and relaxation of the
heart, also known as the cardiac cycle (Figure 2-4). The relaxation state is also known as the
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diastolic state where the ventricles fill with blood, and the contraction state is also known as the
systolic state in which the blood is pumped either to the lungs or rest of the body. When the
cardiac cycle begins, both the atria and ventricles are relaxed. Blood fills into the atrium and then
the AV valve opens and the atrium contracts slightly to allow the blood to flow from the atrium
to the ventricle. Once the ventricle is filled, the AV valve closes and the atrium returns to its
relaxed state. The ventricle then starts to contract and the aortic valve opens to allow the blood to
be pumped into the aorta. The left ventricle experiences a high amount of pressure during this
time. Once all the blood is ejected from the ventricle, the aortic valve closes and the left ventricle
returns to its relaxed state. The atrium starts to fill once more with blood and the cycle starts
again (11).

Figure 2-4. The cardiac cycle and Wiggers diagram (11)
2.2 The Aortic Valve
2.2.1 Anatomy
The aortic valve allows oxygenated blood to flow from the left ventricle to the aorta and
in turn to the rest of the body. The valve opens and closes with each heartbeat. It consists of 3
cusps or leaflets: the right coronary leaflet, non-coronary leaflet, and left coronary leaflet. The
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right and left leaflets correspond to the left and right coronary arteries which are arteries that
specifically provide blood to the heart (13). In the normal condition, each leaflet is less than 1
mm thick, smooth, flexible, and a mobile structure (14). During the systolic state, the aortic valve
opens from 3 to 5 cm2 (15)
The aortic valve predominately contains two cell types: valve endothelial cells (VECs)
and valve interstitial cells (VICs). The VECs regulate valve anti-thrombogenicity, permeability,
inflammatory cell adhesion, and paracrine signaling. The VICs maintain valve homeostasis and
provide the strength and elasticity of the valve by secreting extracellular matrix (ECM) (Figure
2-5) (16). VECs line the surface of the leaflet and can undergo endothelial-mesenchymal
transformation (EndoMT). On the inflow surface, they are oriented circumferential to the leaflet
and have an anisotropic alignment. On the outflow surface, they exhibit no preferred orientation
and have an isotropic alignment. This is due to the fact that they typically orient perpendicular to
the flow, and in the outflow surface, the blood flow has an oscillatory blood flow (17). VICs are
fibroblast-like cells but are phenotypically different from dermal fibroblast and have unique
characteristics. Hence they are considered myofibroblast as they have characteristics of both
fibroblast and smooth muscle-like cells (18). They adapt to their microenvironment, modulating
their phenotype as a function mechanical force and soluble factors. VICs synthesize ECM
components such as collagen, elastin, proteoglycans, and glycoproteins (19).
To meet the demands of the mechanical loading during each cardiac cycle, the valve is
comprised of three different ECM fibrous layers with distinct matrices and mechanical
properties: the fibrosa, spongiosa, and ventricularis (Figure 2-5) (5). The fibrosa is the layer
closest to the aorta, contains type I and III collagen, and serves a load-bearing function. The
spongiosa is the middle layer, contains glycosaminoglycan, and lubricates the other layers as
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they shear and deform during each cardiac cycle. The ventricularis is the layer closest to the left
ventricle, contains elastin fibers, and function to assure effective coaptation during diastolic
closure (16). The leaflets are attached to the aortic root at the annulus which is a dense
collagenous network. The annulus also dissipates the mechanical force the valve leaflets
experience (5).

Figure 2-5. The architecture of the aortic valve (16)
2.2.2 Mechanical forces experienced by the aortic valve
The aortic valve experiences normal, shear and bending stresses. Normal stress is the
stress perpendicular to the surface, and shear stress is the stress parallel to the valve surface.
During systole, the ventricular side of the aortic valve is exposed to laminar shear stress (Figure
2-6a). During the diastole, the aortic side of the aortic valve mostly experiences oscillatory shear
stress (Figure 2-6b). The left and right coronary cusps partially experience laminar shear stress
while the non-coronary cusp only experiences oscillatory shear stress during diastole (Figure
2-6c) (13). The shear stress is highest on the left and right coronary arteries in comparison to the
non-coronary, because they experience the blood flow to the coronary arteries (5). The
circumferential and radial length is also longer during diastolic state in comparison to the systolic
state. The strain the valve experiences during the cardiac cycle is due to the axial blood pressure,
the bending forces, and the changes in tissue length (Figure 2-6) (13).
8

Figure 2-6. Shear stress (dotted arrows) and strain (solid arrows) that the aortic valve
experiences during (A) systole and (B and C) diastole (13)
The fibrosa and ventricularis layers of the leaflet contain collagen and thus these layers
bear the load on the valve during each cycle. The ventricularis contributes to the low strain/stress
behavior, and the fibrosa contributes to the high strain/stress behavior. The mechanical response
of the valve also differs in the circumferential (fiber orientation) and radial (cross-fiber
orientation) direction. The radial direction undergoes higher strain than in the circumferential
direction (20). Stella et.al showed that the fibrosa layer alone showed similar mechanical
responses as an intact leaflet in the circumferential direction and only slightly less extensibility in
the radial direction. The ventricularis layer however showed different mechanical responses to
the intact leaflet. It had a longer toe region in both the circumferential and radial direction
implying a compliant equibiaxial behavior (21).
2.3 Cardiovascular Disease
Cardiovascular disease (CVD) is one of the most prevalent diseases in the United States
and the number one cause of death (1). CVD is any abnormal condition characterized by
dysfunction of the heart and/or blood vessels. The severity of heart disease can vary from
minor/unnoticeable to life threatening. There are two types of heart disease: congenital and
acquired. Congenital heart disease is a genetic condition that comes from birth. There are certain
9

congenital diseases that can be unnoticed by the person their whole life and there are others so
severe that if not treated immediately could cause death days or even hours after birth (22).
Acquired heart disease is developed with time during a person’s lifetime. Some risk factors for
acquired CVD include: smoking, alcohol, physical inactivity, diabetes, overweight/obesity, high
blood pressure, high cholesterol, and old age (23).
2.3.1 Heart valve disease
Heart valve disease is most common on the left side of the heart due to the higher
pressures the left-sided valves experience. There are two types of valve diseases: valvular
stenosis and valvular insufficiency/regurgitation (2). Both types may either be an acquired
disease or a congenital disease. Valvular stenosis is when the leaflets thicken and in turn cannot
open properly. Valvular regurgitation is when the valve cannot close properly thus causing back
flow (2). This is most common in the mitral valve. However, the combination of aortic stenosis
and regurgitation is much higher than each individually (2).
Aortic stenosis (AS) is the second most prevalent adult valve disease in the United States,
accounting for approximately 4% of patient 45 years or older (3). If left untreated, AS can
become fatal with an average survival of 2 to 3 years and an annual mortality of 25% (24).
As AS manifests and the leaflet thickens, the aortic valve area (AVA) begins to decrease to
approximately 2 cm2 in contrast to a healthy valve’s AVA of 3 to 5 cm2. The average decline in
the AVA as AS progresses is 0.1cm2 and an increase of 5 to 8mmHg in the mean gradient across
the valve (15). The narrowing of the aortic valve prevents blood to flow from the left ventricle to
the aorta properly. In elderly patients, aortic stenosis can be due to atherosclerosis and
calcification (25). In contrast to a healthy valve in which leaflets are smooth, flexible, and
mobile, the leaflets in valves that experience aortic stenosis become thickened, fibrosed, and
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calcified. This reduces the mobility in the leaflet and can lead to valvular obstruction (14). It also
increases the valve stiffness and narrows the valve orifice (5).
AS is similar to atherosclerosis which commonly affects the elderly (26). AS is very
similar to the early stages in atherosclerosis in which the valve experiences an increase in
mechanical stress and altered fluid shear stress due to endothelial damage (5). At the cellular
level, VICs transition to osteoblast-like bone forming cells due to their activation, VECs undergo
endothelial-to-mesenchymal transformation (EndoMT) due to their dysfunction or denudation,
and the ECM forms calcific nodules. Inflammatory and immune cells infiltrate the valve and
inhibitors of calcification are downregulated (16).
The mechanisms for AS are still largely unknown, but the importance of determining the
pathological changes is important for the development of therapeutic treatments that might block
or reverse the disease process (27). As of now, there are no drug-based therapies. Current
treatments include balloon valvuloplasty, surgical aortic valve replacement, and transcatheter
aortic valve replacement (24). Balloon valvuloplasty is used in patients who cannot undergo
surgical or transcatheter aortic valve replacement due to the high surgical risks. Long-term
survival however is not changed. There is an approximate 50% survival at 1 year, 35% at 2
years, and 20% at 3 years. Each year in the United States, approximately 67,500 surgical aortic
valve replacements are performed (24). They are performed with either mechanical or
bioprosthetic valves. Though bioprosthetic valves do not require anticoagulants like mechanical
valves, a study showed that there was no significant difference in 15-year survival or stroke in
patients between the ages of 50-69 years old (24). In inoperable and high-risk patients,
transcatheter aortic valve replacement has shown to be beneficial and reduce the mortality by
21.8%. There are several approaches including transfemoral, transapical, transaxillary,
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transcarotid, transcaval, and transaortic. In high risk but operable patients, the 5-year mortality
was similar in patients who underwent transcatheter or surgical aortic valve replacements (24).
2.3.2 Calcific aortic valve disease
Calcific aortic valve disease (CAVD) is the most common form of stenotic aortic valve
disease. CAVD accounts for the majority of severe aortic stenosis in cases in which the patient is
70 years or older (4). In cases involving younger patients, aortic stenosis is due to an abnormal
valve such as a bicuspid valve (4). The degree of the calcification is determined by the severity
of the valve lesions, the progression of the disease, and the development of symptoms and
adverse events (5). Risk factors of CAVD include hypertension, smoking, diabetes, elevated
cholesterol, and male gender. The biological processes involved in CAVD include endothelial
dysfunction and inflammatory responses which lead to the remodeling of the valves (28). As
alluded to earlier, the only treatment for CAVD is aortic valve replacement. Medical therapies to
prevent or decrease the progression of CAVD have not been possible as there is still a need to
better understand the mechanical and biological process that cause CAVD, and to identify
interventions to prevent the initiation and progression of CAVD (6).
The aortic valve of patients with CAVD become progressively thickened, fibrosed, and
calcified. Throughout history, this has been thought to be a result of “wear and tear” and ageassociated valvular degeneration. However, recent studies have shown that due to biochemical,
humoral, and genetic factors, the CAVD occurs via an active disease process that includes
inflammation which then leads to fibrosis and calcification. In areas of inflammation in the
valve, endothelial injury or distribution has been observed. Lipoproteins are able to stimulate
intense inflammatory activation, and are present in early aortic valve lesions. An increase in
mechanical stress and reduced shear stress is believed to be due to endothelial damage. A
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combination of these two events triggers inflammation in the valve. Inflammatory cells penetrate
the valve and may then stimulate the valve to induce a fibrotic and calcific process (Figure 2-7).
The inflammatory activity activates the fibroblast-like cells in the valve, and they differentiate
into a more myofibroblast-like cell. This activity then increases the synthesis and degradation of
fibrous tissue. Fibrous tissue and the remodeling of the ECM thickens the valve. The valve
progressively stiffens affecting the mechanics of the valve. The disease then progresses as the
myofibroblasts differentiate into osteoblast-like cells making the valve stenotic. Osteoblasts
drive the calcification process. Calcific nodules form on the valve and contain a bonelike matrix
of collagen, osteopontin, and other bone matrix proteins. Calcification is known to narrow the
opening of the valve. CAVD develops which can be fatal to patients (5).

Figure 2-7. The process of the progression of healthy valves to CAVD diseased valves (5)
The trilayer structure of the valve is important in both the biological and mechanical
function of the valve. As CAVD develops, the trilayer structure becomes disturbed and
consequently its function is impaired. Type I collagen has features that regulate cellular
behaviors. The length, thickness, alignment, and density of the collagen fibers can modulate cells
proliferation and differentiation, and affect their cell polarity and motility (29). CAVD has been
associated with the remodeling of the collagen fibers, which in turn affects the biological and
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mechanical factors of the valve. In the fibrosa layer, fibers in a diseased valve are shorter than
that of those in a healthy valve (30). As far as fiber number, width, density, and alignment, the
diseased valve seems to have similar properties of that in a healthy valve (30). However, in the
diseased spongiosa layer, the collagen fibers appear to become wider and denser thought with
unchanged length (30). It can be speculated that the crosslinking of the fibers is affected in the
fibrosa layer while the collagen production is affected in the spongiosa layer (30). In the
spongiosa layer, there are more immature fibers while in the fibrosa layer there are more mature
fibers (30). The increased production of collagen and the disorganization of the fibers are an
indication of CAVD, and will be explored in this thesis.
2.3.3 Mechanical alterations in diseased valves
The velocity of blood flow through a diseased aortic valve is higher as the pressure
gradient is higher (mean pressure gradient >40mmHg) between the aorta and left ventricle during
cardiac systole due to the narrowing of the valve. A healthy valve experiences a peak velocity of
1.35 ± 0.35 m/s while the velocity in a valve that has developed AS can exceed 4 m/s (13). The
increase in pressure, increase in forces, and changes in length of the valve increases the stiffness
and hence decreases the strain. The stiffness reduces the opening of the valve which increases the
axial pressure on the ventricular said and in turn changes the direction of the blood flow during
the systolic state (13). The systolic pressure may then exceed the diastolic pressure, and the
pressure gradient can be four to six times higher than normal. During calcification, the cusp loses
its stretch and can also result in regurgitation, that is, blood flowing back from the aorta into the
left ventricle (13). Echocardiography is a useful tool in diagnosing AS by providing clinical
information such as peak velocity of blood flow through the valve, mean pressure gradient, and
aortic valve area. It is essential to know the aortic valve area to determine AS because velocity

14

and pressure gradients are only flow-dependent variables. Changes in velocity and pressure
gradients can also be attributed to other cardiovascular diseases such as impaired left ventricular
contractility. In patients with severe AS, the aortic valve area is estimated to be ≤ 1 cm2 (4).
The mechanical functions of the valve are affected by the collagen alterations in the
trilayer structure (30). In a healthy valve, the collagen fibers in the fibrosa and
spongiosa/ventricularis layers are oppositely aligned (30). In a diseased valve, the alterations to
the fiber alignments seen in the fibrosa and the increased production of fibers in the spongiosa
affect the mechanical load being applied by the mechanical stress the valve experiences. The
stress that the fibrosa and ventricularis layers cause can apply friction between the layers, and
when the density of the fibers increases in the spongiosa, the role of the spongiosa to minimize
that friction is affected (30).
The VECs and VICs are able to actively respond to the biomechanical factors the valves
experience. VECs are the first to experience the shear stress as they line the valve. The changes
in shear stress alter VEC gene expression patterns (31). Unlike laminar shear stress, oscillatory
shear stress does not induce the protective genes suggesting that the change in shear stress could
be responsible for the changes in the VECs function (32). The different biomechanical forces the
VECs experience in the aortic and ventricular side also contribute to the differential gene
expression of the VECs located on either side of the valve. In the aortic side, the VECs have
higher expression of genes associated with calcification, and in the ventricular side, VECs have
higher expression of genes associated with inflammation (33). VICs are protected from shear
stress by the endothelial layer, but they experience the changes in the stress and strain during the
cardiac cycle. In in vitro studies were cells were grown in statistic state, cells became
hypersynthetic, and when exposed to flow, synthesis is maintained at normal levels suggesting
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the importance of strain on VICs (34). The cell physiology is regulated by the mechanical forces
and can affect the biosynthetic activity of the cells. Cyclic stretch can upregulate the expression
of smooth-muscle markers such as α-SMA suggesting that VICs are becoming more
myofibroblast-like or smooth muscle cell-like (35). Increase in VIC stiffness correlates with the
biosynthesis of collagen proteins (18). The stiffness of the environment in conjunction with the
differentiation of VICs can cause calcification (36). The cellular response to environmental
mechanical forces needs to be further studied to have a deeper understanding of valve
mechanobiology for the potential of therapeutic treatments (37).
2.3.4 Mechanisms of CAVD
The development and progression of CAVD is determined by active biological processes
(38). VICs undergo cell differentiation and display osteoblast-like phenotypes. There are various
signaling pathways including the Runx-2/NOTCH-1 signaling, Wnt-2/Lrp5-β catenin signaling
pathway, and the renin angiotensin signaling (RAS) pathways that are thought to modulate the
CAVD process (5). During disease progression, VICs become more bone-like and express
osteoblast markers such as osteopontin, osteocalcin, bone morphogenetic proteins 2 (BMP-2)
and 4 (BMP-4), and osteoblast-specific transcription factors (19). TGF-β1, a cytokine, is present
in the extracellular matrix (ECM) in calcified aortic cusps. The accumulation of TGF-β1 could
be due to the endothelial injury and inflammatory cell infiltration that VICs undergo which
initiates apoptosis of the cells leading to calcification (39). In the presence of cyclic strain, the
upregulation of TGF-β can alter ECM architecture and compromise the valve function (40).
When strain is increased above the normal physiological state, VICs respond by increasing proinflammatory proteins such as VCAM-1, ICAM-1, and E-selection (41). Elevated cyclic pressure
also upregulates the expression of VCAM-1 and down regulates the expression of OPN (42). The
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renin-angiotensin system (RAS) plays a key role in promoting and maintaining inflammation,
and it has shown to upregulate the expression in pro-inflammatory cell adhesion molecules such
as VCAM-1 and ICAM-1 in vascular disease (43). Thus in this thesis, we seek to explore the
how RAS affects the biomechanical functions of valve leaflets.
2.4 Renin-Angiotensin System
2.4.1 Renin-angiotensin signaling pathway
The renin-angiotensin system (RAS) plays a role in the regulation of blood pressure and
is a regulatory system for renal and cardiovascular function (44-46). The RAS is a very complex
signaling pathway (Figure 2-8).

Figure 2-8. The multiple pathways in the renin-angiotensin signaling system (47)
The central pathway in the activation of RAS occurs when angiotensinogen is cleaved by
renin, a proteinase enzyme released by the kidney, to form angiotensin I (1-10) (ang-I). Ang-I is
then converted rapidly to angiotensin II (1-8) (ang-II) by the angiotensin-converting enzyme
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(ACE) or ACE independent pathways such as chymase (47). The concentration of
angiotensinogen, ang-I, and ang-II was measured in the plasma and kidney of rat models. This
study showed that the plasma concentration of angiotensinogen was much greater than the
concentration of ang-I and ang-II implying that the active concentration of ang-II is a small
fraction of what could be produced via the conversion of angiotensinogen to ang-I and ultimately
ang-II (48).
Ang-II then binds to two different receptor subtypes, type 1 ang-II receptor (AT-1R) or
type 2 ang-II receptor (AT-2R), to induce the downstream signaling effects (49). AT-1R is
present in the kidney, heart, brain, adrenal cortex and vessel walls. It mediates the effects of angII in most cardiovascular function. AT-2R is mostly expressed in regions of the brain and adrenal
medulla. Little is known over the role of AT-2R in cardiovascular function, however it is
expressed in the vascular wall, cardiac ventricles, and valve (50, 51). AT-1R causes
vasoconstriction, cell-proliferation, endothelial dysfunction, and hypertrophy whereas AT-2R
causes vasodilation, anti-proliferation, and apoptosis which counterbalances the effects of AT-1R
(Figure 2-9) (52-54).
Angiotensin I

Angiotensin II
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Extracellular Space
ACE
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Intracellular Space

Figure 2-9. The local renin-angiotensin signaling pathway
There are also non-angiotensin converting enzymes such as chymase and cathepsins also
play a role in the conversion of ang-I to ang-II. The ability for chymase to generate ang-II in the
heart tissue is not well known, however it is present in diseased tissue (55). RAS regulates
intravascular volume, blood pressure, and tissue repair, and though can be protective, when
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highly stimulated it can cause vasoconstriction, vascular smooth muscle proliferation, endothelial
dysfunction, inflammation, fibrosis, and thrombosis (50, 56).
2.4.2 Renin angiotensin system inhibitors
Extensive research has been conducted on inhibiting RAS to treat hypertension, renal
failure, cardiac failure, atherosclerosis, and myocardial infarction such as renin inhibitors, ACE
inhibitors (ACEIs), ang-II receptor blocking agents (ARBs), and chymase inhibitors. By
blocking RAS, the formation or binding of ang-II can be prevented and in turn reducing its
downstream effects (57, 58).
ACEIs were discovered in the late 1970s and have been an effective treatment in various
cardiovascular diseases such as hypertension and left ventricular dysfunction. ACEIs prevent
ang-I from converting into ang-II (59, 60). They have been shown to improve endothelial
function and have anti-atherosclerotic, anti-inflammatory, anti-proliferative, and antioxidant
properties (61, 62). Not all ACEIs can be used to treat both hypertension and heart failure but
drugs such as lisinopril, captopril, and quinapril have shown to help greatly with both (44).
However, by targeting ACE there can be an upregulation of ang-I, and ang-I could still be
converted into ang-II through an ACE independent pathway such as chymase (55). Chymase
inhibitors such as chymostatin alone or in combination with ACEIs have been used to treat
atherosclerotic human coronary arteries but further research needs to be conducted on other
effects of ang-II on cardiovascular disease (63).
Due to the ability for ang-I to convert to ang-II even with ACEIs, ARBs are also used to
treat RAS-induced disease. ARBs block ang-II from binding to angiotensin receptors such as
AT-1R. Losartan is an ARB that inhibits ang-II from binding to AT-1R. By blocking AT-1R, the
harmful effects of ang-II such as vasoconstriction and cell proliferation are eliminated (55). An
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ELITE study of over 3,000 patients compared losartan to captopril by randomizing the patients
and assigning them to either treatment (64). Mortality, cardiac death, and hospital admission did
not differ significantly between both treatments, however, there were many more patients that
withdrew from the captopril treatment due to adverse side effects. This study showed that
losartan was a more tolerable treatment that captopril, and that ARBs can be an effective
treatment for those patients that are not able to be treated with ACEIs (64).
2.4.3 Renin angiotensin system and valve disease
Studies have shown that ACE is not present in normal aortic valves but is present in
stenotic valves (65). ACE is carried by low-density lipoprotein (LDL) particles and enters the
lesions in the stenotic valve from circulation bound to it (66). In addition to ACE, ang-II and AT1R are also present in stenotic aortic valves (28). Though ang-II is present and produced in other
parts of the body, the presence of ACE in stenotic valves suggests that ang-II is being converted
locally. This observation implied that the RAS signaling pathway is a factor in the valve disease
process (6). The fibrotic process is thought to be modified by RAS. Stenotic valves have an
upregulation of ACE and ang-II, and AT-1R is present on valve myofibroblasts. The binding of
ang-II to AT-1R can lead to an increase in inflammatory responses, inducing the cells within the
valve to differentiate into osteogenic-like cells (5).
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Figure 2-10. Potential role of RAS in calcific aortic disease and its interaction with lipoprotein
retention and signaling and oxidative stress (67)
Myles et al. demonstrated that ang-II increased the elastic modulus in the radial direction
of the aortic valve via biaxial mechanical testing. They also showed that ang-II decreased the
extensibility of the leaflets which correlates with an increase in stiffness. In addition, ang-II
increased the amount of collagen present in the leaflet. It can be implied that the increase in
collagen synthesis affects the mechanical properties of the tissue as it correlates with the
increased stiffness and inversely correlates with decreased extensibility (7).
Even though ACE inhibitors and angiotensin receptor blockers are well known to reduce
hypertension, the impact they may have in the context AS is not well studied (5). It has been
suggested as a potential therapeutic for CAVD, and studies are currently trying to find the
correlation between the inhibitors and AS (27, 67).
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To evaluate the potential for targeting RAS as a therapeutic strategy against valve
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling
pathway affects the biological and biomechanical function of the aortic valve by investigating
the receptors (AT-1R and AT-2R) in which ang-II binds to and the enzymes (ACE and chymase)
that convert ang-I to ang-II.
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CHAPTER 3 MOTIVATION AND SPECIFIC AIMS
3.1 Motivation of Study
In a previous study conducted by us, the interaction between serotonin (5HT) and
angiotensin II (ang-II) were investigated to understand their effects on aortic valve mechanics
and remodeling (68). In this previous study, there were four treatment groups: control, 5HT, angII, and 5HT/ang-II. VICs were assayed for cellular contractility, cytoskeletal organization, and
collagen remodeling, and in an in vivo mouse model, blood pressure was monitored and
echocardiography were performed in addition to histology and immunohistochemistry. Results
suggested that the interaction of 5HT and ang-II altered the function and remodeling of the valve,
but our results also showed that ang-II alone had detrimental effects on the aortic valve. In vitro,
VICs treated with ang-II had a higher actin orientation parameter and COL1A1 mRNA
expression. In-vivo, ang-II treated mice had a higher blood pressure, ejection fraction, enddiastolic volume, and end-systolic volume after 3 weeks of treatment. Picrosirius red staining
showed that ang-II had a higher percentage of thick fibers in the leaflet attachment region to the
aortic root indicating collagen remodeling (Figure 3-1).

Figure 3-1. (A) H&E staining and (B) Picrosirius red (PSR) staining (scale bar = 200µm).
Arrows point to the valve free edge. Valve attachment zone labeled “a”. (C) Quantification of
PSR stain for valve attachment zone. (* p<0.05) (68)
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Immunohistochemistry showed an increase of expression of Ki-67, α-SMA, TFGβ1,
collagen III, and AT-1R indicating ECM remodeling (68). This prior work is the primary
motivation for us to further investigation the renin angiotensin system (RAS) signaling
pathways, and its effects in both the cellular and tissue level on the aortic valve (Figure 3-2).

Figure 3-2. Representative micrographs of samples immunohistochemically labeled with Ki-67,
α-SMA, TGFβ1, AT-1 receptor, and collagen type III. Arrows indicate the aortic valve leaflets.
The aortic root is indicated by the letter “a”. (scale bar=100µm) (68)
There has been research conducted by others on the influence of ang-II on the
biomechanical properties of aortic valves. Biaxial testing showed that ang-II increased the
stiffness of aortic valve leaflets, and it was believed that an increase in collagen content altered
valve mechanical properties (7). Studies have also shown that stenotic aortic valves have an
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increase in expression of angiotensin converting enzyme (ACE) and type 1 angiotensin II
receptor (AT-1R) in comparison to healthy valves (28). These results suggest that RAS may
participate in the progression of aortic stenosis and that blocking RAS can serve as a therapeutic
strategy (65). Towards this end, further studies need to be conducted to investigate the role of
ang-I and ang-II signaling on the biomechanical properties of the aortic valve. Our collaborators
in Imperial College have studied the role of RAS in cardiac fibroblasts, calcific aortic valves,
blood vessels, radial arteries, and internal thoracic arteries, and have shown that RAS mediators
can be inhibited using ACE inhibitors (ACEIs) quinaprilat, receptor antagonists losartan and
PD123319, and the chymase inhibitor chymostatin (Figure 3-3) (63, 69-71).

Figure 3-3. Inhibitors of the renin angiotensin system receptors and converting enzymes
To evaluate the potential for targeting RAS as a therapeutic strategy against valve
disease, the objective of this thesis is thus to investigate how the renin-angiotensin signaling
pathway affects the biological and biomechanical function of the aortic valve by investigating
the receptors (AT-1R and AT-2R) in which ang-II binds to and the enzymes (ACE and chymase)
that convert ang-I to ang-II. It is hypothesized that a local renin-angiotensin signaling exists
within the valve milieu and affects the biological and mechanical function of the aortic valve.
The first aim focuses on quantifying the biomechanical effects of RAS via biaxial
mechanical testing of porcine aortic valve tissues pretreated with the aforementioned mediators
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of RAS signaling (Figure 22). Tissue tangent modulus, extensibility, areal strain, and anisotropy
index are quantified to assess if RAS inhibition altered tissue mechanical properties.
In the second aim, three non-linear phenomenological constitutive models were used to
characterize the mechanical behavior of aortic valve tissues pretreated with RAS mediators.
The third aim focuses on investigating the biological effects that RAS inhibition had on aortic
valve tissue. The phenotypic changes the cells undergo on the tissue due to RAS were
investigated via immunohistochemistry. The changes in collagen fibers undergo were
investigated with quantitative polarized light microscopy and picrosirius red staining.
The next three sections of this chapter will give a more detailed overview of each aim.

3.2 Specific Aims 1: Quantify the biomechanical effects of mediators of the renin angiotensin
signaling (RAS) system on aortic valves.
In this aim, we sought to quantify the biomechanical effects of RAS on aortic valve
tissues through biaxial mechanical testing. There are two commonly utilized methods for the
tensile testing of soft biological tissues – uniaxial and biaxial mechanical testing. Uniaxial testing
tests the sample in one direction, and is commonly used for failure testing of isotropic or
transversely isotopic materials. However, biaxial mechanical testing is a more effective way of
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testing anisotropic material, directionally dependent material, and for developing
phenomenological constitutive models to characterize their material behavior.
We sought to understand the effects of RAS on valve tissues by testing the ability of angII to bind to the AT-1R and AT-2R sub-types, and the ability for ang-I to convert to ang-II via
ACE and chymase activity. To do so, tissue was treated for 48 hours with either ang-I or ang-II
alone to understand their direct effect. 24 hours prior to being treated with ang-I or ang-II valve
leaflets were treated with only RAS mediator inhibitors, and tissue was the co-treated with ang-I
or ang-II and the inhibitors for 48 hours. To understand the binding to the AT-1R and AT-2R
receptor subtypes, tissue was treated with ang-I or ang-II in combination with AT-1R or AT-2R
inhibitors, losartan and PD123,319 respectively. To understand the conversion of ang-I to ang-II,
tissue was treated with ang-I in combination with the ACE and chymase inhibitors, quinaprilat
and chymostatin, respectively. After appropriate treatment, the tissue was tested via biaxial
tensile testing at five different tension ratio protocols at a maximum membrane tension of 90
N/m: Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1.
The Green strain and the 2nd Piola-Kirchhoff (2nd P-K) stress were calculated for each
individual sample. Mechanical characteristics of the individual samples and the average model
were first calculated using the equibiaxial protocol. The stiffness of a sample was characterized
with the low and high tangent modulus for both the circumferential (fiber direction) and radial
(cross fiber direction) direction. From the gradient of the high tangent modulus, the extensibility
of the tissue was calculated. The higher the extensibility, the more strain the sample underwent
for the given maximum tension. With the maximum Green strain in the radial and
circumferential direction, the areal strain and the strain anisotropy index was calculated. An
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anisotropy index close to one indicated that the sample was more isotropic, whereas an
anisotropy index greater than or less that one indicated that the sample was more anisotropic.
3.3 Specific Aims 2: Utilize phenomenological constitutive models to characterize the
biomechanical changes that occur due to RAS mediators on aortic valves.
In this aim, three finite constitutive models were used to characterize changes in the
mechanical properties of the aortic valve samples due to RAS mediators: modified MooneyRivlin (M-R) isotropic model, modified M-R anisotropic model, and Fung-type model. The
Fung-type constitutive model is typically used to characterize the multiaxial behavior of a soft
anisotropic material, while the Mooney-Rivlin constitutive model is usually used to characterize
isotropic materials. We fit our biaxial mechanical data to these phenomenological models to
better characterize the mechanical changes that occurred due to the RAS mediators.
3.4 Specific Aims 3: Investigate the biological effects of mediators of the RAS system on aortic
valves.
In this aim, we sought to understand the biological effects that mediators of the RAS
system had on aortic valve tissues. Tissue received similar treatment as in specific aim 1. The
changes in valve cell phenotype was analyzed through immunohistochemistry (IHC) by
qualitatively analyzing the expression of certain proteins known to be correlated with the
valvular interstitial cells (VICs) during valve disease progression. The alterations of collagen
fiber due to RAS mediators was quantitatively analyzed with quantitative polarized microscopy
(QPLI) and picrosirius red (PSR).
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CHAPTER 4 SPECIFIC AIM 1
Quantify the biomechanical effects of mediators of the renin angiotensin signaling (RAS)
system on aortic valves
4.1 Introduction
Aortic stenosis (AS) is one of the most common valve diseases in the western hemisphere
(3). Mechanical stress is thought to be one of the factors central to its progression (13). The
renin angiotensin signaling (RAS) system has been implicated in the progression of aortic valve
disease as activated RAS can induce fibrosis within the valve (5), altering the mechanical stress
that the valve experiences, accelerating the progression of the disease (14). In addition, the
endothelial damage observed in the early stages of AS increases the mechanical stress and alters
the fluid shear stress on the valve (5). Calcific aortic valve disease (CAVD) is induced by the
long-lasting mechanical stress and is a degenerative and currently irreversible process (6). The
mobility of the leaflet becomes restricted as the calcification progresses (3).
The aortic valve is comprised of three different layers: the fibrosa, spongiosa, and
ventricularis. This structure is important in the biological and mechanical function the valve (30).
The calcific nodules and lesions that occur due to CAVD are primarily in the fibrosa layer (16).
The progression of this disease can compromise the integrity of the trilayer surface and
consequently its biological and mechanical function. In a healthy valve, the collagen fibers in the
fibrosa and spongiosa/ventricularis layers are oppositely aligned, and the alterations to the fiber
alignments and production seen in the diseased fibrosa and spongiosa layer affect its mechanical
function (30).
Planar biaxial mechanical testing is the ideal method to assess changes in mechanical
properties for incompressible materials such as aortic valve tissue as it allows for the
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quantification of a two-dimensional stress-strain relationship. Biaxial testing is where a material
is subjected to load in both the x and y directions in contrast to uniaxial testing which only
subjects the material to load in one direction (72). In anisotropic materials, uniaxial testing is not
recommended. Mechanical responses in aortic valve leaflets are dependent on the direction of the
load. In a leaflet, the collagen fibers are oriented in the circumferential direction, and thus has a
larger stiffness in the circumferential direction in comparison to the radial direction (73). When
stretched in the circumferential direction, the tension in the fibers prevent the collagen fibers
from further stretching as the fibers are aligned. In the radial direction, the collagen fibers
provide less resistance and hence have a lower stiffness in that direction (7). In biaxial testing, an
equibiaxial loading and proportional loading protocols are used to for mechanical
characterizations. Equibiaxial loading is where the same load is applied in both direction, and
proportional loading is where the load is kept at a constant proportion between both directions
(73). Using equibiaxial loading experimental data, mechanical properties of the leaflets can be
calculated such as extensibility, tangent modulus, and degree of anisotropy. (74).
This aim focuses on quantifying the biomechanical effects of RAS signaling on the aortic
valve via equibiaxial mechanical testing. Tissue tangent modulus, extensibility, areal strain, and
anisotropy index will be calculated using equibiaxial experimental data from biaxial tests. The
average 2nd Piola-Kirchoff stress and Green strain data was used to determine changes in
anisotropy due to due to RAS.
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4.2 Materials and Methods
Protocols can be found in Appendix A. MATLAB codes and instructions can be found in
Appendix B.
4.2.1 Tissue treatment
Fresh porcine hearts (3-6 months old) were provided by Cockrum’s Custom Meat
Processing and Taxidermy (Rudy, AR) or Braunschweig Processing (Neosho, MO), both FDAapproved abattoirs. They were transported in cold sterile dPBS. The hearts were then dissected
aseptically, and the left, right, and non-coronary aortic valve leaflets were pooled and washed in
dPBS. They were then incubated with 150 U/ml penicillin/streptomycin in PBS for 10 mins.
The leaflets were then cultured in DMEM supplemented with 2% FBS, 150 U/ml P/S,
and HEPES. The binding of ang-I and ang-II to the receptors was investigated by inhibiting AT1R or AT-2R. The samples were treated with either AT-1R inhibitor losartan (1μM) or AT-2R
inhibitor PD123-319 (1μM) for 24 hour before being treated in combination with ang-I (10 μM)
or ang-II (10 μM) for an additional 48 hrs (69). The local conversion of ang-I to ang-II was
investigated by inhibiting ACE or chymase. Samples were treated and tested as outlined before
but with ACE inhibitor quinaprilat (1 μM) or chymase inhibitor chymostatin (10 μM) and only
ang-I and not ang-II. Tissue for biaxial mechanical testing was immediately tested following the
treatment period (69).
4.2.2 Biaxial mechanical testing
Samples were cut into 1cm2 square specimens aligned in the radial-circumferential
directions. A four-marker array was then placed in form of beads on the tissue to track the
displacement of the tissue. Tissue was mounted onto a TestResources biaxial testing device
(Figure 4-1) with zinc-plated steel wires with the radial direction aligned with the y-axis and
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circumferential direction aligned with the x-axis. The specimen was then immersed into a saline
bath at 37C (Figure 4-2).

Figure 4-1. Biaxial mechanical testing device.

Figure 4-2. Sample mounted on biaxial testing device.
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The specimen was brought to a tare load of 0.05 N along each axis. The system was
operated in the position-based settings at a data acquisition (DAQ) rate of 100 Hz and cycle rate
(frequency) of 1 Hz. Specimen was then preconditioned by cycling 20 times to a membrane
tension of 90 N/m. Mechanical testing in the circumferential and radial axes consisted of the
following tension ratios with a maximum tension of 90 N/m: T circ:Trad – 1:1, 1:0.75, 1:0.5,
0.75:1, 0.5:1. Tissue was then stretched three times, and data acquired. Only the 1:1 tension data
was used in this aim, while the entire data set was used in aim 2 for constitutive modeling.
A camera placed above the sample captured images at 100 Hz while the tissue was being
stretched. These images were later used to detect the displacement of the beads in the four
marker array to calculate deformation.
4.2.3 Stress and strain calculations
The MATLAB code Biaxial_1 was used to determine which stretch cycle had the closest
desired maximum load (0.9N) for analysis. The code works in the following way. Before running
the code, make sure that columns 2-5 in the csv file output by the system correspond to force x1,
y1, x2, and y2, and then delete all words in the file as it won’t be read correctly otherwise. The
user then runs the code and is then asked to select the csv file. Note: If the system being used
exports an excel file, the code needs to be changed to read an .xls files instead. Next the code
plots the force in all axis and the average of the x and y axis. By doing this, the user can see how
many stretches were completed during the test being analyzed. Usually, only three stretches are
done. However, there were times that the system would falter and export fewer data sets. To
overcome this, sometimes the sample would have to be stretched more than 3 times to get the
data of at least the first 2 to 3 stretches. The user is then asked to input how many stretches were
done. The code then finds the peaks of the x2, and then sorts them in a descending order to find
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the n number of stretches. It indexes the row in which they were found and sorts them in
ascending order. This is done because the max force for each peak varies, and if you use the
order in which they are found, the stretches would be in order of max force and not in order that
they were done.
A cycle is done at a DAQ of 100 Hz and frequency of 1 Hz so 100 data points are
acquired for each cycle. The first 50 data points are the loading curve and the last 50 data points
are the unloading curve. The maximum force reached is point 50 in the cycle. To zero the force,
force at point 50 is subtracted by force at point 1 in the cycle. To do so, the maximum force in
the row indexed for the stretch is subtracted by the force indexed 49 data points before it. The
force from each stretch of the x and y axis is displayed in the command window so the user can
choose the stretch to analyze. Note: The x1 loading cell was not working properly so the force
showed is not an average of x1 and x2 but just x2.
Prior to running MATLAB code Biaxial_2, the images acquired from the camera were
separated into individual folders from each stretch. This is done so by going through the images
and separating the 100 images that correspond to each stretch. Before running the code, the user
must change lines 51-53. Line 51 is the path to the folder containing the images (path1=), line 52
is the file name of the first image excluding the last 3 numbers (name1=), and line 53 is the
pathname for the folder containing the MATLAB code in which the information will be
outputted to (out1). Add “\point” to the end of the path name in line 53 (out1). Lines 51 and 52
will change for every run, but line 53 will stay the same if the MATLAB code run is in the same
folder/path.
The user can then run the program. The user is first asked to input the number of the first
image in the command window. 100 images will be analyzed so to calculate the number of the
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last image, so 99 is added to the number of the first image to index the numbers of the 100
images being analyzed. The first image is then opened. The code is written to track 4 points so
the user clicks the 4 points that will be tracked. The user must choose the area in the center and
must be chosen in the following order:
3---------4
/
/
/
2---------1
/

After clicking the 4th point, the code opens the second file and used the function
automarkertrack to track the distance the points have moved to from the previous image by
analyzing a set distance of pixels from the point chosen. The optimal pixel number was 50. The
code then writes the x and y position of every point chosen into a text file (point1.txt, point2.txt,
point3.txt, and point4.txt) which is exported in the MATLAB folder. The code then reads the
files and makes a 100x8 array containing the x and y positions of each point for all 100 images.
The distance the point has moved is calculated by subtracting the initial coordinates of the points
in the first image. An isoperimetric equation is used to compute the strain at the center of the
element and the element of the Jacobian. The elements of the deformation gradient (F) were
computed using the Jacobian factor and isoperimetric strain-differentials. Green strain (E) is
calculated using F with the following equation: E= 0.5(FTF-1). It then creates an excel file
(deformresults.xlsx) containing the Exx, Eyy, Exy, Ezz, E1, E2, dir1, and dir2. It also saves the
deformation gradient as defg.mat and the lambda z as lamz.mat. Lastly, the code plots the Exx
and Eyy. By doing this, the user can see if the tracking of the points was smooth. If the lines are
not smooth, images need to be reanalyzed with a different pixel number in the
automarkertrack.m function.
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MATLAB code Biaxial_3 then creates the excel file rawdata.xlsx that contains the x and
y force values from the csv file acquired from the system and the deformation calculated from
MATLAB code Biaxial_2 for the stretch being analyzed. The user runs the program and is asked
to input the number stretches done and the stretch that will be analyzed. Like in MATLAB code
Biaxial_1, the code sorts and indexes the force according to each stretch from the csv file. It then
creates matrices of the x and y force of the loading curve of the analyzed stretch and their
averages. It then reads the excel sheet deformresults.xlsx and creates matrices of the deformation
gradient in the x and y deformation of the loading curve. It then creates an excel file
(rawdata.xlsx) containing the force and deformation gradients.
The last MATLAB code (Biaxial_4) calculates the x and y tension as well as the 1st and
2nd Piola-Kirchhoff (P-K) stress. The excel file rawdata.xlsx is read and the x and y force and the
green strain in the circumferential and radial direction are loaded. The user is then prompted to
input the thickness of the sample. This can be measured by placing a portion of the sample tested
into OCT, sectioning samples, and then measuring the thickness in ImageJ. The width is
assumed to be 1 cm. The 1st P-K stress is calculated by dividing the force by the area of the
sample. Defg.mat and lamz.mat is loaded, the deformation gradient at F11 and F22 is extracted
from defg.mat. The 2nd P-K stress is calculated by multiplying the inverse of F by 1st P-K stress.
Areal strain is calculated by multiplied the E in the circumferential direction by E in the radial
direction. The anisotropy index is calculated by dividing the max E in the circumferential
direction by E in the radial direction. In the command window, the maximum areal strain and the
anisotropy index will be shown. It then creates an excel file (plotdata.xlsx) containing E, S, and P
in both the circumferential and radial direction and the areal strain.
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4.2.4 Quantifying mechanical properties
Using the equibiaxial data, various mechanical properties can be quantified. As biological
soft tissues have non-linear mechanical properties, we quantified the low and high tangent
moduli as follows. The low tangent modulus is the stiffness in the toe region that represents the
uncrimping of the collagen fibers in the tissue. The high tangent modulus is the stiffness in the
linear region that represents the stretching of tissue collagen fibers. The best fit line (y=mx+b)
was calculated these two tangent moduli in the circumferential and radial directions, where the
slope (m) of each line was the tangent modulus (74). Extensibility was calculated by the xintercept of the high tangent modules. The intersection on the x-axis was calculated by using the
high tangent modulus best fit line (x= (y-b) ÷ m) (Figure 4-3) (74).

Figure 4-3. 2nd P-K stress vs Green strain graph indicating (A) high and low tangent modulus
and (B) extensibility.
Areal strain was calculated by multiplying the maximum Green strain in the
circumferential and radial direction (ECIRC,MAX * ERAD,MAX). Strain anisotropy index was
calculated by dividing the maximum Green strain in the circumferential and radial direction
(ECIRC,MAX ÷ ERAD,MAX) (Figure 4-4). A strain anisotropy index close to 1 indicated a more
isotropic tissue while a value deviating from 1 indicated increasing tissue anisotropy.
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Figure 4-4. 2nd P-K stress vs Green strain graph indicating maximum Green strain used to
calculate areal strain and strain anisotropy.
4.2.5 Statistical methods
Results are reported as mean with standard error. Data was first analyzed for normality
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison
followed by the Tukey post hoc test for normally distributed data. Analyses were performed
using Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.
4.3 Results
A total of 6-8 samples were tested for each treatment group. After testing, some samples
were excluded from the analysis (Table 4-1). See Appendix C for images of samples during
testing (Figure 0-1). Reasons to exclude samples:


Steel wires ripped off during testing



Steel wires were not placed properly causing the sample to be loaded unevenly



Sample believed to be mounted backwards (circumferential in y axis and radial in x axis)



Sample completely tore and all tension ratio tests were not completed

38

Table 4-1. Number of samples tested and number of samples excluded and included in analysis
Treatment
Control
Ang-I
Ang-II
Ang-I+Quinaprilat
Ang-I+Chymostatin
Ang-I+Losartan
Ang-II+Losartan
Ang-I+PD123,319
Ang-II+PD123,319

Number of
samples tested
8
8
8
7
6
7
8
7
8

Number of
samples excluded
3
3
2
3
1
2
4
2
3

Number of
samples analyzed
5
5
6
4
5
5
4
5
5

Equibiaxial stress-strain data allows the quantification of the mechanical properties of the
aortic valve leaflets. The max areal strain (ASmax), anisotropy index (AI), low (TML) and high
(TMH) tangent modulus for the circumferential and radial direction, and extensibility for the
circumferential and radial direction was calculated for each individual sample and were then
averaged by treatment groups (Table 4-2).
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Table 4-2. Max areal strain (ASmax), anisotropy index (AI), low (TML) and high (TMH) tangent
modulus for the circumferential and radial direction, and extensibility for the circumferential and
radial direction for the average (ave) of each individual specimens and standard error (SEM).
Treatment

ASmax

AI

Circ
TML

Circ
TMH

Rad
TML

Rad
TMH

Circ
Ext

Rad
Ext

Control

Ave
SEM

0.097
0.014

0.525
0.084

54.8
10.1

3107.0
523.5

22.5
5.9

1102.8
71.0

0.176
0.024

0.338
0.029

Ang-I

Ave
SEM

0.115
0.017

0.581
0.084

41.8
8.1

2522.0
276.3

20.6
5.5

1275.5
169.4

0.201
0.018

0.379
0.057

Ang-II

Ave
SEM

0.083
0.018

0.463
0.083

56.3
17.2

3604.2
750.0

19.1
3.1

1344.7
228.2

0.138
0.036

0.337
0.035

Ang-I+
Quinaprilat

Ave
SEM

0.098
0.011

0.513
0.119

56.0
7.8

2986.4
778.3

21.5
4.3

1146.2
192.0

0.168
0.013

0.375
0.054

Ang-I+
Chymostatin

Ave
SEM

0.083
0.013

0.507
0.084

53.8
10.7

3268.5
277.3

33.9
4.4

1295.8
193.5

0.163
0.025

0.325
0.032

Ang-I+
Losartan

Ave
SEM

0.110
0.025

0.385
0.055

37.7
6.5

2690.7
643.6

12.6
1.9

1101.0
283.1

0.158
0.022

0.440
0.044

Ang-II+
Losartan

Ave
SEM

0.076
0.011

0.321
0.054

42.1
8.4

5147.7
1145.7

16.7
5.0

1079.2
78.0

0.126
0.016

0.395
0.044

Ang-I+
PD123,319

Ave
SEM

0.094
0.012

0.361
0.062

64.6
11.0

5214.7
496.6

19.7
4.8

1198.4
116.9

0.154
0.019

0.433
0.048

Ang-II+
PD123,319

Ave
SEM

0.094
0.012

0.455
0.072

60.9
6.4

3388.1
463.9

17.3
2.0

1415.0
319.9

0.158
0.014

0.398
0.035

4.3.1 Areal strain and strain anisotropy index
The max areal strain (ASmax) and strain anisotropy (AI) were calculated from the
maximum Green strain (E) in the equibiaxial loading condition. The ang-I treated group had a
higher ASmax than the control while the ang-II treated group had a lower ASmax than the control
(Figure 4-5a,b). When ang-I was supplemented with an ACE inhibitor, it had a similar ASmax to
the control and lower ASmax than the ang-I treated group. When ang-I was supplemented with a
chymase inhibitor, it had a lower ASmax than the control and ang-I treated group (Figure 4-5a).
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Ang-I supplemented with an AT-1R antagonist had similar ASmax than the ang-I treated group
and higher ASmax than the control. When ang-II was supplemented with an AT-1R antagonist, it
had a lower ASmax than the control and ang-II treated group. Ang-I supplemented with an AT-2R
antagonist had a similar ASmax than the control and lower ASmax than the ang-I treated group.
Ang-II supplemented with an AT-2R antagonist had a higher ASmax than the ang-II treated group
and a lower ASmax than the control (Figure 4-5b). Ang-I treated group had a higher AI than the
control while the ang-II treated group had a lower AI than the control (Figure 4-5c,d). Ang-I
supplemented with an ACE and chymase inhibitor had a lower AI than the control and ang-I
treated group (Figure 4-5c). When ang-I and ang-II were supplemented with an AT-1R
antagonist, it had a lower AI than the control, ang-I, and ang-II treated groups. When ang-I was
supplemented with an AT-2R antagonist, it had a lower AI than the control and ang-I treated
group. When ang-II was supplemented with an AT-2R antagonist, it had a lower AI than the
control but a similar AI than the ang-II treated group (Figure 4-5d).
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Figure 4-5. The areal strain for (A) enzyme and (B) receptor inhibitors and the strain anisotropy
for (C) enzyme and (D) receptor inhibitors. Red dotted line is the untreated, native leaflets.
4.3.2 Tangent modulus
The low tangent modulus (TML) is the stiffness in the toe region where the fibers are “uncrimping”. In the circumferential region, the control and ang-II had a similar TML whereas the
TML for samples treated with ang-I was slightly less (Figure 4-6a,b). When treated with ang-I
supplemented with the ACE or chymase inhibitors, the TML was similar to that of the control
(Figure 4-6a). When treated with ang-I or ang-II supplemented with the AT-1R inhibitor, the
samples had a lower TML than when treated with ang-I or ang-II alone implying that by
inhibiting binding of ang-II to AT-1R the samples are less stiff. When treated with ang-I or angII supplemented with the AT-2R inhibitor, the samples had a higher TML than when treated with
ang-I or ang-II alone. This implies that by inhibiting AT-2R and allowing more ang-II to bind to
AT-1R, the leaflets are stiffer (Figure 4-6b). In the radial direction, the control, ang-I, and ang-II
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had a similar TML (Figure 4-6c,d). When treated with ang-I supplemented with the ACE
inhibitor, the TML was similar to that of the control. However, ang-I supplemented with the
chymase inhibitor had a higher TML (Figure 4-6c). When treated with ang-I or ang-II
supplemented with the AT-1R inhibitor, the samples had a lower TML than when treated with
ang-I or ang-II alone. When treated with ang-I or ang-II supplemented with the AT-2R inhibitor,
the samples had a similar TML than when treated with ang-I or ang-II alone (Figure 4-6d).
The high tangent modulus (TMH) is the stiffness in the linear region where the fibers have
been “uncrimpled” and are now being stretched. In the circumferential direction, ang-I had a
lower tangent modulus than the control, and ang-II had a higher TMH than the control (Figure
4-6e,f). The TMH of samples treated with ang-I supplemented with ACE and chymase inhibitor
was similar to that of the control (Figure 4-6e). Tissue treated with ang-I supplemented with the
AT-1R inhibitor had a lower TMH, and tissue treated with ang-I supplemented with AT-2R
inhibitor had a higher TMH. On the contrary, tissue treated with ang-I supplemented with the AT1R inhibitor had a higher TMH, and tissue treated with ang-I supplemented with AT-2R inhibitor
had a lower TMH (Figure 4-6f). In the radial direction, ang-I treated tissue had a higher TMH
than the control, and ang-II treated tissue had a higher TMH than both the control and ang-I
(Figure 4-6g,h). When treated with ang-I supplemented with the ACE inhibitor, the TMH was
similar to that of the control. However, tissue treated with ang-I supplemented with chymase
inhibitor had a similar TMH than when treated with ang-I alone (Figure 4-6g). When treated with
ang-I or ang-II supplemented with the AT-2R inhibitor, the TMH was similar to that of the
control. When treated with ang-I or ang-II supplemented with the AT-2R inhibitor, the TMH was
similar to those treated with ang-I or ang-II alone (Figure 4-6h).
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Figure 4-6. The low tangent modulus (TM) for (A) enzyme and (B) receptor inhibitors in the
circumferential direction and for (C) enzyme and (E) receptor inhibitors in the radial direction.
The high tangent modulus (TM) for (E) enzyme and (F) receptor inhibitors in the circumferential
direction and for (G) enzyme and (H) receptor inhibitors in the radial direction. Red dotted line
is the untreated, native leaflets.
4.3.3 Extensibility
In the circumferential direction, ang-I had a higher extensibility than the control, and angII had a lower extensibility than the control (Figure 4-7a,b). When treated with ang-I
supplemented with the ACE or chymase inhibitors, the extensibility was similar to that of the
control (Figure 4-7a). When ang-I and ang-II were supplemented with an AT-1R antagonist,
they had a lower extensibility than the control, ang-I, and ang-II treated group. When ang-I was
supplemented with an AT-2R antagonist, it had a lower extensibility than the control and ang-I
treated group. Ang-II supplemented with an AT-2R antagonist had a lower extensibility than the
control but a higher extensibility than the ang-II treated group (Figure 4-7b). In the radial
direction, ang-II treated group had a similar extensibility than the control, but the ang-I treated
group had a greater extensibility than the control (Figure 4-7c,d). Ang-I supplemented with an
ACE inhibitor had a similar extensibility than the ang-I treated group. When ang-I was
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supplemented with a chymase inhibitor, it had a similar extensibility than the control (Figure
4-7c). When ang-I and ang-II were supplemented with an AT-1R inhibitor, they had a greater
extensibility than the control, ang-I, and ang-II treated group. Ang-I and ang-II supplemented
with an AT-2R inhibitor had a higher extensibility than the control, ang-I, and ang-II treated
group (Figure 4-7d).

Figure 4-7. The extensibility in the circumferential direction for (A) enzyme and (B) receptor
inhibitors and in the radial direction for (C) enzyme and (D) receptor inhibitors. Red dotted line
is the untreated, native leaflets.
4.4 Discussion
When the anisotropy index (AI) was calculated with the equibiaxial data, all treatment
groups had an AI of less than 0.6. An AI close to 1 means that a sample is isotropic so our results
showed that all samples were anisotropic as the AI was less than 1. The treatment groups where
ang-I and ang-II were supplemented with an AT-1R had the lowest calculated AI. This implies
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that when the ability for ang-II to bind to AT-1R is mitigated, the anisotropic qualities of the
tissue increases. Ang-II supplemented with an AT-2R antagonist had a similar AI than the ang-II
treated groups. This indicates that the effects seen in the AI of ang-II treatment is due to the
binding of ang-II to AT-1R.
The enzyme inhibited groups showed a similar tangent modulus in the toe and linear
region in the circumferential and radial direction with the exception of the chymase inhibitor in
the toe and linear region in the radial direction. This implies that by preventing ang-I to convert
to ang-II the stiffness is similar to that of the non-treated samples. Though ang-I and ang-II
treated groups did not seem to have a different tangent modulus in the circumferential direction
or in the toe region in the radial direction, in the linear region in the radial direction ang-I and
ang-II had a higher tangent modulus. This implies that in the cross-fiber direction the stiffness of
the collagen fibers does increase. In the toe region in the circumferential and radial direction as
well as the linear region in the radial direction, ang-I and ang-II supplemented with an AT-1R
antagonist had the lowest tangent modulus overall. Only in the linear region in the
circumferential direction did ang-II supplemented with AT-1R antagonist have a greater tangent
modulus, however ang-I supplemented with AT-1R antagonist did have a lesser tangent modulus
in that region. This implies that by inhibiting the ability for ang-II to bind to AT-1R the stiffness
decreases. This is further verified in the AT-2R inhibited treatment groups. Ang-I and ang-II
supplemented with the AT-2R antagonist had a higher tangent modulus in the toe and linear
region in the circumferential and radial direction with the exception of ang-II supplemented with
AT-2R antagonist in the linear region in the circumferential direction. By inhibiting the ability
for ang-II to bind to AT-2R, ang-II will bind more to AT-1R increasing the stiffness of the
sample. There was a high variation in the extensibility, and it seems to be highly unreliable
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because small changes in the high TM fit will result in wide changes in where the line cuts the xaxis, thereby affecting extensibility.
Tissue being treated with ang-I and ang-II may not have shown a trend in the change of
mechanical behaviors as this was a short term treatment. Though ang-II is more prone to bind to
AT-1R, the amount of time may not have been sufficient to increase the binding of AT-1R over
AT-2R. However, limiting the ability to bind to just one receptor did show a trend in mechanical
behavior.
In the next chapter, we will use the multiple tension loading ratios to develop three nonlinear phenomenological constitutive models to characterize the mechanical behavior of aortic
valve tissues pretreated with RAS mediators. In this aim, all these measurements are very
dependent on fitting to inherently non-linear data, and the constitutive models we’ll use are nonlinear models that fit the data properly.
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CHAPTER 5 SPECIFIC AIM 2
Utilize phenomenological constitutive models to characterize the biomechanical changes
that occur due to RAS mediators on aortic valves
5.1 Introduction
Phenomenological constitutive models can be used to quantify the anisotropic and
nonlinear material properties of soft tissue such as aortic valve leaflets (75). They can account
for the regional variation and the properties of the leaflet layers, and the stress environment the
cells undergo can be predicted with the appropriate model (76). In incompressible materials such
as isotropic rubber materials, they undergo finite deformation in which a two-dimensional stressstate is sufficient to develop constitutive equations such as the Mooney-Rivlin (M-R) (77, 78).
However, biological tissue require more rigorous models due to their complex mechanical
behavior (77). Viscoelastic behavior of materials is discussed through mechanical models in
terms of how a material behaves when stress or strain is applied (79). Isotropic models such as
M-R have been modified to be used for anisotropic material by adding an additional anisotropic
term (80). A more commonly viscoelastic anisotropic model used for valve leaflets is the Fungtype model (75, 81). Material constants derived from constitutive models are important for
generating computational simulations of tissue deformation. Simulations can be performed using
specimen-specific constants, however, having material constants that represent a generic
(average) response is favorable (75).
This aim focuses on selecting an appropriate constitutive model that mimics the
biomechanical changes that occur in aortic valves due to RAS mediators. In addition, material
constants will be derived from an average response to simulate the generic mechanical behavior.
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Mechanical properties will be assessed through the anisotropy index calculated through material
constants and the stress-strain response graphs from the average model.
5.2 Methods
MATLAB codes can be found in Appendix B. Prior to running the MATLAB codes,
excels sheets need to be created with the appropriate information. Refer to Appendix B as it is
important to create the excel file in the correct order as MATLAB codes load the data
accordingly.
5.2.1 Average model
The average stress-strain response can be calculated by using an average model based on
identical tension states (75). The user is asked to first choose the file containing the thickness of
each sample and then the file containing the x and y-force and E11 and E22. The MATLAB code
will then extract the information and create an individual matrix for each. The x and y-tension is
calculated by dividing the force by the width which is assumed to be 1 cm. The average tension
(Tavg,ii) for x and y is calculated by averaging the individual x and y tensions. The same is done
to calculate the average green strain (Eavg,ii) for the x (circumferential, E11) and y (radial, E22)
directions. The average 1st P-K stress (Pavg,ii) is calculated with Eq. (5.1).
n

Pavg,ii

Tavg,ii
1
=
∑
n
hi

(5.1)

i=1

n is the number of samples and hi is the thickness of the individual leaflets. The average
deformation gradient (Favg,ii) is calculated using Eq. (5.2) assuming negligible shear deformation.
The average 2st P-K stress (Savg,ii) is given by Eq.(5.3).
Favg,ii = √2Eavg,ii + 1
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(5.2)

−T
Savg = Pavg Favg

(5.3)

The average anisotropy index AIavg is calculated by dividing the max Eavg,11 and Eavg,22.
The code then exports two excel files. AveragePlotData.xlsx contains the average of E, S, and P
for each direction and ASavg. AverageEandTandStandardError.xls contains the average E and T
and the standard errors for E and T in each direction. The code then creates two figures. Figure 1
is Savg,ii vs Eavg,ii including the standard error bars, and figure 2 is Savg,ii vs Eavg,ii without the
standard error bars.
5.2.2 Mooney-Rivlin model
Two modified Mooney-Rivlin (M-R) constitutive models were used: an isotropic and an
anisotropic model. The strain energy equation function for the isotropic M-R model is given by
Eq (5.4), and the strain energy (W) equation function for the anisotropic M-R model is given by
Eq (5.5) (80).
W=c1 (I1-3) + c2 (I2-3) + D1 [exp (D2 (I1 - 3)) - 1]

(5.4)

W=c1(I1-3) + D1 [exp (D2 (I1 - 3)) - 1] + (k1/2k2) [exp [k2 (I4 - 1)2 - 1]

(5.5)

W is a function of the strain invariants (I) can be calculated using Eq. (5.6) (78).
I1=tr (B)=λ12+ λ22+ λ32

(5.6)

I2=0.5 [ (trB)2-tr(B2)]= λ12 λ22+ λ22 λ32+ λ32 λ12
I4=Cij(nc)i(nc)j
λ1, λ2, and λ3 are the principal stretches and the left Cauchy-Green tensor (B) can be
calculated by B=FFT. nc refers to the principle direction of the material fibers. The standard
constitutive model for an incompressible, isotropic, elastic material can be determined with Eq.
(5.7) (78).
𝜎 = −𝑝1 + 2

𝑑𝑊
𝑑𝑊 −1
𝐵−2
𝐵
𝑑𝐼1
𝑑𝐼2
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(5.7)

p is a hydrostatic pressure term associated with the incompressibility constraints and σ is
Cauchy stress. For this study, the stress for the models needs to be in 2nd P-K stress (S) and
relative to Green strain (E). The relationship between σ, P, and S are the following (82):
σ=

1
FP
J

(5.8)

P=FS
J is the Jacobian and F is the deformation gradient. J is a measurement of the volume
change produced by the deformation. We assumed that there is no change in volume so J=1
hence σ relates to S by Eq. (5.9).
σ=F2S

(5.9)

The relationship between E and λ1, λ2, and λ3 can be calculated using F with Eq. (5.11) (82).
λ1
F=[ 0
0

0
λ2
0

0
0]
λ3

E=0.5(FTF-I)

(5.10)

(5.11)

Using Eq. (5.9) the following can be said about S in the circumferential and radial direction:
S11= σ/ λ12

(5.12)

S22= σ/ λ22
Using Eq. (5.11), the following can be said about λ in terms of E:
λ12=2E11+1

(5.13)

λ22=2E22+1
λ32=2E33+1
Using the strain energy equation for the isotropic and anisotropic modified M-R, Eq.
(5.4) and Eq. (5.5) respectively , S in the circumferential and radial direction were calculated in
terms of E. Note: E33 was assumed to be 0 from deformation results in Aim 1.
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Isotropic modified M-R:
S11= [2c2 – 2 (c1 + D1 [D2 exp (D2 (2E11 + 2E22 + 3) - 3D2)]) + 2(2E11+1) (c1 +
D1[D2exp(D2(2E11 + 2E22 + 3) - 3D2)]) - 2c2 (2E11 + 1)-1] ÷(E11+1)
S22= [2c2 – 2 (c1 + D1 [D2 exp (D2(2E11 + 2E22 + 3) - 3D2)]) + 2(2E22 + 1)
(c1+D1[D2exp(D2(2E11 + 2E22 + 3) - 3D2)]) - 2c2 (2E22 + 1) -1] ÷ (E11+1)

(5.14)

(5.15)

Anisotropic modified M-R:
S11=[4E11 (c1 + D1D2 exp (2E11 + 2E22)) + 4k1E11 (2E11 + 1) exp (k2(2E11)2)] ÷
(2E11+1)

(5.16)

(5.17)
S22=[4E22 (c1 + D1D2 exp(2E11 + 2E22))] ÷ (2E22 + 1)
The constants for the M-R constitutive model were calculated using MATLAB,
ModifiedMooneyRivlin_Isotropic.m for the modified M-R isotropic model and MATLAB code
ModifiedMooneyRivlin_Anisotropic.m for the modified M-R anisotropic model. The MATLAB
code uses the objective function to calculate the sum of squares of the residuals given by Eq.
(5.18) (82).
𝑛
𝑚 2
𝑚 2
𝛾 = ∑(𝜎11 − 𝜎11
) + (𝜎22 − 𝜎22
)
2

(5.18)

𝑖=1

In the isotropic model, it used Eq. (5.14) and Eq.(5.15), and in the anisotropic model it
used Eq. (5.16) and Eq. (5.17). The minimization of the objective function was done by using the
function fmincon. In the anisotropic model, D2 was set to 2 without appreciably reducing the
goodness of fit (82). The code then calculates the constants and total R2. The isotropic MATLAB
code exports an excel sheet (Modified M-R (Isotropic) Constants.xlsx) containing the c1, c2, D1,
and D2 constants and the R2 combined. The anisotropic MATLAB code exports an excel sheet
(Modified M-R (Anisotropic) Constants.xlsx) containing the c1, D1, D2, k1, and k2 constants and
the R2 combined.
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Using the constants, it generates values for plotting the model fit for each tension load
ratio using the experimental values E11 and E22 in Eq. (5.21) and Eq (5.22). It plots two figures
using the model fit. Figure 1 plots the individual ratios (5 subplots) with the circumferential and
radial direction in one graph. Figure 2 plots all the ratios in either the circumferential or radial
direction (2 subplots).
5.2.3 Fung Type model
The strain energy density (W) function of the fung-type model utilized is given by Eq.
(5.19).
W=0.5c (eQ-1),

(5.19)

where Q=c1E112+ c2E222+2 c3E11E22. The second P-K stress tensor (Sij) is evaluated by Eq. (5.20).
Sij=dW/dEij,

(5.20)

Eij are the components of the Green strain tensor and i and j are dummy indices (75). S11 and
S22, circumferential and radial directions respectively, were evaluated using Eq. (5.21) and Eq
(5.22).
S11=0.5c*exp( c1E112+ c2E222+2 c3E11E22)*(2c1 E11+2c3E22)

(5.21)

S22=0.5c*exp( c1E112+ c2E222+2 c3E11E22)*(2c2 E22+2c3E11)

(5.22)

The constants for the Fung-type constitutive model were calculated using MATLAB code
FungModelFit_EnergyPlot.m. The MATLAB code uses the objective function to calculate the
sum of squares of the residuals using Eq. (5.21) and Eq. (5.22) for each tension load ratio. The
minimization of the objective function was done by using the function fmincon which was
performed with the following constraints (81):
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c>0
c1 > |c3|
c2 > |c3|
The code calculates the optimal c, c1, c2, and c3 constants, and calculates the total R2.
Using the constants, a non-linear anisotropy index (AI) was calculated using Eq. (5.23) (75).
𝑐1 + 𝑐3 𝑐2 + 𝑐3
AI = min(
,
)
𝑐2 + 𝑐3 𝑐1 + 𝑐3

(5.23)

It then exports an excel sheet (Fung-type Constants.xlsx) containing the c, c1, c2, and c3
constants, the condition number, R2 combined, and the AI. Using the constants, it generates
values for plotting the model fit for each tension load ratio using the experimental values E11
and E22 in Eq. (5.21) and Eq (5.22). It plots two figures using the model fit. Figure 1 plots the
individual ratios (5 subplots) with the circumferential and radial direction in one graph. Figure 2
plots all the ratios in either the circumferential or radial direction (2 subplots).
In addition to calculating the Fung-type constants, the MATLAB code also generates a strain
energy contour plot. Contour plots are used to show that the material constants fulfill the positive
definiteness requirement of elasticity tensor by satisfying the strain energy convexity constraints.
Contour plots are generated by graphing E11 and E22 in a range from -1.5 to 1.5 into the strain
energy Eq. (5.19) using the material constants. The contours are plotted at W= 0.01, 0.5, 3, 10,
and 30 (75).
5.2.4 Average stress-strain graph analysis
By graphing the 2nd P-K Stress vs green strain of the various tension ratios in the
circumferential and radial direction, there are mechanical properties that can be observed.
(Figure 5-1). First is the mechanical anisotropy which shows if samples have a different stressstrain behavior in the circumferential and radial direction. The native valve is typically highly
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anisotropic and any trend towards less anisotropy suggest pathological changes. An anisotropic
sample will show a spacing between the circumferential and radial curves. The second is the
cross coupling of the fibers which is where the stress in one direction affects the mechanical
behavior of the orthogonal direction. If we look at circumferential curves, the equibiaxial, black
dots, is in the middle as it was stretched equally in both directions. The green diamonds are in
which it was stretch 3/4 in the circumferential direction and full tension in the radial direction,
and the blue diamond’s half the tension as the radial direction. As it can be seen, the sample
underwent less strain in the circumferential direction in comparison, but in the radial direction
(grey diamond) corresponding to that stretch, it underwent the most strain. This means that the
strain in each direction is affected by how much stress is applied in the perpendicular direction.
This is the cross-coupling affect and can be seen by the spreading out of the stress strain curves.

Figure 5-1. (A) Aortic valve leaflet (73) showing circumferential and radial direction. (B) 2nd PK stress vs Green strain graph for tension ratios 1:1, 1:0.75, 0.75:1, 1:0.50, 0.50:1
5.2.5 Statistical methods
Results are reported as mean with standard error. Data was first analyzed for normality
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison
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followed by the Tukey post hoc test for normally distributed data. Analyses were performed
using Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.
5.3 Results
The material constants for the modified M-R isotropic and anisotropic constitutive model
and the Fung-type model were calculated for each individual sample using the green strain
acquired from the experimental data acquired during biaxial testing. In addition, the material
constants were calculated for the average stress-strain response given from the average model.
A total of 6-8 samples were tested for each treatment group. After testing, some samples were
excluded from the analysis (Table 5-1). See Appendix C for images of samples during testing.
Reasons to exclude samples:


Steel wires ripped off during testing



Steel wires were not placed properly causing the sample to be loaded unevenly



Sample believed to be mounted backwards (circumferential in y axis and radial in x axis)



Sample completely tore and all tension ratio tests were not completed

Table 5-1. Number of samples tested and number of samples excluded and included in analysis
Treatment
Control
Ang-I
Ang-II
Ang-I+Quinaprilat
Ang-I+Chymostatin
Ang-I+Losartan
Ang-II+Losartan
Ang-I+PD123,319
Ang-II+PD123,319

Number of
samples tested
8
8
8
7
6
7
8
7
8

Number of
samples excluded
3
3
2
3
1
2
4
2
3
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Number of
samples analyzed
5
5
6
4
5
5
4
5
5

5.3.1 Average model
Mechanical testing in the circumferential and radial axes consisted of the following
tension ratios with a maximum tension of 90 N/m: Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1. In
the circumferential direction, most tension ratios and treatment groups had a low standard error.
However, in the radial direction, some tension ratios had a higher standard error suggesting
greater variation between samples in each treatment group in the cross fiber direction (Figure
5-2).
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Figure 5-2. Average response based on identical tension states for each tension ratio with a
Green strain standard error of each treatment group
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5.3.2 Model Fit
Modified M-R isotropic model
The material constants for each individual specimen varied greatly as can be seen in
Table 5-2 . For example, in the control, the D1 constant was 0.14 in one sample whereas it was 1144.73 in another sample. When the D1 constant was averaged in the control treatment group, it
had a value of 45.23 with a standard error of 398.71. This trend is seen in the majority material
constants in treatment groups. This showed that by averaging the individual constants in each
treatment group an accurate finite constitutive model would not be possible. Table 5-2 also
shows that the R2 is very low in all samples and in their average implying that this model was not
a good fit for the data.
Table 5-2. Material constants c1, c2, D1, and D2 for the Modified Mooney-Rivlin isotropic
constitutive model and the R2 of the fit for individual specimens by fitting the experimental data.
Treatment
Control

Ang-I

Sample
No.
1
2
3
4
5
Ave
SEM

c1
80.71
207.56
191.83
151.45
61.04
138.52
29.26

c2
D1
D2
-81.99
0.14 -4145.97
-259.20 -1144.73 -5473.06
-229.31
-0.04 -178.03
-133.34 1370.82 -4903.07
-23.75
-0.05 -677.56
-145.52
45.23 -3075.54
44.13
398.71 1104.08

R2
0.25
0.64
0.57
0.32
0.22
0.40
0.09

1
2
3
4
5
Ave
SEM

106.20
82.65
18.94
215.97
198.03
124.36
36.74

-122.06 -835.07 -4574.14
-79.13 -1057.92 -5163.50
4.29 -649.32 -4278.89
-262.82
-0.03 -532.76
-199.26 -1384.41 -4663.88
-131.79 -785.35 -3842.63
46.43
231.39
839.64

0.35
0.34
0.11
0.55
0.45
0.36
0.07
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Table 5-2 (Cont.)
Sample
Treatment
No.
Ang-II
1
2
3
4
5
6
Ave
SEM

c1
36.14
195.13
84.99
34.62
128.70
62.07
90.27
25.38

c2
D1
D2
-7.08
0.67 -4194.06
-237.35
-0.08 -5183.26
-80.49
0.02 -357.33
17.48
110.39 -5234.66
-128.81 -1524.30 -5137.66
-16.25
-0.13 -174.45
-75.42 -235.57 -3380.24
39.12
258.37
997.59

R2
0.19
0.50
0.32
0.17
0.28
0.16
0.27
0.05

Ang-I+
Quinaprilat

1
2
3
4
Ave
SEM

233.03
72.30
40.61
87.98
108.48
42.67

-269.64 -1305.74 -4869.95
-65.57 -836.17 -4118.82
-3.61 -1135.49 -5420.32
-75.42 -967.25 -4806.53
-103.56 -1061.16 -4803.90
57.60
101.97
266.72

0.53
0.34
0.15
0.22
0.31
0.08

Ang-I+
Chymostatin

1
2
3
4
5
Ave
SEM

54.40
98.27
70.80
97.99
268.02
117.90
38.45

-20.81
-1.20 -4613.05
-110.17 -936.59 -4757.37
-55.94 -1154.65 -5296.60
-76.44 -1461.78 -4934.57
-310.07 -1357.86 -5374.42
-114.69 -982.42 -4995.20
50.95
261.28
148.48

0.22
0.35
0.25
0.23
0.45
0.30
0.04

Ang-I+
Losartan

1
2
3
4
5
Ave
SEM

34.55
10.69
37.28
96.43
64.93
48.78
14.69

-21.38
25.09
-16.19
-102.93
-33.10
-29.70
20.77

0.00 -588.39
0.00 -132.06
0.00 -1014.24
0.01 -470.80
1764.85 -5845.27
352.97 -1610.15
352.97 1068.13

0.23
0.12
0.21
0.37
0.19
0.22
0.04

Ang-II+
Losartan

1
2
3
4
Ave
SEM

12.72
58.95
114.31
65.13
62.78
20.78

25.44
-0.01 -406.89
-41.56 -928.54 -4367.70
-94.39
-0.03
-76.93
-39.46 -1569.22 -5748.08
-37.49 -624.45 -2649.90
24.53
383.50 1420.12

0.10
0.24
0.28
0.18
0.20
0.04
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Table 5-2 (Cont.)
Sample
Treatment
No.
Ang-I+
1
PD123,319
2
3
4
5
Ave
SEM
Ang-II+
PD123,319

1
2
3
4
5
Ave
SEM

c1
91.85
35.33
157.00
48.22
22.74
71.03
24.44

c2
D1
D2
-85.76 -909.63 -4431.09
0.22 -616.77 -3975.13
-145.60
-0.02 -130.82
-9.93 -1421.68 -6139.60
11.06 -505.32 -4237.18
-46.00 -690.68 -3782.76
30.16
234.43
988.82

R2
0.28
0.15
0.33
0.18
0.10
0.21
0.04

66.49
32.89
153.77
87.05
62.79
80.60
20.23

-51.45
2.36
-166.82
-81.27
-39.29
-67.29
28.27

0.25
0.15
0.38
0.32
0.22
0.26
0.04

-825.04
-999.52
-0.04
0.02
0.31
-364.85
225.18

-4154.06
-4733.29
-42.21
-210.23
-4146.38
-2657.23
1039.09

In (Table 5-3), the material constants were derived from the average model. The material
constants from the average model are very different than those from when the material constants
of each sample were averaged. The R2 in all treatment group was less than 0.50 which indicates a
poor fit.This is expected as valve leaflets are anisotropic material and not isotropic material.
Table 5-3 Material constants c1, c2, D1, and D2 for the Modified Mooney-Rivlin isotropic
constitutive model and the R2 of the fit for the average response based on identical tensions.
Treatment
Control
Ang-I
Ang-II
Ang-I + Quinaprilat
Ang-I + Chymostatin
Ang-I + Losartan
Ang-II + Losartan
Ang-I + PD123,319
Ang-II + PD123,319

c1
164.49
118.73
115.69
112.46
135.84
66.20
88.79
90.61
103.65

c2
D1
D2
-182.48 -1044.68 -4696.10
-127.76 -901.80 -4468.60
-110.49 -1183.05 -4892.73
-109.37 -941.61 -4311.37
-139.62 -1195.81 -5114.54
-54.61
0.03 -1721.22
-72.32
-0.01 -430.03
-72.76 -941.24 -4661.92
-98.93
0.03 -269.10

R2
0.44
0.40
0.33
0.34
0.36
0.29
0.27
0.27
0.32

When the model fit was plotted with the experimental data, it can be seen that it does not
follow the shape of the stress strain curve (Figure 5-3). The 1fit for the different tension loading
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ratios are all similar to one another meaning that there is no spreading between the loading ratios.
The max 2nd P-K stress of the model fit in the circumferential and radial direction was half if not
much less than that of the experimental data.

Figure 5-3. The Modified Mooney-Rivlin isotropic constitutive model fit along the experimental
data in the circumferential and radial direction for the average response of each treatment
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Modified M-R anisotropic model
The material constants for each individual specimen did not vary as drastically in the MR anisotropic model as they did in the isotropic model (Table 5-4). It was only the SEM for the
k2 constant that was large. Table 5-4 also shows that the R2 is higher in all samples and in their
average in comparison to the isotropic model implying that this modified M-R anisotropic model
is a better fit than that of the modified M-R isotropic model.
Table 5-4. Material constants c1, D1, D2, k1, and k2 for the Modified Mooney-Rivlin
anisotropic constitutive model and the R2 of the fit for individual specimens by fitting the
experimental data
Sample
No.
1
2
3
4
5
Ave
SEM

-60.20
-73.37
-74.13
-157.19
-94.38
-91.86
17.22

11.55
18.40
20.94
45.51
26.32
24.55
5.75

Ang-I

1
2
3
4
5
Ave
SEM

-67.07
-51.08
-23.58
-81.49
-133.81
-71.41
18.32

Ang-II

1
2
3
4
5
6
Ave
SEM

-45.35
-82.16
-51.80
-103.81
-161.89
-178.02
-103.84
22.71

Treatment
Control

c1

D1

D2

R2

k1

k2

2.00
2.00
2.00
2.00
2.00
2.00
0.00

6.98
31.47
0.07
24.99
24.66
17.64
5.99

2.97
-24.78
13.95
4.76
10.83
1.54
6.88

0.68
0.84
0.84
0.81
0.82
0.80
0.03

13.37
12.92
4.16
21.33
43.39
19.04
6.67

2.00
2.00
2.00
2.00
2.00
2.00
0.00

5.33
0.78
7.47
18.55
1.03
6.63
3.24

2.90
15.49
8.14
-41.20
30.01
3.07
11.97

0.77
0.85
0.74
0.78
0.89
0.81
0.03

9.77
21.22
13.99
28.89
46.47
57.31
29.61
7.66

2.00
2.00
2.00
2.00
2.00
2.00
2.00
0.00

13.69
30.30
3.03
38.61
34.10
16.26
22.66
5.63

7.41
-17.23
9.58
8.09
-9.51
47.97
7.72
9.21

0.80
0.74
0.78
0.74
0.65
0.78
0.75
0.02
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Table 5-4 (Cont.)
Sample
Treatment
No.
Ang-I+
1
Quinaprilat
2
3
4
Ave
SEM

c1

D1

D2

k1

k2

R2

-94.70
-49.62
-70.22
-63.88
-69.61
9.41

28.94
12.30
16.73
15.40
18.34
3.65

2.00
2.00
2.00
2.00
2.00
0.00

5.90
2.48
16.19
5.07
7.41
3.02

4.54
13.34
15.43
9.23
10.63
2.40

0.84
0.88
0.77
0.72
0.80
0.03

Ang-I+
Chymostatin

1
2
3
4
5
Ave
SEM

-72.75
-45.02
-54.78
-157.51
-141.42
-94.30
23.10

18.51
10.62
15.32
46.46
38.71
25.92
7.02

2.00
2.00
2.00
2.00
2.00
2.00
0.00

19.64
1.15
9.28
15.20
2.25
9.50
3.59

8.76
9.29
9.10
16.35
9.55
10.61
1.44

0.85
0.76
0.64
0.74
0.81
0.76
0.03

Ang-I+
Losartan

1
2
3
4
5
Ave
SEM

-28.36
-32.18
-44.90
-55.79
-134.37
-59.12
19.43

5.12
7.45
10.41
13.39
37.63
14.80
5.87

2.00
2.00
2.00
2.00
2.00
2.00
0.00

10.38
27.91
3.03
1.97
20.38
12.73
5.02

2.94
5.60
23.06
8.76
20.26
12.13
4.03

0.76
0.70
0.81
0.84
0.74
0.77
0.02

Ang-II+
Losartan

1
2
3
4
Ave
SEM

-40.79
-63.83
-112.86
-120.65
-84.53
19.25

8.88
15.67
27.81
34.62
21.74
5.81

2.00
2.00
2.00
2.00
2.00
0.00

3.42
8.10
7.33
24.31
10.79
4.62

32.71
12.54
15.83
26.04
21.78
4.64

0.67
0.73
0.85
0.72
0.74
0.04

Ang-I+
PD123,319

1
2
3
4
5
Ave
SEM

-68.37
-40.11
-109.57
-92.01
-62.44
-74.50
12.05

15.62
7.59
30.11
23.43
13.71
18.09
3.93

2.00
2.00
2.00
2.00
2.00
2.00
0.00

4.45
27.58
6.23
28.22
32.22
19.74
5.94

7.69
4.24
13.63
6.80
14.51
9.37
2.00

0.75
0.70
0.82
0.72
0.73
0.74
0.02
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Table 5-4 (Cont.)
Sample
Treatment
No.
Ang-II+
1
PD123,319
2
3
4
5
Ave
SEM

c1

D1

D2

k1

k2

R2

-60.96
-65.41
-97.77
-44.89
-62.17
-66.24
8.65

14.09
15.78
26.65
12.85
16.29
17.13
2.46

2.00
2.00
2.00
2.00
2.00
2.00
0.00

0.93
17.98
10.19
5.23
14.16
9.70
3.05

23.89
19.90
4.73
7.35
7.17
12.61
3.87

0.81
0.77
0.80
0.73
0.66
0.76
0.03

In Table 5-5, the material constants were derived from the average model. The material
constants from the average model are still quite different than those from when the material
constants of each sample were averaged. It is very clear in the k2 constant where the average of
the k2 constants in the control group was 1.54 (Table 5-4) and the k2 for the average model is
7.96. The R2 in all treatment group was more than 0.75 which indicates a better fit.
Table 5-5. Material constants c1, D1, D2, k1, and k2 for the Modified Mooney-Rivlin
anisotropic constitutive model and the R2 of the fit for the average response based on identical
tensions.
Treatment
Control
Ang-I
Ang-II
Ang-I + Quinaprilat
Ang-I + Chymostatin
Ang-I + Losartan
Ang-II + Losartan
Ang-I + PD123,319
Ang-II + PD123,319

c1
-92.38
-65.72
-101.31
-78.69
-97.94
-64.06
-96.89
-86.33
-83.19

D1

D2

24.09
15.96
27.42
20.31
25.94
14.55
24.00
20.10
21.07

2.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00
2.00

k1

k2

2.70
1.85
6.49
4.28
4.11
8.06
8.97
13.58
2.77

7.96
10.63
10.79
11.29
11.51
8.92
19.30
8.62
16.56

R2
0.83
0.85
0.79
0.83
0.79
0.82
0.78
0.78
0.82

When the model fit was plotted with the experimental data, it can be seen that it does not
follow the shape of the stress strain curve (Figure 5-4). However, in this model the different
tension loading ratios are spreading as seen in the experimental data, suggesting that the
modified M-R is able to capture the cross-coupling between the fiber and cross-fiber directions
in the samples. The max 2nd P-K stress of the model fit in the circumferential and radial direction
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was also closer to that of the experimental data in comparison to the modified M-R isotropic
model.

Figure 5-4. The Modified Mooney-Rivlin anisotropic constitutive model fit along the
experimental data in the circumferential and radial direction for the average response of each
treatment

66

Fung-type model
The Fung-type model provided the best fit. The material constants for each individual
samples was consistent as can be seen by the low standard error (Table 5-6). All samples had a
much greater R2 than either of the modified M-R models.
Table 5-6. Material constants c, c1, c2, and c3 for the Fung-type constitutive model, R2 of the fit,
and anisotropy index (AI) for individual specimens by fitting the experimental data.
Treatment

Sample
No.

c(kPa)

c1

c2

R2

c3

AI

Control

1
2
3
4
5
Ave
SEM

0.519
0.828
0.650
1.025
0.768
0.758
0.085

9.273
13.507
15.021
23.489
36.907
19.639
4.896

5.750
10.866
12.657
12.816
9.974
10.413
1.284

3.427
0.143
2.263
3.983
2.432
2.450
0.658

0.789
0.929
0.917
0.953
0.968
0.911
0.032

0.723
0.807
0.863
0.612
0.315
0.664
0.097

Ang-I

1
2
3
4
5
Ave
SEM

1.020
0.446
1.252
1.117
0.834
0.934
0.140

13.428
26.804
22.536
18.514
55.868
27.430
7.445

6.171
8.946
3.497
11.811
22.981
10.681
3.373

0.634
-0.413
-1.407
-2.554
-9.307
-2.609
1.756

0.797
0.932
0.773
0.878
0.911
0.858
0.031

0.484
0.323
0.099
0.580
0.294
0.356
0.083

Ang-II

1
2
3
4
5
6
Ave
SEM

1.016
0.613
2.109
1.190
0.303
0.145
0.896
0.293

19.318
15.122
15.167
26.848
19.716
124.516
36.781
17.634

5.132
15.580
7.231
9.286
17.911
31.700
14.473
3.985

0.958
-1.391
-0.482
4.411
11.475
-4.411
1.760
2.274

0.897
0.830
0.799
0.853
0.847
0.958
0.864
0.023

0.300
0.968
0.460
0.438
0.942
0.227
0.556
0.131

Ang-I+
Quinaprilat

1
2
3
4
Ave
SEM

1.295
0.410
0.266
1.305
0.819
0.279

19.452
31.756
43.667
19.559
28.609
5.791

15.117
9.752
10.297
7.445
10.653
1.611

-0.026
-2.171
-0.128
-0.453
-0.695
0.501

0.867
0.977
0.920
0.756
0.880
0.047

0.777
0.256
0.234
0.366
0.408
0.126
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Table 5-6 (Cont.)
Sample
Treatment
No.

c(kPa)

c1

c2

c3

R2

AI

Ang-I+
Chymostatin

1
2
3
4
5
Ave
SEM

0.745
0.263
2.687
0.202
0.569
0.893
0.459

35.161
24.898
15.398
47.316
19.440
28.443
5.767

8.706
12.574
6.111
19.776
13.074
12.048
2.318

-0.210
-3.234
0.601
8.456
5.374
2.197
2.087

0.947
0.874
0.661
0.932
0.898
0.863
0.052

0.243
0.431
0.419
0.506
0.743
0.469
0.081

Ang-I+
Losartan

1
2
3
4
5
Ave
SEM

1.124
1.616
0.147
0.440
0.054
0.676
0.301

11.492
16.468
47.865
29.980
84.662
38.093
13.239

3.380
3.648
10.640
13.038
21.148
10.371
3.297

0.960
2.534
-2.500
-5.049
7.781
0.745
2.201

0.822
0.802
0.944
0.909
0.971
0.889
0.033

0.349
0.325
0.179
0.320
0.313
0.297
0.030

Ang-II+
Losartan

1
2
3
4
Ave
SEM

0.148
0.373
0.876
0.247
0.411
0.162

49.333
20.683
34.483
75.102
44.900
11.643

8.734
8.121
8.960
15.093
10.227
1.632

-0.303
4.874
0.080
4.835
2.372
1.436

0.833
0.912
0.903
0.960
0.902
0.026

0.172
0.508
0.262
0.249
0.298
0.073

Ang-I+
PD123,319

1
2
3
4
5
Ave
SEM

0.238
2.177
1.863
0.357
0.168
0.961
0.436

25.266
11.520
35.166
29.659
53.634
31.049
6.869

10.718
3.095
11.017
9.811
8.830
8.694
1.451

0.786
1.361
-4.903
5.883
2.424
1.110
1.744

0.875
0.792
0.872
0.926
0.955
0.884
0.028

0.442
0.346
0.202
0.442
0.201
0.326
0.054

Ang-II+
PD123,319

1
2
3
4
5
Ave
SEM

0.167
0.296
1.163
3.373
1.553
1.311
0.578

46.462
68.502
17.597
14.523
16.063
32.630
10.739

10.402
9.727
8.951
5.380
6.792
8.250
0.940

-2.232
-2.616
3.697
-0.476
1.733
0.021
1.198

0.906
0.943
0.823
0.750
0.747
0.834
0.040

0.185
0.108
0.594
0.349
0.479
0.343
0.090

In Table 5-7, the material constants were derived from the average model. The material
constants from the average model are very similar than those from when the material constants
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of each sample were averaged. The R2 in all treatment group was greater than 0.90 indicating
that the Fung-type model was an excellent fit for our experimental data.
Table 5-7. Material constants c, c1, c2, and c3 for the Fung-type constitutive model, R2 of the fit,
and anisotropy index (AI) for the average response based on identical tensions.
Treatment
Control
Ang-I
Ang-II
Ang-I + Quinaprilat
Ang-I + Chymostatin
Ang-I + Losartan
Ang-II + Losartan
Ang-I + PD123,319
Ang-II + PD123,319

c(kPa)
c1
c2
c3
R2
AI
0.729
18.099
10.770
1.528
0.934
0.627
0.758
24.682
9.308
-2.028
0.911
0.321
0.428
26.315
13.746
1.768
0.941
0.552
0.496
28.738
11.999
-1.437
0.946
0.387
0.433
26.628
12.961
1.208
0.911
0.509
0.264
29.547
9.158
1.052
0.952
0.334
0.326
41.367
10.903
1.132
0.934
0.283
0.599
28.018
8.701
0.146
0.922
0.314
0.665
26.950
9.675
0.294
0.913
0.366

When the model fit was plotted with the experimental data, it can be seen that it does
follow the shape of the stress strain curve (Figure 5-5). The model fit overlaps the experimental
data which shows that by using the material constants in the Fung-type model the responses the
aortic valve leaflets have to RAS can be modeled effectively.
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Figure 5-5. The Fung-type constitutive fit along the experimental data in the circumferential and
radial direction for the average response of each treatment
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Model Fit
The modified M-R isotropic model had a significantly lower R2 than the modified M-R
anisotropic model and the Fung-type model. This implies that it was the worst fit for the
experimental data. The Fung-type model had the highest R2.

Figure 5-6. The R2 fit for each constitutive model in the 9 treatment groups
5.3.3 Fung-type material constants
The material constants of the Fung-type model were used to plot a constant strain energy
contour over the strain field. This was done to verify the convexity of the strain energy function
over a range of strains (75). Figure 5-7 shows that the plots for all the average treatment groups
were all convex. This shows that the developed models are reliable. Contour plots were also
done on each individual sample, and all samples satisfied the strain energy convexity constraints.
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Figure 5-7. Constant strain energy contours plotted over the Green strain field for the average
response of each treatment
A non-linear anisotropy index (AI) can also be calculated using the material constants
derived from the Fung-type model which is more ideal than the linear anisotropy index from aim
1. An isotropic response would have an AI value close to one, and the smaller the value of AI the
more anisotropic the material is. The treatment groups had an average AI of 0.66 or lower
implying that all treatment groups kept their anisotropic qualities. Control had the highest
average AI at 0.664 for averaged samples and an AI of 0.637 for the average model. The AI was
the lowest when treated with receptor antagonist with the AI being less than 0.34 for averaged
individual samples in each treatment group. The AI was also low for the ang-I treated group and
the ang-I supplemented with enzyme inhibitors. Ang-II had a lower AI than the control, but a
higher AI than the ang-I treated group.
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Figure 5-8. The anisotropy index for the (A) enzyme and (B) receptor inhibitors calculated
using the Fung-type material constants. Red dotted line is the untreated, native leaflets.
5.3.4 Anisotropy and cross-coupling
The average stress-strain behavior was used to identify the anisotropy and cross-coupling
of the fibers (Figure 5-9). The anisotropy of a sample can be identified by the spacing between
the circumferential and radial experimental data, and the cross-coupling of the fibers can be
identified by analyzing the stress-strain behavior at the different loading ratios (addressed in aim
2). All treatment groups showed that the leaflets kept their anisotropic qualities as the spacing
between the circumferential and radial loading directions is clear. However, the cross-coupling
between the fibers was affected. In the control, a consistent spreading of the stress strain curves
of the tension ratios can be seen in both the circumferential and radial direction. When treated
with ang-I, the spreading decreases in the circumferential direction in comparison to the radial
direction, and when treated with ang-II, the spreading decreases in the radial direction in
comparison to the circumferential direction (Figure 5-9a,b). When ang-I was supplemented with
an ACE inhibitor (quinaprilat), the spreading in the radial direction was slightly less than in the
circumferential direction. Ang-I supplemented with a chymase inhibitor (chymostatin) had a
consistent spreading in both the circumferential and radial direction, and had a higher spreading
in the circumferential direction than the ang-I treated group (Figure 5-9a). When ang-I and ang73

II was supplemented with an AT-1R antagonist, it had a greater spacing between the
circumferential and radial direction than the ang-I and ang-II treated groups implying that they
were more anisotropic. The spreading of the stress strain curves in the circumferential and radial
direction was also consistent in the ang-I supplemented with AT-1R antagonist, however when
ang-II was supplemented with an AT-2R antagonist, the spreading was less in the circumferential
direction. When ang-I and ang-II were supplemented with an AT-2R antagonist, they showed
similar results to those supplemented with AT-1R antagonist.

Figure 5-9. 2nd P-K stress vs Green strain graph for tension ratios 1:1, 1:0.75, 0.75:1, 1:0.50,
0.50:1 for (A) enzyme and (B) receptor inhibitors of the average response based on identical
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5.4 Discussion
Aortic valve tissue is an anisotropic material, and an anisotropic constitutive model was
used to characterize the mechanical changes that occur due to RAS activation and inhibition. The
modified M-R isotropic constitutive model was the worst fit model for the aortic valve tissue
since tissue since it is a model used for isotropic materials. The R2 ranged from 0.10 to 0.64 for
individual samples and ranged from 0.27 to 0.44 in the average response model. The material
constants were also not consistent between the samples in the same treatment group nor were
they similar to the material constants derived from the average stress strain response model. The
modified M-R anisotropic constitutive model was a better fit than the isotropic model with an R2
ranging from 0.65 to 0.89 for each sample and an R2 ranging from 0.78 and 0.89 for the average
response for each treatment. However as it was derived from the Mooney-Rivlin model, the
stress-strain curve was linear which was not consistent with the experimental data. The Fungtype model was the best fit model with an R2 ranging from 0.75 to 0.98 for each individual
sample. In the average model, the R2 ranged from 0.91 to 0.95. When the model fit was graphed
with the experimental data, it had the same stress strain response. The Fung-type model was the
best constitutive fit to use to model the effects that RAS has on aortic valve tissue mechanics.
The contour plots showed that the Fung-type models were all convex verifying that they do
satisfy the strain energy convexity constraints. The AI calculated with the fung-type material
constants showed that the samples maintained their anisotropic qualities. When samples were
treated with receptor inhibitors, the AI was less than 0.5 implying that they were highly
anisotropic. The stress-strain graphs for each treatment group showed a clear spacing between
the circumferential and radial direction of loading, implying that the samples preserved their
anisotropic qualities under all treatment groups. The treatment groups where ang-I and ang-II
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were supplemented with an AT-1R had the greatest spacing in the stress-strain graphs and the
lowest calculated AI. Though the control had the highest AI, it was seen that it had the greatest
cross-coupling. This suggests that the stress in one direction affects the mechanical behavior in
the orthogonal direction. This cross-coupling affect is important as the mechanical behaviors in
the native valve are dependent of direction. In the next chapter, we will attempt to relate these
results to changes in tissue biology.
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CHAPTER 6 SPECIFIC AIM 3
Investigate the biological effects of mediators of the RAS system on aortic valves
6.1 Introduction
There are two phases during aortic valve disease progression: (I) the early initiation
phase, and (II) the propagation phase. The initiation phase involves valvular lipid deposition,
injury and inflammation (14). This phase has many similarities to atherosclerosis. The
propagation phase is where pro-calcific and pro-osteogenic factors drive the progression of the
disease (14). It is believed that the renin-angiotensin system (RAS) plays a role in the
progression of aortic valve disease as the angiotensin-converting enzyme (ACE) is upregulated
in calcified valves which facilitate angiotensin I (ang-I) to convert to angiotensin II (ang-II). This
then affects the valve via the angiotensin II type I receptor (AT-1R) by mediation of its
profibrotic effects. Angiotensin II type 2 receptor (AT-2R) mediation the antifibrotic and antiinflammatory effects of ang-II, but differentiation of expression favors AT-1R (14).
The extracellular matrix (ECM) is composed of three different layers: the fibrosa,
spongiosa, and ventricularis. The fibrosa is located near the aorta, the ventricularis near the left
ventricle, and the spongiosa between both those layers (13). In a healthy valve, the fibrosa is
predominately comprised of circumferentially-aligned type 1 collagen; the spongiosa is
composed of proteoglycans; and the ventricularis is composed of a radially-aligned
collagen/elastin network (30). Valve endothelial cells (VECs) are located in the outer layers of
the leaflet, and within these layers, valve interstitial cells (VICs) are arranged in subpopulations.
VECs maintain valve homeostasis, and the VICs secret ECM proteins to maintain valve strength
and stability (16).
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AS can proceed to calcific aortic valve disease (CAVD) from the initial cellular changes
seen in the stenotic valve leaflets. Differentiation of VICs to other cell types, including
myofibroblasts and osteoblasts, can be triggered from factors such as fluid shear stress,
inflammatory cytokines, and growth factors (28). Inflammation in the valve is triggered by
endothelial damage which release pro-inflammatory cytokines such as transforming growth
factor-beta-1 (TGF-β1). This inflammatory activity activates the cells within the valve, and VICs
differentiate from fibroblast-like cells to myofibroblast cells (5). As the disease progresses, VICs
become further activated and differentiate into osteoblast-like bone-forming cells and respond to
osteogenic mediators such as bone morphogenetic proteins (BMPs) which are member of the
TGF-β superfamily (16). Calcified valves have an increased presence of TGF-β1 in the ECM and
may contribute to the progression of CAVD by initiating apoptosis (6, 39). VECs may also
undergo differentiation into osteoblast-like bone-forming cells through endothelial-tomesenchymal-transformation (EndoMT) in which they lose their endothelial cell properties.
These transformed VECs begin to acquire phenotypic characteristics of myofibroblasts and
express myofibroblast-specific markers such as α-SMA, Type I collagen, and vimentin. Similar
to VICs, they can be stimulated by osteogenic mediators such as TGF-β and undergo osteogenic
differentiation and fibrosis (16).
The increased production of collagen and the disorganization of the fibers are an
indication of CAVD. In a diseased valve, the structure of the valve trilayer is disturbed. The
crosslinking of the fibers is affected in the fibrosa layer while collagen production is affected in
the other layers. In the fibrosa layer, fibers are shorter than that of those in a healthy valve, and in
the spongiosa layer, the collagen fibers appear to become wider and denser. There are typically
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more immature fibers in the spongiosa and are more mature fibers in the fibrosa during CAVD
progression (30).
As phenotypic changes and alterations in tissue collagen are integral during the valve
disease process, this aim focuses on investigating these biological effects that RAS has on the
leaflet tissue. The phenotypic changes that VICs undergo due to RAS were investigated via
immunohistochemistry, and the alterations in collagen fibers were investigated via quantitative
polarized light microscopy and Picrosirius red staining.
6.2 Materials and Methods
Protocols can be found in Appendix A. MATLAB codes and instructions can be found in
Appendix B.
6.2.1 Tissue treatment
Fresh porcine hearts (3-6 months old) were provided by Cockrum’s Custom Meat
Processing and Taxidermy (Rudy, AR) or Braunschweig Processing (Neosho, MO), both FDAapproved abattoirs. Samples were transported in cold, sterile dPBS. The hearts were then
dissected aseptically, and the left, right, and non-coronary aortic valve leaflets were pooled and
washed in sterile dPBS. They were then supplemented with 150 U/ml penicillin/streptomycin in
PBS for 10 mins.
The leaflets were then incubated in DMEM, 2% FBS, 150 U/ml P/S, and HEPES, and
treated with the following. The binding of ang-I and ang-II to the receptors was investigated by
inhibiting the AT-1R or AT-2R receptor subtypes. The samples were treated with either AT-1R
inhibitor losartan (1μM) or AT-2R inhibitor PD123-319 (1μM) for 24 hours before being treated
in combination with ang-I (10 μM) or ang-II (10 μM) for an additional 48 hours (69). The local
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conversion of ang-I to ang-II was investigated by inhibiting ACE or chymase. Samples were
treated with ACE inhibitor quinaprilat (1 μM) or chymase inhibitor chymostatin (10 μM) (69).
Following treatment, samples for immunohistochemistry and picrosirius red (PSR)
staining were immediately placed in optimum cutting temperature (OCT) compound and flash
frozen at -80˚C. Tissues for quantitative polarized light microscopy (QPLI) were obtained from
the biaxial testing experiments (Aims 1 and 2). The tissues were placed in a cryopreservation
agent and flash frozen at -80˚C.
6.2.2 Immunohistochemistry
Immunohistochemistry was performed against the primary antibodies rabbit anti- α-SMA
(1:100, Abcam) and mouse anti-calponin (1:100, Abcam) in 2% goat serum and 1x PBS. Either
1:200 Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibodies (Life Technologies)
was used to label primary antibodies of the proteins of interest. Secondary solution also
contained 1:200 DAPI and 1x PBS.
Briefly, 5 µm thick sections were cryosectioned in the transverse plane and stored in 80˚C freezer until staining. Slides were fixed in ice-cold acetone for 5 minutes and placed on a
paper towel for 10 minutes to allow acetone to evaporate. A square was placed around each
section with a water/alcohol proof marker and let dry for 10 minutes. Slides were rehydrated in
1x PBS for 5 minutes. Slides were placed in a humid chamber and 195 µL of 20% goat serum in
1x PBS was placed on each section as a blocking agent. They were incubated at 37 ˚C for 60
minutes. Blocking solution was removed by carefully holding the coverslip perpendicular to the
bench and edge blotted with a kimwipe. 195 µL of desired primary antibody solution was placed
on each section and incubated at room temperature for 2 hours in the humid chamber. Slides
were washed by dipping three times in a staining jar containing 1x PBS and let sit for 5 minutes.
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This was repeated three times in fresh 1x PBS. Slides were placed back in humid chamber and
195 µL of secondary antibody was placed on each sectioned. Samples were incubated for 2 hours
at room temperature. Slides were washed again as stated before but in the dark to not photobleach the sample. Samples were mounted with pro-long gold and mounted media was allowed
to cure for 24 hours. A thin layer of nail polish was placed around the cover slip and allowed to
dry for 2 hours. Separate slides were stained with secondary antibody only and served as
negative controls to assess non-specific binding of the secondary reagent. Slides were stored in
the -20˚C freezer until imaging. Images were acquired via a regular epifluorescence microscope.
6.2.3 Picrosirius red (PSR) staining
5 µm thick sections were cryosectioned in the transverse plane and stored in the -80˚C
freezer until staining. Slides were fixed in cold acetone for 5 minutes and then washed under
running tap water for 10 minutes. Slides were then rinsed by dipping into distilled water three
times. They were then placed on a paper towel, a few drops of phosphomolybdic acid 0.2%
aqueous were placed on each tissue section, and treated for 5 minutes. Slides were placed in a
glass staining jar containing 100ml of sirius red, 0.1% in saturated picric acid, for 90 minutes.
Slides were washed for 2 minutes in 0.01N hydrochloric acid and then rinsed in 70% alcohol for
45 seconds. Slides were dehydrated by placing in 95% ethanol for 3 minutes two times and
100% ethanol for 3 minutes two times. They were cleared in xylene for 5 minutes two times and
then mounted with cytoseal. Mounting medium was allowed to cure for at least 24 hours before
imaging.
PSR stained samples were imaged via polarized light microscopy, and were subsequently
analyzed using a custom MATLAB (Mathworks Inc.) script based on a published algorithm to
quantify the red, orange, yellow, and green pixel count by their respective hue and saturation
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levels (68). The colors red, orange, yellow, and green correspond to the thickness of the collagen
fibers present from thickest to thinnest respectively. The pixel count for each color was divided
by the total pixel count for the four colors to acquire the percentage of each color present in the
image.
6.2.4 Quantitative polarized light imaging (QPLI)
Tissue was in washed in dPBS after biaxial testing and placed in a solution of 85%
DMEM, 5% FBS, and 10% dimethyl sulfoxide (DMSO) to prevent ice crystal from damaging
the tissue when frozen, as a cryopreservation agent. Samples were flash frozen at -80˚C. Prior to
imaging, samples were defrosted by placing at room temperature for 30mins.
A custom-built trans-illumination based QPLI microscope (Olympus BX51, Olympus Corp.,
Tokyo, Japan) setup was used which utilizes a rotating polarizer and circular analyzer (83, 84).
Images were collected using a 20x objective (UPlanFL N 20x, 0.5 NA, Olympus Corp.) and data
was collected using a 10x objective (UPlanFL N 10x, 0.3 NA, Olympus Corp.). Full field images
were produced via image stitching. The images were analyzed using a custom MATLAB code.
Average light retardation was measured as proportional to the amount of collagen in the tissue. A
rotating polarizer and circular analyzer enabled the assessment of variance in collagen fiber
alignment as a measure of collagen fiber orientation.
6.2.5 Statistical methods
Results are reported as mean with standard error. Data was first analyzed for normality
using the Shapiro-Wilk normality test. For the enzyme inhibition, a one way ANOVA was run
using multiple comparisons versus the diseased (ang-II) state using the Dunnett’s Method. For
the receptor inhibition, a two way ANOVA was run using all pairwise multiple comparison
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follow by the Tukey post hoc test for normally distributed data. Analyses were performed using
Sigma Plot. A p value of less than 0.05 was used to indicate statistical significance.
6.3 Results
6.3.1 Cellular phenotypic changes in tissue
Via immunohistochemistry (IHC), we observed that activation or inhibition of the RAS
pathway altered the valve cell phenotype in the valve tissue. α-SMA and calponin were not
expressed in the control samples (Figure 6-1a.I,II & b.I,II), implying that when treated with only
media, the cells in the tissue were not being activated. When the tissue was treated with ang-I or
ang-II, α-SMA and calponin expression was upregulated, suggesting that the cells were being
activated and becoming more contractile and myofibroblast-like (Figure 6-1a.III-VI & b.III-VI).
Additionally, the upregulation of these markers in the ang-I treated groups suggests that ang-I is
being converted to ang-II locally on the valve leaflet. To validate that enzymes are present
locally to convert ang-I to ang-II, valves leaflets were treated with an ACE and chymase
inhibitors, quinaprilat and chymostatin respectively, prior to and during treatment of ang-I. The
upregulation of α-SMA and calponin seen when treated with ang-I alone was mitigated in the
ACE and chymase inhibitor groups. This suggests that ang-I activates the cells due to it
converting to ang-II locally through either ACE (Figure 6-1a.VII,VIII) or an ACE-independent
pathway (Figure 6-1a.IX,X).
When the tissue was treated with an AT-1R inhibitor (losartan) in conjunction with ang-I
or ang-II, α-SMA and calponin were not expressed (Figure 6-1b.VII-X). This suggests that by
inhibiting the ability for ang-II to bind to AT-1R the activation of the cells was being mitigated.
When the tissue was treated with an AT-2R inhibitor (PD123,319) in conjunction with ang-I or
ang-II, α-SMA and calponin were expressed (Figure 6-1b.XI-XIV). This suggests that by
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inhibiting the ability for ang-II to bind to AT-2R, ang-II is binding to AT-1R causing the
activation of the cells. It should be noted that this last observation is supported in the literature as
the AT-1R receptor subtype is known to be pro-atherosclerotic and AT-2R antagonizes its effects
(55).

Figure 6-1. Representative micrographs of aortic valve leaflets immunohistochemically labeled
with α-SMA (green), calponin (red) and DAPI (blue) treated with (a) enzyme inhibitors and (b)
receptor inhibitors. Arrows indicate expressed areas. (scale bar=100µm)
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6.3.2 Alterations of collagen structure
Next, we wanted to relate the mechanical observations from aims 1 and 2 to possible
alterations in the collagen structure of the leaflets. To do so we utilized two techniques that
leverage the birefringence of collagen fibers: picrosirius red staining (PSR) and quantitative
polarized light imaging (QPLI).
In the enzyme inhibition treatment groups, ang-I (21.53±0.77) and ang-II (22.80±1.77)
had a higher percentage of the thinnest fibers than the control (17.35±3.42). When ang-I was
supplemented with the ACE (19.77±3.16) and chymase (20.32±2.57) inhibitors, they showed a
higher percentage of thinnest fibers to the control but a lower percentage than the ang-I and angII treated groups (Figure 6-2b). The control (27.62±1.45), ang-I (28.24±1.52), and ang-II
(28.63±.097) treatment groups showed a similar percentage of thin intermediate fibers. The ang-I
supplemented with ACE (25.76±2.55) and chymase (26.52±1.47) inhibitors showed a lower
percentage of thin intermediate fibers (Figure 6-2c). The control (44.97±4.68) and ang-I
supplemented with ACE (45.52±4.69) and chymase (46.84±4.02) inhibitors treatment groups had
a similar percentage of thinnest and thin intermediate fiber percentage combined while the ang-I
(49.77±0.91) and ang-II (51.43±2.51) treated samples showed a higher thinnest and thin
intermediate fiber percentage combined (Figure 6-2a). The ang-I (36.43±0.60) and ang-II
(37.18±2.01) treated group had a lower percentage of thick intermediate fibers than the control
(40.29±1.80). The ang-I supplemented with ACE (38.18±2.02) and chymase (38.74±2.09)
inhibitors had a lower percentage of thick intermediate fibers than the control but a higher
percentage than the ang-I and ang-II treated groups (Figure 6-2d). The ang-I (13.81±1.47) and
ang-II (11.39±1.15) treated group had a lower percentage of thickest fibers than the control
(14.74±2.89). The ang-I supplemented with ACE (16.30±2.83) and chymase (15.70±2.96)
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inhibitors had a higher percentage of thickest fibers than the control, ang-I and ang-II treated
groups (Figure 6-2e). The control (55.03±4.68) and ang-I supplemented with ACE (54.48±4.69)
and chymase (54.43±4.99) inhibitors treatment groups had a similar percentage of thickest and
thick intermediate fiber percentage combined while the ang-I (50.23±0.91) and ang-II
(48.57±2.51) treated samples showed a lower percentage of thickest and thick intermediate fiber
percentage combined (Figure 6-2a). This indicates that when samples are treated with ang-I and
ang-II there is more newly synthesized collagen fiber, and when the conversion of ang-I to ang-II
is inhibited by either ACE or an ACE-independent pathway, there is more mature fiber and
similar to what is seen when tissue is not treated with ang-I or ang-II.

Figure 6-2. (A) Quantification of picrosirius stain for enzyme inhibitors of collagen fiber
thicknesses of (B) thinnest, (C) thin intermediate, (D) thick intermediate, and (E) thickest
collagen fiber present. Red dotted line is the untreated, native leaflets.
In the receptor inhibition treatment groups, ang-II (28.88±4.62) had a higher percentage
of the thinnest fibers than the control (21.14±1.27) while ang-I (19.42±3.21) had a similar
percentage of thinnest fibers than the control. When ang-I was supplemented with AT-1R
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antagonist (22.46±5.77), there was a higher percentage of thinnest fibers than the ang-I treated
group, and when ang-II was supplemented with an AT-1R antagonist (19.94±5.26), it had a
lower percentage of thinnest fibers and a similar percentage than the control. When ang-I was
supplemented with an AT-2R antagonist (20.75±7.66), it had a similar percentage of thinnest
fibers than the control and ang-I, but when ang-II was supplemented with AT-2R antagonist
(25.87±4.81), it had a higher percentage of thinnest fibers than the control but lower than the
ang-II treated group (Figure 6-3b). The control (34.07±1.57) had the highest percentage of thin
intermediate fibers. The ang-I (26.83±.85) and ang-II (28.28±2.81) treated group had a lower
percentage of thin intermediate fibers than the control. When ang-I was supplemented with an
AT-1R antagonist (27.68±3.06), it had a similar percentage of thin intermediate fibers than the
ang-I treated group. When ang-II was supplemented with AT-1R antagonist (25.57±3.69), it had
a lower percentage of thin intermediate fibers than the ang-II treated group. When ang-I was
supplemented with an AT-2R antagonist (26.57±2.8), it showed a similar percentage of thin
intermediate fibers than the ang-I treated group. When ang-II was supplemented with AT-2R
antagonist (26.84±2.34), it had a similar percentage of thin intermediate fibers than the ang-II
treated group (Figure 6-3c). The ang-I (46.25±2.52) treatment group had a lower percentage of
thinnest and thin intermediate percentage combined than the control (55.20±2.68). The ang-II
(57.16±7.27) treatment group had a higher percentage of thinnest and thin intermediate
percentage combined than the control and ang-I. The ang-I supplemented with AT-1R antagonist
(50.14±8.69) treatment group had a similar percentage of thinnest and thin intermediate fiber
percentage combined than the ang-I treatment group. The ang-II supplemented with AT-1R
antagonist (45.51±8.94) treatment group had a lower percentage of thinnest and thin intermediate
fiber percentage combined than the ang-II treatment group. The ang-I supplemented with AT-2R
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antagonist (47.32±10.42) treatment group had a similar percentage of thinnest and thin
intermediate fiber percentage combined than the ang-I treatment group and lower percentage
than the control group. The ang-II supplemented with AT-2R antagonist (52.72±6.34) treatment
group had a lower percentage of thinnest and thin intermediate fiber percentage combined than
the control and ang-II treatment group (Figure 6-3a). Ang-II (33.04±3.41) had a lower
percentage of the thick intermediate fibers than the control (38.42±2.45) while ang-I
(40.24±2.62) had a higher percentage of thick intermediate fibers than the control. When ang-I
was supplemented with AT-1R antagonist (39.15±4.53), there was a similar percentage of thick
intermediate fibers than the ang-I treated group, and when ang-II was supplemented with an AT1R antagonist (40.72±4.92), it showed a higher percentage of thick intermediate fibers as the
ang-II treated group. When ang-I was supplemented with an AT-2R antagonist (39.38±5.37), it
had a similar percentage of thick intermediate fibers than the ang-I treated group, and when angII was supplemented with AT-2R antagonist (35.79±3.15), it had a higher percentage of thick
intermediate fibers than the ang-II treated group but lower percentage than the control (Figure
6-3d). The control (6.38 ±0.76) had the lowest percentage of thick fibers. The ang-I (13.52±0.19)
and ang-II (9.80±3.98) treated groups had a higher percentage of thick fibers than the control.
When ang-I was supplemented with an AT-1R antagonist (10.71±4.29), it had a lower
percentage of thick fibers than the ang-I treated group. When ang-II was supplemented with AT1R antagonist (13.77±4.07), it had a higher percentage of thickest fibers than the ang-II treated
group. When ang-I was supplemented with an AT-2R antagonist (13.29±5.06), it had a similar
percentage of thickest fibers than the ang-I treated group and higher percentage than the control.
When ang-II was supplemented with AT-2R antagonist (11.49±3.38), it had a higher percentage
of thickest fiber percentage than the control and ang-II treated group (Figure 6-3d). The control
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(44.80±2.68) and ang-II (42.84±7.27) treatment group had a similar percentage of thickest and
thick intermediate percentage combined, and ang-I (53.75±2.52) and a higher percentage of
thickest and thick intermediate than the control and ang-II treated group. When ang-I was
supplemented with an AT-1R antagonist (49.86±8.69), it had higher thickest and thick
intermediate percentage combined than the control and lower percentage to the ang-I treated
group. When ang-II was supplemented with an AT-1R antagonist (54.49±8.94), it had a higher
thickest and thick intermediate percentage combined than the ang-II and control. When ang-I
was supplemented with an AT-2R antagonist (52.68±10.42), it had a similar thickest and thick
intermediate percentage combined than the ang-I treated group and higher percentage than the
control. When ang-II was supplemented with an AT-2R antagonist (47.28±6.34), it had higher
thickest and thick intermediate percentage combined than the control and lower percentage than
the ang-II treated group (Figure 6-3a).

Figure 6-3. (A) Quantification of picrosirius stain for receptor inhibitors of collagen fiber
thicknesses of (B) thinnest, (C) thin intermediate, (D) thick intermediate, and (E) thickest
collagen fiber present. Red dotted line is the untreated, native leaflets.
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The QPLI set up uses a rotating polarizer and a circular analyzer allowing for the
quantification of fiber amount and orientation via the measurement of average retardation
(collagen amount) and the local directional variance (variance of the collagen orientation). The
ang-I (35.83±4.26) treated group had a lower average retardation than the control (43.68±5.53)
while the ang-II (47.55±3.17) treated group had a higher average retardation than the control.
The ang-II treated group had the overall greatest average retardation (Figure 6-4a,b). When angI was supplemented with the ACE (40.98±4.95) and chymase (37.27±4.08) inhibitors, they
showed a lower average retardation than the control and ang-II treated group but a higher
average retardation than the ang-I treated group (Figure 6-4a). When ang-I was supplemented
with an AT-1R antagonist (44.35±3.02), it had a higher average retardation than the ang-I treated
group but similar average retardation than the control. When ang-II was supplemented with an
AT-1R antagonist (41.72±3.06), it had a lower average retardation than the control and ang-II
treated group. Ang-I supplemented with an AT-2R antagonist (28.20±4.43) had a lower average
retardation than the control and ang-I treated group. Ang-I supplemented with an AT-2R
antagonist (38.05±2.86) had a lower average retardation than the control and ang-II treated group
(Figure 6-4b).
The ang-I (0.064+0.025) treated group had a lower higher local directional variance than
the control (0.032±0.14) while the ang-II (0.022±0.007) treated group had a lower local
directional variance than the control (Figure 6-4c,d). When ang-I was supplemented with an
ACE (0.037±0.015) and chymase (0.052±0.017) inhibitors, it had a lower local directional
variance than the ang-I treated group but higher local directional variance than the control and
ang-II treated group (Figure 6-4c). When ang-I was supplemented with an AT-1R antagonist
(0.035±0.020), it had a higher local directional variance than the control but lower variance than
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the ang-I treated group. When ang-II was supplemented with an AT-1R antagonist
(0.044±0.013), it had a higher local directional variance than the control and ang-II treated
group. When ang-I was supplemented with an AT-2R antagonist (0.157±0.035), it had the
highest local directional variance. Ang-II supplemented with an AT-2R antagonist (0.053±0.020)
had a higher local directional variance than the control and ang-II treated group (Figure 6-4d).

Figure 6-4. Quantification of the average retardation (collagen amount) in the (A) enzyme and
(B) receptor inhibitors and local directional variance (variance of collagen orientation) in the
(C) enzyme and (D) receptor inhibitors using quantitative polarized light imaging. Red dotted
line is the untreated, native leaflets.
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6.4 Discussion
Immunohistochemistry (IHC) showed that RAS affects the phenotypic properties of the
cells in the aortic valve tissues. Tissue treated with ang-I and ang-II showed an upregulation in
expression of α-SMA and calponin implying that cells were becoming activated. When ang-I
was supplemented with an ACE and chymase inhibitor, these effects were mitigated implying
that by inhibiting the ability for ang-I to convert to ang-II cells maintain their quiescent state.
This also strongly suggests that the effects seen by treating samples with ang-I is due to its
ability to convert locally into ang-II. Ang-I and ang-II supplemented with an AT-1R receptor
inhibitor also mitigated the effects of ang-I and ang-II mediated pathological signaling. This
result indicates that the quiescent state can be maintained by inhibiting the binding of ang-II to
AT-1R. When ang-I and ang-II were supplemented with an AT-2R antagonist, there was an
upregulation of α-SMA and calponin. This indicates that when the ability for ang-II to bind to
AT-2R is inhibited, ang-II will bind to AT-1R causing the cells to become activated.
The sample size for picrosirius red (PSR) staining was small (n=3) and so it was
underpowered and did not show significant difference. However, PSR showed various trends,
and the sample size will be increased to verify its significance. Tissue treated with ang-I and angII had a higher percentage of thin collagen fibers suggesting more newly synthesized fibers. This
suggests that there is an increase in production of collagen which is a hallmark for early
progression of valve fibrosis. When ang-I was supplemented with an ACE and chymase
inhibitor, there was a similar percentage of thin fibers than that of the control suggesting that by
inhibiting the ability of ang-I to convert to ang-II, the pathological increased production of
collagen fiber is mitigated.
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When ang-II was supplemented with an AT-1R antagonist, there was a lower percentage
of thin fibers than the ang-II treated group, and when supplemented with an AT-2R antagonist, it
had a similar percentage of thin fibers as the ang-II group. Overall, this suggested that by
inhibiting that the binding of ang-II to AT-2R increases pathologic-like collagen production as
seen in the ang-II groups alone.
In contrast to PSR, QPLI was conducted on tissue after biaxial mechanical testing. QPLI
showed the maximum collagen amount in Ang-II, which matches PSR. Perhaps ang-II treatment
increased collagen synthesis while reducing collagen degradation. AT-2R inhibitor seemed to
reduce collagen amount significantly. QPLI showed that there was an increase in the variance of
the collagen orientation in ang-I treated samples. When ang-I was supplemented with an ACE
and chymase inhibitor, the collagen orientation was similar to that of the untreated leaflet. Ang-I
and ang-II supplemented with an AT-2R antagonist also showed an increase in variance of
collagen orientation while ang-I and ang-II supplemented with AT-1R had a similar directional
variance than the control. This suggests that the binding of ang-II to AT-1R increases the
disorganization of the fibers. By inhibiting the ability for ang-I to convert to ang-II and inhibiting
the ability for ang-II to bind to AT-1R these effects are mitigated. There may be increased
collagen degradation in the AT-2R inhibitor groups caused by elevated signaling at the AT-1R.
The activation of VICs, an increase production of collagen fibers, and disorganization of
collagen fibers are hallmarks of early disease progression. Two days of treatment were enough to
alter phenotype, but not long enough to observe significant changes at the collagen fiber level. In
the future, total collagen amount will be analyzed using a hydroxyproline assay.
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CHAPTER 7 LIMITATIONS AND FUTURE DIRECTIONS
One of the limitations in the study was the amount of time the samples were treated.
More time in culture was needed as there were very little changes in collagen observed. Though
the effects could be seen when limiting ang-II to bind to just one receptor, the time given for
ang-II to bind to either receptor when given the option to bind to both AT-1R and AT-2R was
not enough. Though ang-II is prone to bind to AT-1R, a longer time period is needed to increase
the potential binding to AT-1R over AT-2R. The study had to be limited to a 48 hour treatment
of ang-I and ang-II as samples are more prone to become contaminated if treated for longer
periods of time.
Another limitation was the mechanical testing in the current biaxial system. Our current
loading cells are not capable of detecting very low tensions properly. The load cells in the
upgraded biaxial system will allow for detection of the lower tensions seen in the toe region.
This would allow for more sensitive reading of the stiffness in the toe region and also help in
obtaining better constitutive model fits. In addition, our system was displacement based. This
means that to stretch the samples to the desired tension multiple tests had to be run to determine
the correct displacement needed for it. In addition, the samples were stretched close to their
desired tension such as 90 N/m, but the tension could vary approximately from ± 7N/m on
certain samples. This could affect the calculations using the max green strain such as anisotropy
index and areal strain.
The alterations of the collagen measured using QPLI was done on samples after the
biaxial testing. Using QPLI while running the mechanical tests would be ideal as it would
provide information on the instantaneous alterations of the collagen fibers in real time. In
addition, QPLI was done on a portion of the sample tested and not on the sample as a whole. The
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current biaxial system did not have the ability to do this, but the biaxial system which we are
currently upgrading will have the ability to do QPLI during the mechanical testing and image the
sample as a whole and not just a small portion. In the future, the new biaxial system will
eliminate these limitations seen during the mechanical testing and QPLI performed during this
thesis.
In this study, we sought to investigate the affects that RAS has on aortic valve tissue
mechanical and phenotypic properties. In the future, we will investigate how RAS affects the
aortic valve at the cellular level. We conducted some preliminary studies on the effects that RAS
has on valvular interstitial cells (VICs), but there were a few limitations in the study.
Traditionally, VICs were grown in media containing basal Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). However, studies have shown that
by growing VICs in this “classical DMEM” VICs become activated and exhibit myofibroblast
qualities instead of the fibroblast-like qualities which quiescent VICs have (85). To overcome
this, a study conducted by Latif, et al showed that growing VICs in DMEM supplemented with
2% FBS, 50 ng/ml insulin, and 10 ng/ml fibroblast growth factor-2 (FGF2) allow the cells to
maintain their fibroblast phenotype (85). In our preliminary studies, we cultured VICs in this
“fibroblast media” and treated them with ang-I, ang-II, ang-I supplemented with an AT-1R or
AT-2R antagonist, and ang-II supplemented with an AT-1R or AT-2R antagonist in the same
manner as we treated the tissue in our study. However, culturing cells in fibroblast media
presented us with some limitations in the thin-film experiment and western blots. Thin-film
experiments allow us to measure the contraction and relaxation of cells when stimulated with
endothelin-1 (ET-1) and relaxed with HA-1077. In a previous study conducted by our lab, we
were able to measure the contraction and relaxation of VICs treated with ang-II (68). In that
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study, VICs had been cultured in classical DMEM. When we tried to conduct thin film
experiments in VICs cultured in fibroblast media, the VICs were not strong enough to lift the
thin film when they were stimulated. It the lifting and curling of the thin film that allows the
measurement of the VICs contractility and relaxation. To overcome this limitation, we will be
conducting traction force microscopy (TFM) to measure the mechanical properties of VICs
instead of the thin film experiment. In TFM, VICs are cultured on an acrylamide membrane
containing fluorescent beads. Using a multi-photon microscope, the beads can be tracked when
the VICs are stimulated instead. The VICs in our preliminary study were also treated in a static
state which means that the VICs were not undergoing strain as they are within their native
environment in the body. When western blotting was done to determine the expression of
vimentin and calponin, there was no significant difference between the expression of calponin or
vimentin in the treatment groups (Figure 7-1). To overcome this limitation, VICs will be
exposed to mechanical strain in all future studies.

Figure 7-1. (A) Western blot analysis of VICs treated with receptor inhibitors for vimentin and
calponin. Expression of (B) vimentin and (C) calponin normalized with β-actin.
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CHAPTER 8 SUMMARY AND CONCLUSIONS
The objective of this study was to investigate how renin-angiotensin signaling (RAS)
pathway mediators affect the biological and mechanical function of the aortic valve tissue by
further understanding the ACE or ACE independent pathway in which angiotensin I (ang-I)
converts to angiotensin II and also the binding of ang-II to type 1 ang-II receptor (AT-1R) and
type 2 ang-II receptor (AT-2R). This was done so by treating porcine aortic valve tissues with
ang-I, ang-II, ang-I+ACE inhibitor (quinaprilat), ang-I+chymase inhibitor (chymostatin), angI+AT-1R antagonist (losartan), ang-II+AT-1R antagonist, ang-I+AT-2R antagonist (PD123,319),
ang-II +AT-2R antagonist, or vehicle (DMEM).
In the first aim, aortic valve tissue was exposed to biaxial mechanical testing after being
pre-treated. The samples were tested at five different tension load ratio protocols at a maximum
tension of 90 N/m: Tcirc:Trad – 1:1, 1:0.75, 1:0.5, 0.75:1, 0.5:1. Key findings from this study are
outlined below:


The cross-coupling of the fibers was affected as can be seen by the spreading of the
stress-strain curves in the 2nd P-K stress vs Green strain graph



The anisotropic properties were not affected as can be seen by the clear spacing between
the circumferential and radial curves in the 2nd P-K stress vs Green strain graph and a
strain anisotropy index of less than 0.6.
In most cases, the mechanical properties exhibited by enzyme inhibitors were similar to

the control which could suggest that when ang-I is not able to convert to ang-II it can sustain its
native properties. However the mechanical properties exhibited by ang-I and ang-II were similar
to the control as well. Though ang-II is more prone to bind to AT-1R, the amount of treatment
time may not have been sufficient to increase the binding of AT-1R over AT-2R. However,
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limiting the ability to bind to just one receptor did show a trend in mechanical behavior. In most
cases, the tangent modulus was lower in samples treated with an AT-1R antagonist than those
with an AT-2R antagonist implying that the binding of ang-II to AT-1R increases the stiffness of
the sample. There was a high variation in the extensibility, and it seems to be highly unreliable
because small changes in the high TM fit will result in wide changes in where the line cuts the xaxis, thereby affecting extensibility.
In specific aim 2, three phenomenological constitutive models were utilized to
characterize the biomechanical changes that occur due to RAS mediators on aortic valves: (1)
modified Mooney-Rivlin (M-R) isotropic model, (2) modified M-R anisotropic model, and (3)
Fung-type model. Typically M-R constitutive models are used to characterize the behavior of
isotropic materials, but the modified anisotropic model adds an anisotropic term to the modified
M-R isotropic model. The Fung-type constitutive model is typically used to characterize the
behavior of a non-linear anisotropic material. Material constants for each model was derived for
each individual sample and averaged, and material constants were also calculated using data
from an average stress strain response model. Key findings from this study are outlined below:
(1) The modified Mooney-Rivlin (M-R) isotropic model fit the experimental data the least
having an R2 ranging from 0.27 to 0.44 in the average response model for the treatment
groups. It was the least adequate for the experimental data.
(2) The modified M-R anisotropic model fit the experimental data better than the isotropic
model having an R2 ranging from 0.78 and 0.89 for the average response for each
treatment. However, it still had a linear-like stress-strain response for our strain range,
making it inadequate for the experimental data.
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(3) The Fung-type model had the best fit model with an R2 ranging from 0.91 to 0.95 in the
average response model for the treatment groups. The curve was also non-linear as seen
in the experimental data.
The material constants derived from the Fung-type model can give us some insight on the
convexity of the model and the anisotropy of the samples. The contour plots showed that the
Fung-type models were all convex verifying that they do satisfy the strain energy convexity
constraints. The treatment groups had an average AI of 0.66 or lower implying that all treatment
groups kept their anisotropic qualities. Limiting the ability to bind to just one receptor did show a
trend in the AI derived from the Fung-type model in which the AI was the lowest when treated
with receptor antagonist implying that they are highly anisotropic. Samples treated with receptor
inhibitors had the greatest spacing between curves and lowest AI implying that the samples
became highly anisotropic.
It was clear that an anisotropic model would provide a better model fit to characterize the
biomechanical changes that occur due to RAS mediators on aortic valves. Though the modified
M-R anisotropic model was a good fit, a non-linear model such as the Fung-type model was the
best phenomenological constitutive model.
In specific aim 3, we sought to understand the biological effects that mediators of the
RAS system had on aortic valve tissues. The phenotypic changes the cells undergo on the tissue
due to RAS were investigated via immunohistochemistry (IHC), and the changes that collagen
fibers undergo were investigated with quantitative polarized light microscopy (QPLI) and
picrosirius red staining (PSR).
VICs were becoming activated when aortic valve tissue was treated with ang-I, ang-II,
and ang-I or ang-II supplemented with an AT-2R as an upregulation of α-SMA and calponin was
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seen. The upregulation in expression of α-SMA and calponin was mitigated in ang-I or ang-II
supplemented with an AT-2R antagonist and ang-I supplemented with an ACE or chymase
inhibitor implying that cells are maintaining their quiescent form.
PSR showed an increase in production of collagen fibers in tissue treated with ang-I and
ang-II. When the binding of AT-1R was impeded, there was lower production of collagen fibers,
and when the binding of AT-2R was impeded, there was higher production of collagen fibers.
This suggests that the binding of ang-II to AT-1R increased the collagen production.
QPLI showed an increase in disorganization of collagen fibers. Ang-I and ang-II
supplemented with an AT-2R antagonist also showed an increase in variance of collagen
orientation while ang-I and ang-II supplemented with AT-1R had a similar directional variance
than the control. This suggests that the binding of ang-II to AT-1R increases the disorganization
of the fibers. QPLI showed the maximum collagen amount in Ang-II, which matches PSR.
Perhaps ang-II treatment increased collagen synthesis while reducing collagen degradation.
This study showed that ang-I and ang-II activated VICs, increased production of collagen
fibers, and increased disorganization of collagen fibers. By inhibiting the binding of ang-II to
AT-2R and only to AT-1R, these same effects were shown. When ability for ang-I to convert to
ang-II and inhibiting the ability for ang-II to bind to AT-1R was inhibited, these effects are
mitigated.
In this study, we were able to see that ang-I had an effect on the aortic valve which leads
to believe that it can be converted locally. Ang-II may increase in the plasma during illnesses
such as hypertension (66), but ang-II production could also increase in the heart via ACE or
chymase locally. We observed the activation valvular interstitial cells both in ang-I and ang-II
treated tissue. The upregulation of α-SMA and calponin has been seen in calcified aortic valves
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(86), and we can infer that the activation we observed by RAS mediators can potentially lead to
the progression of valve disease. Ang-II has also shown to increase the thickness and endothelial
derangements in aortic valves which have been linked to early progression of aortic stenosis
(87). Thickening and calcification in the aortic valve can lead to reduced opening of the valve
and increased stiffness (13). In our study, we observed that RAS mediators altered the stiffness
of the aortic valve in addition to other biomechanical behaviors observed in stenotic aortic
valves. Quinaprilat and losartan showed to mitigate these effects at the whole-tissue level, and
more studies need to be conducted to further understand if common ACE inhibitors and ARBs
used to treat other diseases such as hypertension can also be used as therapeutic treatments for
the prevention of the progression of aortic stenosis that could lead to more severe conditions
such as calcific aortic valve disease (CAVD).
In conclusion, through this thesis we were able to see that RAS mediators affected the
biological and mechanical functions of the aortic valve leaflet. The activation of VICS and
increased production and disorganization of collagen fibers correlated to the stiffness of the
tissue which is linked to aortic stenosis. The finite Fung-type constitutive model was the best fit
model to characterize the changes in the mechanical properties of the tissue due to RAS
mediators. Further understanding of the role of the local RAS pathway in potentiating early
CAVD could lead to potential therapeutic treatments by targeting RAS mediators.
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APPENDIX A PROTOCOLS
Protocols listed here are for methods mentioned. Additional protocols for cell work not included
in Chapter 4 but in preliminary studied are also included. MATLAB codes for analysis of
methods are in Appendix B.
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Preparing for Slaughterhouse trip to Collect Large Animal Samples

Reagents and Materials:
Reagent
10x PBS
70% EtOH
Penicillin-Streptomycin (10,000 U/mL)
Distilled water

Notes
VWR #101076-194
In spray-bottle
ThermoFisher #15140122
(15 mL aliquots; -20°C freezer)
40 mL in 50 mL conical

Materials
30 mL syringe
Filter
6L container
Aluminum foil
Surgical tools

Notes
Sterile

Large scissors, small scissors, scalpel
handle, larger straight and smaller curved
tweezers

Stainless steel tray
Absorbent pads (2)
250 ml beaker
Protocol:
Calling slaughterhouses and schedules
MSML works with two slaughterhouses. As of November 2018, the following is the contact
information and schedules for them:




Cockrum’s Meat Processing (Rudy, AR)
o Phone number: (479) 474-3012
o Receive pigs on Sundays and Thursdays. Slaughter on Mondays and Fridays.
o Open Mon-Fri 8am-5pm; Saturday 8am-noon; Sunday 2pm-5pm
o Call two days before as sometimes they slaughter a day early if they have to many
Braunschweig Processing (Neosho, MO)
o Phone number: (417) 451-3150
o Receive pigs on Sundays, Tuesdays, and Wednesdays. Slaughter on Mondays,
Wednesdays, and Thursdays.
o Open Mon-Fri 8am-5pm; Saturday 9am-12pm

Always call day before close to closing time to see how many pigs they will have. Call the
morning of to remind them to save the hearts and make sure what time the hearts will be ready.
Time will vary as they slaughter beef prior to pork and time depends on how many beef they
have.
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Preparing diluted pen/strep (can be days before dissecting)
1.
2.
3.
4.
5.

Thaw pen/strep in water bath
In hood, mix 1 mL pen-strep with 40 mL ddH2O
Sterilize with 30 mL syringe and filter
Aliquot in ~12 mL of reagent into three 15 mL conicals
Place in -20°C freezer

Preparing PBS (day before dissecting)
1. Prepare required amount of 1x PBS from 10x PBS stock. (Call slaughterhouse day before to
know how many hearts will be available)
a. 300 ml 10x PBS + 2700 ml ddH2O if picking up less than 3 hearts
b. 200 ml 10x PBS + 1800 ml ddH2O if picking up more than 4 hearts. Max that can fill
is 8
2. Fill appropriate sized polycarbonate containers with 1x PBS.
3. Cover top of container with aluminum foil.
4. Autoclave in liquid setting. Do not remove foil at any point when container is outside
5. Return autoclaved containers to biosafety hood in lab using sterile technique.
a. Container is very hot after autoclaving. Either wait for it to cool down or use gloves
to carry.
b. Sterile technique: spray container with 70% alcohol before placing in hood
6. Remove foil, switch on UV light and expose overnight.
Preparing tools (day before dissecting)
1. Autoclave the following surgical tools in wrapped setting
a. Small pack: Large scissors, small scissors, scalpel handle, larger straight and smaller curved
tweezers
b. Large pack: Stainless steel tray and absorbent pads (2 sheets)
c. 250 ml beaker with top covered in aluminum foil
2. Place in lab bench until use
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Biaxial stretching of soft tissues
Important things to remember:



If using tissue samples, make sure it doesn’t dry out by constantly adding a few drops of
deionized water.
When you turn on the actuators sometimes one of the axis might make a noise trying to pull
itself inside. Make sure to switch off the controller on the software and follow these steps for
trouble shooting;
o In the cycle menu, change the settings to regular mode.
o Check all the actuators are being operated in position mode and not in load mode.
o Bring all the actuators closer and change the settings back to biaxial mode in the
cycle menu.
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Reagents and Materials:
Reagents
0.9% Saline
PDMS
Materials
Water Sprayer
Small and large petri dish
1cm x 1cm metal stamp
Cardboard frame
Staples
Super glue
Black beads
Scissors
Razor blade and forceps
Water pump

Notes
Dissolve 54 grams of NaCl in 6 L of DI water
For mold to fix sample
Notes
Keep sample moist at all times
For PDMS mold and to cut samples
Used as stencil to cut sample
Sample is fixed to cardboard frame and is
gripped onto grips
To fix sample to cardboard frame
To administer tracking nodes
To administer tracking nodes
To cut cardboard frame
To excise sample and mount on frame
To empty and fill water bath

Protocol:
Preparing material prior to day of testing
Prior to testing on day of
1. Place 6L of saline solution into water bath and turn on heating unit. Wait for at least 1
hour for solution to reach 37ºC.
Setting up system
1. Turn on all the actuators using the power knob under the desk.
2. Start the application named “MTL32” and once it loads, open “Testbuilder.”
3. In Testbuilder application, click on Proceed.
4. On the tab choose Test > Function generator.
5. On the right screen, open the tracking software named “Video Gauge.”
6. Transfer the 6 L of prepared saline into the bath and turn on the heater
7. Start the application Pylon Viewer
8. On the tab choose View>Devices and choose the Basler camera
9. On the tab choose View>Features and enable the acquisition frame rate and type 100 Hz
for the frame rate
10. Mount the sample onto the cardboard frame and clamp them using grips.
11. Mark four points forming a square on the tissue sample using India ink and let it dry for a
couple of minutes. (Will use 16 or 32 points later)
12. Mount the cardboard frame with the loaded sample onto one of the actuators and clamp
it.
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13. Now move the actuators one by one using the Jog function on the testbuilder screen and
mount the other sides of the cardboard frame to the other actuators.
14. Cut the cardboard pieces in such a way that each actuator is gripping onto one side of the
sample.

15. Use the DAQ settings to create a new file for each test and set the frame rate at 50 Hz.
16. Using the jog function bring all the actuators closer so that the sample is not expressing
any load from any side.
17. Offset all the loads of the actuators. Setup > Offset readout.
18. Move each of the actuators until they all reach a tear load of 0.05N.
19. Offset all the positions of the actuators. Setup > Offset readout
20. Choose the Cycle function and choose General > Biaxial > input the dimensions of the
samples. The Biaxial tab is where you can control if you want your actuators to work
individually or biaxially. Make sure to set it up at biaxial before running the test.
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21. Set waveform to “Ramp” with a mean strain of 0.75 and amp of 0.75. Ensure you select
the “start point min” option to ensure the test begins at the relaxed state and proceeds to
stretching. This will result in a displacement of 1.5 mm in each direction.
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22. Run 20 cycles of preconditioning. Wait for 5 minutes.
23. Click Start on Pylon Viewer. Run and record three cycles of stretch. Click Stop on Pylon
Viewer when cycles have been completed
24. Once the test is done, click on “Report” and in the following screen choose single and
click on “Single File”. This brings up another dialog box where you choose the file name
that was created in the DAQ settings.
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25. In the following screen, choose the file type as “CSV”; select all the loads for each
actuator and export it. Save this CSV file to your desired location.

26. The saved file is ready to be analyzed using MATLAB.
27. Optional: For a quick view at the results, in the above shown screen you can choose
“Preview” to look at the graphs.
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Immunohistochemistry
Reagents and Materials:
Reagent
1x PBS
Acetone
Goat serum
Primary antibodies
Secondary antibody

Note
100 ml 10x PBS
900 ml ddH2O
-20ºC freezer
Look at primary antibody table
GAM 488 (green) (4 ºC fridge)
GAR 594 (red) (4 ºC fridge)
DAPI (blue) (-20ºC freezer)

Pro-long Gold

Material
Plastic slide jar and carrier
Water/Alcohol proof marker
Humid chamber
Coverslip
Slide box
Nail polish

Note

Protocol:
Preparing serum and antibodies
For each section, make 200µL i.e. multiply number of sections by 200 and do calculations
Note: Following are with blocking serum as goat serum. Donkey serum can also be used, just
replace goat serum with donkey serum and secondary as DAM 488 and DAR 594.
Example of calculations for 1 section:
1. 20% blocking serum
a. 4 µL goat serum (20%)
b. 196 µL PBS
2. Primary
a. See table
3. Secondary
Note: Keep in dark because it is fluorescent.
a. 1 µL GAM 488 (green) (1/200)
b. 1 µL GAR 594 (red) (1/200)
c. 2 µL DAPI (blue) (1/100)
d. 196 µL PBS
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Fixation
1. Remove slides and allow to reach room temperature
2. Soak for 5 minutes in ice-cold acetone
3. Leave out for 5-10 mins till acetone evaporates
4. Put square sharpie mark around each section & wait 5-10 mins to dry
5. Put in a slide jar filled with 1x PBS to rehydrate section for 5 mins or more
a. DO NOT TAKE OUT until ready to start block
Block
6. Place slides in humid chamber
a. Place 1 slide at a time. Put blocking serum immediately as to not dry out the sample
7. Place 195 µl of 20% goat serum on each section
8. Incubate at 37ºC for 30-60 mins
Primary Stain
9. Remove the slide from the blocker solution.
a. DO NOT WASH!
10. Blot the slide. This is done by carefully holding the coverslip perpendicular to the lab bench.
Once a bead of liquid builds up at the bottom of the coverslip, press the edge of the coverslip
again a Kim Wipe to wick away the excess moisture
a. Goal is NOT to completely dry the slide-simply remove excess PBS from glass
surface.
11. For each section, place 195 µl of the primary.
12. Cover and incubate at room temperature for 1-2 hours in humid chamber
Wash 2
13. In plastic slide container, dip 3 x in 1x PBS and then let sit for 5 min
14. Repeat step 1 3x in new solution of PBS
Secondary
15. With a pipette place 195 µl of secondary antibody solution on each sections
16. Incubate for 1-2 hours in room temperature
Wash 3
17. Repeat wash 2 in dark area
Mount (in dark)
18. Place drop of Pro-long Gold ant fade reagent (brown bottle)
19. Cover slip and wait 12-24 hours
20. Then thin layer of nail polish around the cover slip
21. Let set for 2 hours
22. Once dry, they are ready for microscopy. When not imaging them, store in a slide box or a
dark box in 20C freezer. Slides will keep for several months but deteriorate over time.
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Primary & Secondary Antibodies
Primary
TGF-β1
(-20 freezer)

Species
Rb

Block
Goat

Concen.
1/25

RUNX2
(-20 freezer)

Ms

Goat

1/50

Ki-67
(-20 freezer)

Rb

Goat

1/250

Vimentin
(-20 freezer)

Ms

Goat

1/300

AT-1
(-20 freezer)

Rb

Goat

1/100

α-SMA
(-20 freezer)

Ms

Goat

1/200

Calponin
(-20 freezer)

Rb

Goat

1/100

Secondary Antibodies that we have
GAR 594 (red)
(Goat-anti rabbit)

Primary for 1 slide
8 µl TGF-β1
4 µl (2%) Goat
188 µl PBS
4 µl RUNX2
4 µl (2%) Goat
192 µl PBS
0.8 µl TGF-β1
4 µl (2%) Goat
195.2 µl PBS
0.67 µl vimentin
4 µl (2%) Goat
195.33 µl PBS
2 µl AT-1
4 µl (2%) Goat
194 µl PBS
1 µl α-SMA
4 µl (2%) Goat
195 µl PBS
2 µl Calponin
4 µl (2%) Goat
194 µl PBS

GAM 488 (green)
(Goat-anti mouse)
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Secondary
Goat antirabbit
GAR 594
Goat antimouse
GAM 488
Goat antirabbit
GAR 594
Goat antimouse
GAM 488
Goat antirabbit
GAR 594
Goat antimouse
GAM 488
Goat antirabbit
GAR 594

Picrosirius Red Protocol
Reagents:
Reagent
Phosphomolybdic Acid 0.2% Aqueous
Sirius Red, 0.1% in Sat/d Picric Acid
0.01 N Hydrochloric Acid
70% Alcohol
Xylene
95% Ethanol, 100% Ethanol
Ultrapure water (ddH2O)
Cytoseal mounting medium
Coplin/staining jars

Notes

Electron Microscopy Sciences #18006
Electron Microscopy Sciences #71388-01

Protocol:
1.
2.
3.
4.
5.

Let slides come close to room temperature
Fix in cold acetone for 5 min.
Wash in running tap water, 10 minutes.
Rinse in distilled water.
Treat in Phosphomolybdic Acid 0.2% Aqueous (1-5 minutes). Place the slides on a paper
towel and put a few drops of the acid on each tissue section.
6. Stain in Sirius Red, 0.1% in Sat'd Picric Acid , for 90 minutes. Note: You can filter and reuse sirius red stain.
7. Wash for 2 minutes in 0.01 N Hydrochloric Acid .
8. Rinse in 70% Alcohol for 45 seconds.
9. Dehydrate:
a. EtOH 95% (3 min, 2x)
b. EtOH 100% (3 min, 2x)
10. Clear in xylene (5 min, 2x).
11. Mount with cytoseal in fume hood and coverslip.
12. Let mounting medium cure for 24 h before imaging.
Results:
Collagen Fibers
Order of colors from least mature to most mature (thinnest fibers to thickest fibers):
Green < Yellow < Orange < Red
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Protein Isolation
Reagents and Materials:
Reagent/Material
RIPA Lysis Buffer System

Notes
Santa Cruz # sc-24948
1x lysis buffer (pH 7.4)
PMSF in DMSO (200mM)
Protease inhibitor cocktail (PIC) in DMSO
Sodium orthovanadate (NaVO) in water (100mM)

1xPBS
0.5 and 1.5 mL microcentrifuge tube
Protocol:
1. Culture cells or tissues under the appropriate conditions (if relevant). Proteins are
typically extracted using lysis buffers. We use a strongly denaturing urea lysis buffer as
outlined below. You may wish to use other lysis buffer formulations if you don’t want the
protein to be as denatured or if you are running the gel in native conditions.
2. For every 1mL of lysis buffer, add 10μL of PMSF, PIC, and NaVO.
3. For cells:
a. Wash cells 3x with sterile dPBS.
b. Aspirate all PBS
c. Add ~ 30-60μL of cold lysis buffer per coverslip and scrape using cell scraper.
d. Using a 100μL pipet, suction up and down until the solution becomes less viscous
(~10 times).
e. Transfer to a clean 0.5mL microcentrifuge tube.
4. For tissues:
a. Wash tissue 3x with sterile dPBS.
b. Pulverize tissue in a mortar and pestle under liquid nitrogen.
c. Transfer pulverized tissue to a clean microcentrifuge tube.
d. Add cold lysis buffer. In general, we use 3mL of lysis buffer per gram of tissue.
(I.e. for a 5x5 mm valve leaflet sample, we would use 200μL lysis buffer).
5. Centrifuge at max speed, 4°C, for 5 mins to pellet cell/tissue debris. 0.5mL tubes too
small for the centrifuge so put inside capless, empty 1.5 mL tube or tube will break.
6. Carefully withdraw supernatant into a separate clean 1.5 mL microcentrifuge tube labeled
with sample information.
7. Quantify protein yield using the micro-BCA protein assay kit.
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BCA Protein Assay
Reagents and Materials:
Reagent
RIPA Lysis Buffer System

Micro BCA Protein Assay Kit

Notes
Santa Cruz # sc-24948
1x lysis buffer (pH 7.4)
PMSF in DMSO (200mM)
Protease inhibitor cocktail (PIC) in DMSO
Sodium orthovanadate (NaVO) in water
(100mM)
ThermoFisher # 23235
Micro BCA Reagent A, B, & C
Albumin Standard Ampules (BSA), 2mg/mL

Protocol:
Preparing Samples
1. Label microcentrifuge tubes with BCA, lysis, and the names of each of your samples.
You need one tube per sample.
2. Add the appropriate amount of ddH2O water to each microcentrifuge tube, depending on
what dilution you want to use:
a. For 1:100: Add 45 L of ddH2O
b. For 1:200: Add 47.5 L of ddH2O
3. Add 5 L (for 1:100) or 2.5 L (for 1:200) of each sample to appropriate microcentrifuge
tube. Mix by vortexing.
4. Make up the dilute BSA solution ( final - 0.4mg/ml)
a. 320 L ddH2O
b. 80 L 2 mg/mL BSA (vial in the kit)
5. Make up the dilute lysis buffer solution (or whatever solvent your proteins are in):
a. Stock: For every 1mL of lysis buffer, add 10μL of PMSF, PIC, and NaVO.
b. Dilution: 360 µL ddH2O + 40 µL stock lysis buffer
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Adding in 96 well plate
1
2
3

4

A

C0

C0

S1

S1

B

C4

C4

S2

S2

C

C8

C8

S3

S3

D

C16

C16

S4

S4

E

C24

C24

etc.

etc.

F

C32

C32

G

C40

C40

5

6

7

8

9

10

H
Do duplicates for each control and sample well
6. For each control well, add the following amount of ddH2O:
a. C0  90 L
b. C4  89 µL
c. C8  88L
d. C16 86L
e. C24  84 L
f. C32  82 L
g. C40  80 L
7. Add 90 L of MilliQ water to each Sample well.
8. Add 10 µL of the dilute lysis buffer to each control well.
9. Add the following dilute BSA to each control well:
a. C0  0 L
b. C4  1 µL
c. C8  2 µL
d. C16 4 µL
e. C24  6 L
f. C32  8 L
g. C40  10 L
10. Add 10 L the dilute sample to the appropriate well in the 96-well plate.
11. Calculate the amount of BCA reagent that you need: 100 L / well
12. Make up the BCA Assay reagent (Pierce kit)
a. Add 50% Solution A
b. Add 48% Solution B
c. Add 2% Solution C
d. Mix
13. Add 100 L of the reagent to each well
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11

12

14. Incubate at 37°C for 30-60 min (you need to optimize this)
15. Read the absorbance at 562 nm on the plate reader.
Calculating protein concentration
16. Average the absorbance reading for the duplicates
17. Subtract the absorbance of CO from the absorbance of all samples to normalize
18. Graph the normalized absorbance of the control wells vs known concentration of control
wells and calculate the equation of the best fit line
a. y=absorbance and x=known concentration (0,4,16, etc.)
19. Using the equation, calculate the concentrations of sample with their absorbance
20. Samples were diluted by 100 so multiply the calculated concentration with 100 to
calculate true concentration
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Gel Electrophoresis
Protocol:
Sample Preparation
To get a good signal in the gel scanner, approximately 5-20μg of protein is recommended per
well of an electrophoresis gel. Prepare your gel samples in a 0.5 mL microcentrifuge. Sample for
SDS-Page consists of the protein sample + 4x sample buffer + reducing agent (β MeEth) +
ddH2O. Amount of total sample depends on gel and the volume each well can take.
1. Divide amount of protein (i.e. 10 μg) by the concentration of the specimen sample and
multiply by 1000 to calculate the amount of sample volume (μL) needed.
2. ¼ of volume is the sample buffer with or without the reducing agent.
a. Sample buffer with reducing reagent is 90% 4x sample buffer and 10% β MeEth.
b. Sample without reducing reagent is used only for the standard.
3. Add the volume of the protein sample, 2x sample buffer, and reducing agent and subtract
by the total volume needed to calculate the volume of ddH2O.
4. Mix sample
a. Tip: It’s easiest to put the water first into the 0.5 mL microcentrifuge tube, then
the reducing agent, and last the specimen volume. Can label the 0.5 mL
microcentrifuge tube as well as pipetting in the amount of water days before
running the gel. For best results, wait till the morning to pipette in the reducing
agent and specimen sample.
5. Boil sample at 95°C for 5 min using heating block. This ensures complete denaturation
and breakage of any disulfide links in the protein.
6. Condensation will happen so spin the samples down and the water will go back to the
bottom of the tube.
Standard Preparation
The standard is what shows the molecular weight bands on the membrane. You can have more
than 1 lane of standard depending on how many samples you have as long as there is at least one
lane in front of your set of samples. i.e. if you have 16 samples and an 18 well gel, you can put
one in the 1st and 18th well, if you have 14 samples, you can put one in the 2nd and 17th well, or if
you have 17 samples, you can only put in the 1st well. Standard consists of the protein standard +
4x sample buffer + ddH2O.
1.
2.
3.
4.

Multiply the number of lanes by the volume per well to get total volume.
Multiply 5 by the number of lanes for amount of protein standard.
Divide total volume by 4 for amount of 4x sample buffer.
Subtract amount of protein standard and 4x sample buffer from the total volume for
amount of ddH2O.
5. Mix sample. DO NOT BOIL!
a. Tip: It’s easiest to put the water first into the 0.5 mL microcentrifuge tube, then
the reducing agent, and last the protein standard.
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Running the Gel Electrophoresis
1. Prepare the appropriate amount of buffer for the electrophoresis depending on the type of
gel you are running:
a. Tris-HCl/TGX gel: Tris/glycine/SDS running buffer
i. 100 ml buffer + 900 ml ddH2O
b. Tris-acetate gel:
Tricine buffer
c. Bis-tris gel:
MES or MOPS buffer
2. Each precast gel is packaged individually in a plastic storage tray, which can also be used
as its own staining dish.
3. Remove tape from bottom of the cassette.
4. Insert precast gels in electrophoresis tank making sure that the integral buffer chamber
faces the center of the tank.
5. Fill the integrated upper buffer chamber with running buffer (~60mL).
6. Carefully remove the comb and top up any spilt running buffer. DO NOT THROW THE
COMB AWAY AT THIS POINT!
7. Fill each half of the lower buffer tank with ~400mL running buffer to the marked fill line.
8. Load samples using a pipet with gel loading tips. Using the sample loading guide will
ensure that there are no “parallax” errors.
9. Load protein standard to appropriate lane (s).
10. Place lid on the tank, aligning the color coded banana plugs with the corresponding jacks
on the lid. Run gels as follows. Run time is approximately 45 – 65 min.
a. Tris-HCl:
200V constant
b. TGX:
200V constant
c. Tris-acetate: 150V constant
d. Bis-tris:
200V constant
11. After electrophoresis is complete, turn off power supply and disconnect the electrical
leads.
12. Remove the lid from tank and remove gel and discard running buffer.
13. Insert comb into the slits on either side of the cassette and gently crack open the cassette.
14. Pull the two halves of the cassette apart to completely expose the gel. BE CAREFUL!
THE GEL IS EXTREMELY FRAGILE!
15. If you are going to do a western blot, proceed to that protocol. For staining the gel go to
the next section.
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Western Blotting
Protocol:
Before starting:




Make sure you know what antibodies you will be doing as the molecular weight of the
primaries dictates where the membranes will be cut. Can do 2 antibodies on the same
membrane with similar MW if different species (rabbit and mouse). Otherwise, cut the
membrane so as to have thinner strips.
Have at least 1.5L cold transfer buffer already made.

Preparation for Transfer/Western blot
1. When the electrophoresis is halfway done, cut a section of PVDF membrane of
approximately the same size as the gel. DO NOT TOUCH THE MEMBRANE EVEN
WITH GLOVED HANDS AS THAT WILL CAUSE TRANSFER OF “SELF”
PROTEINS WHICH WILL CONFOUND YOUR RESULTS!
2. The PVDF membrane is extremely hydrophobic so we need to “prewet” it. Dip it in
methanol, and then soak it in cold Transfer buffer on the belly button shaker in the 4°C
fridge for the remainder of the duration of the electrophoresis. You can use the tray that
came with the gel for this purpose.
3. Recipe for 10L 1x transfer buffer is (scale for your needs accordingly) as follows. Store
buffer in the 4°C fridge.
i. 2L methanol
ii. 1L 10x TG buffer
iii. 7L ddH2O
4. Prepare sponges by adding transfer buffer on the plate and soak them. Roll out all
bubbles. Leave in transfer buffer and re-roll right before assembly incase bubbles were
formed.
5. After electrophoresis is complete, turn off power supply and disconnect the electrical
leads.
6. Remove the lid from tank and remove gel
a. Save the running buffer as it can be reused at most 3 times.
7. Insert comb into the slits on either side of the cassette and gently crack open the cassette.
8. Pull the two halves of the cassette apart to completely expose the gel. BE CAREFUL!
THE GEL IS EXTREMELY FRAGILE!
Western blot
1. In the provided plastic tray, assemble the Bio-rad transfer cassette as follows, starting
from black side (negative) to red (positive):
a. Sponge
b. Filter paper
c. Gel
d. PVDF membrane
e. Filter paper
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2.

3.

4.
5.
6.

7.

8.

f. Sponge
When assembling the above, make sure you don’t rub or smudge the gel with the PVDF
membrane. The PVDF membrane is extremely protein-philic, so any smudge of the gel
(which is full of your protein samples) will appear when you are scanning the membrane.
It is absolutely crucial that the PVDF membrane is on the red (positive) terminal. If you
reverse the gel and PVDF membrane, the proteins will travel the opposite way and will
go out of the cassette into solution. That is, you have lost everything!
Once the assembly has been made, use the roller to roll out any air bubbles as presence of
bubbles will appear as empty circles on your PVDF membrane scan.
Close and lock cassette and assemble in Bio-Rad transfer tank. Don’t forget to insert
cooling block as tank gets very hot when running.
Run western/transfer blots in the 4°C fridge under the following conditions:
a. Standard (1 hour): 100V constant voltage
b. Overnight (16 hours): 10V constant voltage
At the end of the transfer step, disassemble cassette and place PVDF membrane protein
side up on gel cassette and using the molecular weight markers as a guide, cut PVDF
membrane horizontally into regions of interest. Can use the comb as a guide but make
sure to clean it first with distilled water. YOU MUST USE A CLEAN RAZOR BLADE
AND COMB!
Immediately place membrane strips in full strength Li-cor blocking buffer. Use the black
Li-cor boxes for this purpose.

Immunolabeling
This procedure is similar to immunostaining, in the sense that it involves blocking, primary and
secondary antibody incubations.
Blocking
1. Blocking is done in full strength Li-cor blocking buffer for 1.5 hours at room temperature
on belly dancer (speed 0.5).
a. 10 ml for long membrane and 5 ml for small membrane (can vary as long as
covered)
2. When done, store blocking buffer in a 100-250ml container and store in 4°C. Can be
reused at most 3 times.
Primary antibody incubation
3. Prepare appropriate dilution of primary antibody in full strength Li-cor buffer.
4. Place a 300-500μL drop of antibody on petri dish (can have multiple membranes but have
to be same primaries) and invert membrane onto the drop. Amount depends on length of
membrane. This is similar in technique to immunostaining of coverslips.
5. Incubate the membranes in primary antibody for 16 hours (overnight) at 4°C.
Washing
6. Make washing buffer. One quarter strength Li-cor blocking buffer diluted in PBS (1:3).
7. Return the membranes face up, and wash in washing buffer 3 times, 5 min each on the
belly dancer (speed 4).
8. During this time, pipette the primary from the petri dish into a 1.5ml Eppendorf and store
in -20°C. Can be reused at most 3 times.
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Secondary antibody incubation (LIGHT-SENSITIVE)
9. Prepare appropriate dilution of secondary antibody during washing (cover conicals with
aluminum).
a. 1/15,000 DAM 700 or DAR 800
b. 1:1 dilution of Licor buffer in PBS
c. 15 ml for long membranes and 10 ml for small membranes. Can vary as long a
covered but more than washing as it is highly important that it is completely
immersed since speed is slower on belly dancer and incubation is longer.
10. Incubate membranes in secondary antibody for 1 hours at room temperature on belly
dancer (speed 1).
a. If done in black Licor box, it can just be placed on belly dancer, but if done in a
box that allows light to go through, cover them with a cardboard box that won’t
allow light in (i.e. careful with holes on box).
Washing
11. Discard the secondary and wash the membranes in washing buffer 3 times, 5 min each on
the belly dancer.
12. Wash the membranes in ddH2O 2 times, 5 min each on the belly dancer.
Imaging
1. Clean odyssey scanner using ddH2O and Kim wipes only.
2. Place membranes face down on the glass and orient them appropriately.
3. Cover the membranes with the thick rubber mat and use the roller to roll out air bubbles.
This roller is larger and different from the one you used for the western/transfer blot step.
4. Close the odyssey scanner lid.
5. Open the Odyssey program and do: File  New
6. Select your folder and click open.
a. Password: Admin
7. On toolbar click blue icon with blue arrow
8. Another window will open. With mouse double click on grid that is shown, and drag the
box to match where your membranes were. Click flip image
a. The greater the area, the longer the scan
b. The greater the resolution, the slower the scan
9. Select the channel in which you want to scan your membrane. For antibodies labeled with
IR680, select channel 700. For antibodies labeled with IR800, select channel 800. Both
channels can be selected at once, but the scan will be slower.
10. Select intensity. The starting point is usually “5”.
11. Select appropriate resolution, and thickness setting.
12. Click scan. Once scan runs, you can save your image and use the Odyssey software to
analyze your bands.
Tips:
If you want stronger signal, you can place the membranes on the scanner, and let them
completely dry up (protected from light) before placing the rubber mat etc.
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APPENDIX B MATLAB CODE
MATLAB codes listed here are to analyze methods mentioned in methods sections of each
chapter. Each code has instructions on how to use the codes.
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Biaxial Testing MATLAB Instructions
Use:
Manual to analyze data acquired from biaxial mechanical testing.
Images:
Collected during biaxial testing from Basler AC640 camera. 100 images of desired stretch.
Tension:
Collected during biaxial testing from biaxial mechanical tester (Test resources) and software
provided by test resources.
Measurements:
Thickness of sample measured by placing sample in OCT compound after biaxial testing,
sectioning the samples with the cryotome, imaging with darkfield microscope, and measuring
length with imageJ.

MATLAB Instructions:
MATLAB codes required to analyze data: Biaxial_1.m, Biaxial_2.m, Biaxial_3.m, Biaxial_4.m,
automarkertrack.m, leastsq.m.
Troubleshooting:
In earlier testing, tensions were being read accurately in all directions. However at a later time
point, x1 is not able to read the tension being applied in the x1 direction properly. The code must
be changed accordingly to average or not average the tensions in the x direction. There may be
times where there can also be an issue in the y direction. Check and change the following lines in
the code if you desire to use only one directional tension or the average tension of both.
Biaxial_1.m
Line 102:
For average x, x_tension(j)=(x1x2(row(j)))-(x1x2(row(j)-49));
For only x1, x_tension(j)=(x1(row(j)))-(x1(row(j)-49));
For only x2, x_tension(j)=(x2(row(j)))-(x2(row(j)-49));
Line 103:
For average y, y_tension(j)=(y1y2(row(j)))-(y1y2(row(j)-49));
For only y1, tension(j)=(y1(row(j)))-(y1(row(j)-49));
For only y2, y_tension(j)=(y2(row(j)))-(y2(row(j)-49));
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Biaxial_2.m
No changes
Biaxial_3.m
Line 116:
For average x, plot ([1:50],x1x2s);
For only x1, plot ([1:50],x1s);
For only x2, plot ([1:50],x2s);
Line 119:
For average y, plot ([1:50],y1y2s);
For only y1, plot ([1:50],y1s);
For only y2, plot ([1:50],y2s);
Biaxial_4.m
Line 29:
For average x, x_ten=data([1:50],5);
For only x1, x_ten=data([1:50],1);
For only x2, x_ten=data([1:50],2);
Line 30:
For average y, y_ten=data([1:50],6);
For only y1, y_ten=data([1:50],3):
For only y2, y_ten=data([1:50],4);
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Biaxial_1.m
This code creates a matrix containing the max x and y tension to allow the user to choose the
stretch that was stretched to the most accurate tension. This is due to the fact that our biaxial
machine is not load bearing but by displacement so the tension can vary through test. In addition,
our biaxial machine does not detect low tensions well so even though it may look like the tension
reached the desired tension, once substracted by the starting tension, it may be different. When
testing user does choose a stretch that looks good, but this code allows the user to make sure that
it is the best.
Input:
Biaxial Machine csv file: x1,x2,y1,y2
Output:
Matrix: x_tension and y_tension on command window (in order of stretches)
Instructions on how to use this in following biaxial codes:
This code will allow the user to determine which stretch has most appropriate tension. Make sure
to write down the stretch for further use. User analyzes the deformation of that stretch in
biaxial_2.m and calculates the needed tensions in biaxial_3.m.
Notes:
File must be .csv, have no text, and at least the following columns:
Column B (2nd) is Rel. LOAD - X1 (N)
Column C (3rd) is Rel. LOAD - Y1 (N)
Column D (4th) is Rel. LOAD - X2 (N)
Column E (5th) is Rel. LOAD - Y2 (N)
Insturctions:
1.
2.
3.
4.
5.
6.

Delete all words in .csv file.
Drag file to MATLAB folder
Run code
Input how many stretches were done
Choose stretch that best fits ratio
In excel sheet, put how many stretches were done, what stretch will be analyzed, and
what the tensions are of that stretch
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Biaxial_2.m
This code is used to analyze the deformation the sample undergoes during testing. Samples must
have 4 marks on the surface (2x2 square array) to trace and must be consecutive. Code will trace
the movement of the markers during testing from the 100 images provided.
Input:
 Images collected from Basler AC640 camera
 MATLAB functions: automarkertrack.m and leastsq.m
Output:
 Two figures will pop up: figure (1) plot of Exx and (2) plot of Eyy. This is to insure that
the code tracked the points correctly and did not scew. If they are not a peak, repeat
analysis and choose a different area in the point that could be tracked easily.
Ex.





Excel file: deformresults.xlsx.
o File contains Exx, Eyy, Exy, Ezz, E1, E2, dir1, dir1, dir2, and dir2. This file will
be used in Biaxial_3.m.
o Will be saved in output folder
Two MATLAB data files: defg.mat and lamz.mat.
o These will be used in Biaxial_4.mat.
o Will be saved in output folder

Note:
 The function leastsq.m is used in the function automarkertrack.m.
 If there is noise when tracking the dots, change the pixel and num in the function
automarkertrack.m
o Make sure to write down the ideal pixel and num on excel sheet for future use.
Instructions:
1. Change path to folder containing the images. (Will always change )
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a. Click the drop down menu and copy and paste the path name that appears onto
line 27 of the code (path1= “pathname”).
Ex. path1='J:\Biaxial\20171230\ AngII \test
18_1_0.5\stretch 2+';
2. Change file name to retrieve images (Will always change )
a. Click on first image of the set of images you will be analyzing and copy and paste
name onto line 28 of code (name1= “filename” ).
b. Erase the last three numbers of file name
Ex. File name: “Basler acA640-750um
(21856823)_20171230_185607817_0389” to
“Basler acA640-750um (21856823)_20171230_185607817_0”
name1='Basler acA640-750um
(21856823)_20171230_185607817_0';
3. Change output file path (Will be same as long as in same computer path)
a. Click the drop down menu and copy and paste the path name that appears onto
line 29 of the code (path1= “outputpathname”).
b. Make sure to add \point at the end
Ex. out1='C:\Users\jxp040\Desktop\test\point';
Note: Make output folder same folder that contains the MATLAB codes
4. Run program
5. User will be asked to input the number of the first image on command window
Ex. 389
6. Click on 4 points to track in the following order:
3---------4
/
/
/
/
2---------1
Note: Click on an area in the point that is in the center and dark
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Biaxial_3.m
This code creates an excel sheet containing x1,x2,y1,y2 and average of x1&x2 and y1&y2 from
the csv file provided by the biaxial machine containing the forces from different axis for the first
50 points as well as the Exx and Eyy for the first 50 points.
Input:
Excel file: deformresults.xlsx
Output:
 Four plots: x axis load, y axis load, Exx and Eyy.
Ex.



Excel file will be saved in output folder: rawdata.xlsx. File contains x1, x2, y1, y2, x1x2,
y1y2, Exx, and Eyy. These will be used in Biaxial_3.mat.

Instructions:
1. Run program
2. Choose csv file provided by the biaxial testing machine
a. Words should have been deleted prior to running biaxial_1.m and placed in folder
b. The columns must contain the following information:
A: Time
B: Rel. LOAD - X1 N
C: Rel. LOAD - Y1 N
D: Rel. LOAD – X2 N
E: Rel. LOAD – Y2 N
3. Input how many stretches were done
4. Input what stretch will be analyzed
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Biaxial_4.m
This code creates an excel sheet E11, E22, S11, S22, P11, and P22 by using the excel sheet
rawdata.xlsx from biaxial_3.m and mat files defg and lamz from biaxial_2.m. The excel file
plotdata.xlsx can then be used to graph stress and strain data on sigma plot.
Input:
 Excel file: rawdata.xlsx
o x1,x2,y1,y2,x1x2, y1y2, Exx, and Eyy
 Mat files: defg.mat and lamz.mat
o defg.mat: deformation gradient
o lamz.mat: lambda
 Measurement: sample thickness
Output:
 Excel file: plotdata.xlsx.
o Will be saved in output folder.
o File contains E11, E22, S11, S22, P11, and P22.
o These will be used in sigma plot to create graphs and MATLAB to make
constitutive models.
Instructions:
1. Run program
2. Input the thickness of the samples in mm
a. Note: width is assumed to be 1cm.
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Final Instructions
Cut and paste all output files into sample folder.
 Csv file from biaxial machine
 Excel files: deformresults.xlxs, rawdata.xlsx, and plotdata.xlsx
 MATLAB files: defg.m and lamz.m
 Txt files: point1.txt, point2.txt, point3.txt, and point4.txt
Graphing and statistical analysis
 Use the information on plotdata.xlsx
 Data can be grouped by condition or ratios used for that particular sample. Discuss with
PI.
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Biaxial Testing MATLAB Codes
To calculate the stress and strain for each tested sample, four MATLAB codes and two
MATLAB functions were used. Biaxial_1 allows the user to choose which stretch had the most
adequate force applied as our biaxial machine is displacement based. Biaxial_2 tracks the fourdot array to calculate the deformation gradient and strain. Biaxial_3 extracts the force and
displacement data for the chosen stretch (50 data points as it was at 100 Hz). Biaxial_4 calculates
the stress and output the stress and strain. The automarkertrack function automatically tracks the
4-dot array and the pixel size can be altered depending on the size of the dot being tracked. If the
camera was move to where the x axis was in the y axis, the images need to be rotated and
Rotate.m MATLAB code can be used to do so.
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Biaxial_1.m MATLAB Code
%Biaxial Part 1
close all
clear all
clc
%Written by Jessica Perez
%Version June 2018
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code creates a matrix containing the max x and y tension to allow the
%user to choose the stretch that was stretched to the most accurate
%tension. This is due to the fact that our biaxial machine is not load
%bearing but by displacement so the tension can vary through test. In
%addition, our biaxial machine does not detect low tensions well so even
%though it may look like the tension reached the desired tension, once
%substracted by the starting tension, it may be different. When testing
%user does choose a stretch that looks good, but this code allows the user
%to make sure that it is the best.
%Input:
% Csv file: x1,x2,y1,y2
%Output:
% Matrix: x_tension and y_tension on command window (in order of stretches)
%Instructions on how to use this in following biaxial codes:
% See which stretch has most appropriate load and use images of that
% stretch in biaxial part 2 and input the stretch number in biaxial part 3.
%Notes:
% File must be .csv, have no text,
% Column B (2nd) is Rel. LOAD - X1
% Column C (3rd) is Rel. LOAD - Y1
% Column D (4th) is Rel. LOAD - X2
% Column E (5th) is Rel. LOAD - Y2

and at least the following columns:
(N)
(N)
(N)
(N)

%choosing file
[filename,pathname]=uigetfile('*.csv', 'Select file');
data=csvread(filename);
index=size(data,1);
%Note:currently x1 doesn't read properly so we only look at x2. See
%instructions on what lines to change if all tensions are reading properly.
%creating matrix of x1,x2,y1,y2 load from file data
i=1:index;
x1=data([1:index],2);
x2=data([1:index],4);
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y1=data([1:index],3);
y2=data([1:index],5);
x1x2=mean([x1,x2],2);
y1y2=mean([y1,y2],2);
%plot tension. This allows user to see how many stretches were done and
%what tensions may not be reading properly
figure(1)
subplot(2,3,1);
plot ([1:index],x1 );
title ('x1 load');
subplot(2,3,2);
plot ([1:index],x2 );
title ('x2 load');
subplot(2,3,3);
plot ([1:index],x1x2 );
title ('x1x2 load');
subplot(2,3,4);
plot ([1:index],y1 );
title ('y1 load');
subplot(2,3,5);
plot ([1:index],y2 );
title ('y2 load');
subplot(2,3,6);
plot ([1:index],y1y2 );
title ('y1y2 load');
%prompt user to how many stretches there were.
prompt='How many stretches were done? ';
st=input(prompt);
%Each stretch has a peak when graphed. This find the peaks that correspond
%to each stretch
pks = findpeaks(x2);
max = sort( pks, 'descend' );
n = max(1:st);
%index the row for the max of each stretch
for j=1:st;
q=n(j);
r(j)=find(x2==q);
end
%row where max is for desired stretch
row=(sort(r, 'ascend'));
%difference between forces of peaks at DAQ of 100 Hz and frequency of 1 Hz.
%i.e 100 data points, peak at 50 data points, subtract 49 to zero out
for j=1:st;
x_load(j)=(x2(row(j)))-(x2(row(j)-49)); %only use x2 and not x1
y_load(j)=(y1y2(row(j)))-(y1y2(row(j)-49)); %use y1y2
end
y_load
x_load
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Biaxial_2.m MATLAB Code
Contact Dr. Kartik Balachandran for code.
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Biaxial_3.m MATLAB Code
%Biaxial Part 3
close all
clear all
clc
%Written by Jessica Perez
%Version June 2018
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code creates an excel sheet containing x1,x2,y1,y2 and average of
%x1&x2 and y1&y2 from the csv file provided by the biaxial machine
%containing the forces from different axis.
%Input:
% CSV file: Forces from biaxial Machine
% Excel file: derform deformresults.xlsx
%Output:
% Excel files: rawdata.xlsx
% Four plots: x axis load, y axis load, Exx and Eyy.
%Notes:
% File must be .csv, have
% Column B is Rel. LOAD % Column C is Rel. LOAD % Column D is Rel. LOAD % Column E is Rel. LOAD -

no
X1
Y1
X2
Y2

text, and at least the following columns:
(N)
(N)
(N)
(N)

%Instructions:
% 1. Run program
% 2. Choose csv. file
% 3. Input how many stretches were done
% 4. Input what stretch will be analyzed
%choosing file
[filename,pathname]=uigetfile('*.csv', 'Select file');
data=csvread(filename);
index=size(data,1);
%creating matrix of x1,x2,y1,y2 from file data
i=1:index;
x1=data([1:index],2);
x2=data([1:index],4);
y1=data([1:index],3);
y2=data([1:index],5);
x1x2=mean([x1,x2],2);
y1y2=mean([y1,y2],2);
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%Prompt how many stretches were done
prompt='How many stretches were done? ';
st=input(prompt);
%Prompt what stretch will be analyzed
prompt= 'Which stretch will be analyzed? ';
sn=input(prompt);
%Each stretch has a peak when graphed. This find the peaks that correspond
%to each stretch
pks = findpeaks(x2);
max = sort( pks, 'descend' );
n = max(1:st);
%index the row for the max of each stretch
for j=1:st;
q=n(j);
r(j)=find(x2==q);
end
%row where max is for desired stretch
row=sort(r, 'ascend');
snrow=row(sn);
%Index first and last value of stretch (1-50)
f=snrow-49;
l=snrow;
%First 50 values for x1,x2,y1,and y2 of desired stretch
x1s=x1([f:l])-x1(f);
x2s=x2([f:l])-x2(f);
y1s=y1([f:l])-y1(f);
y2s=y2([f:l])-y2(f);
x1x2s=x1x2([f:l])-x1x2(f);
y1y2s=y1y2([f:l])-y1y2(f);
%First 50 values of E11 and E22 from derfomresults.xlsx output from
%Biaxial_2.m
def=xlsread ('deformresults.xlsx');
E11=def([1:50],1);
E22=def([1:50],2);
%Output file
raw=[x1s,x2s,y1s,y2s,x1x2s,y1y2s,E11,E22];
h={'x1', 'x2', 'y1', 'y2', 'x1x2', 'y1y2', 'E11', 'E22'};
m=[h;num2cell(raw)];
filename='rawdata.xlsx';
xlswrite(filename,m);
%Output figure of first 50 E11, E22, and average x and y load
figure(1)
subplot (2,2,1)
plot ([1:50], E11);
title ('E11');
subplot (2,2,2)
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plot ([1:50], E22);
title ('E22');
subplot (2,2,3)
plot ([1:50],x2s); %x1 load is not reading properly so x value is just x2s
title ('x load');
subplot (2,2,4)
plot ([1:50],y1y2s);
title ('y load');
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Biaxial_4.m MATLAB Code
%Biaxial Part 4
close all
clear all
clc
%Edited by Jessica Perez
%Version June 2018
%Written by Prashanth Ravishankar, 2016
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code creates an excel sheet E11,E22,S11,S22,P11,and P22 by using
%the excel sheet rawdata.xlsx from biaxial_3.m and mat files defg and lamz
%from biaxial_2.m. The excel file plotdata.xlsx can then be used to graph
%stress and strain data on sigma plot.
%Input:
% Excel file:rawdata.xlsx
% mat files: defg.mat and lamz.mat
%Output:
% Excel file: plotdata.xlsx
data=xlsread('rawdata.xlsx');
x=data([1:50],2); %x value is just x2 because x1 load was not reading
y=data([1:50],6); %y value is y1y2
E11=data([1:50],7);
E22=data([1:50],8);
%Assume width is 1cm and thickness 1mm so area equals 10^-5
prompt= 'What is the thickness of the sample (mm)? ';
t=input(prompt)*10^-3; %in mm
w= 1*10^-2; %assumed 1 cm
A=t*w;
%1st P-K (P) equals tension/area
P11=x./A./1000; % (Unit kPa)
P22=y./A./1000; % (Unit kPa)
%2nd P-K (S) equals F^-1 x P
load('defg.mat'); %gives you F [ lam1 0; 0 lam2]
load('lamz.mat'); %gives you lam3 i.e F33
F11=F(1:50,1);
F22=F(101:150,2);
F11_i=F11.^(-1); %inverse of F

150

F22_i=F22.^(-1); %inverse of F
S11=F11_i.*P11; % (Unit kPa)
S22=F22_i.*P22; % (Unit kPa)
%Cauchy stress (sigma) equals (1/J)x(F x P)
J=1 % J is the measure of volume change, assume no volume change so J=1
sigma11=(1./J).*F11.*P11; % (Unit kPa)
sigma22=(1./J).*F22.*P22; % (Unit kPa)
%Areal strain and anisotropy index
AS=E11.*E22; %areal strain is Ecirc*Erad
ASmax=max(AS)
AI=max(E11)./max(E22) %anisotropy index is Ecirc/Erad
output=[E11, E22, S11, S22, P11, P22,AS];
h={'E11', 'E22','S11{kPa}', 'S22{kPa}', 'P11{kPa}', 'P22{kPa}','AS'};
m=[h;num2cell(output)];
filename='plotdata.xlsx';
xlswrite(filename,m);
lam1=F([1:50],1);
lam2=F([101:150],2);
lam3=lamZ([1:50],1);
output=[lam1, lam2, lam3, sigma11, sigma22];
h={'lam1', 'lam2', 'lam3','sigma11','sigma22'};
m=[h;num2cell(output)];
filename='LambdaandCauchystress.xlsx';
xlswrite(filename,m);
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Automarkertrack.m MATLAB Function Code
%Automarker function used in Biaxial_2.m
%Written by Kartik Balachandran
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%Instructions:
% Change pixel and num accordignly to avoid noise
function N=automarkertrack(M,N)
pixel=50;
num=10;
distance=[-pixel:pixel]';
count=1;
for angle=0:pi/num:pi/num*(num-1)
p=[distance*cos(angle)+N(1), distance*sin(angle)+N(2)];
p=round(p);
[s1 s2]=size(p);
int=[];
for i=1:s1
int(i)=M(p(i,2),p(i,1));
end
fitpol=leastsq(distance,int',8);
int2=fitpol{1};
beta=fitpol{2};
beta=flipud(beta);
s1=length(beta);
index=[1:s1-1]';
p=beta(1:s1-1).*index;
r=roots(p);
%this portion has been changed due to difficulty in tracking
a=find(abs(r)==min(abs(r)));
if length(a)>1
a=a(1);
end
centroid(count)=real(r(a));
count=count+1;
end
angle=[0:pi/num:pi/num*(num-1)]';
cosine=cos(angle);
sine=sin(angle);
centroid2=[centroid'.*cosine, centroid'.*sine];
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[s1 s2]=size(centroid2);
centroid3=sum(centroid2)/s1;
N=N+centroid3;
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Leastsq.m MATLAB Function Code
%Leastsq function used in function automarkertrack to be used in Biaxial.m
%Written by Kartik Balachandran
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%least square fit to find Gfit.
%z is unvaried x-axis parameter
%ord is the order of the polynomial used for the fit
%Basic principles:
% fitted values {Gfit}=[X]*{beta}
% {beta} is vector of coefficients
% For least square, [X]*{beta}-{G} is orthogonal to [X]
% thus [X]'*([X]*{beta}-{G})=0
function results=leastsq(z,G,ord)
zz=ones(length(z),1);
X=[zz];
for i=1:ord
zz=z.*zz;
X=[X zz];
end
beta=inv(X'*X)*X'*G;
Gfit=X*beta;
results={Gfit beta};
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Rotate.m MATLAB Code
clc
clear all
close all
%Paths and file names
path1='I:\Biaxial\Biaxials Fresh\analyzed images\Ang-II+Los_FB4b\test
19_0.5_1\stretch 3';%where orignal images are
path2='I:\Biaxial\Biaxials Fresh\analyzed images\Ang-II+Los_FB4b_rotate\test
19_0.5_1\stretch 3'; %where rotated images go
name1='Basler acA640-750um (21856823)_20180830_191536482_0'; %image name
without last three numbers
%Frame number
prompt= 'What is the number of the first image? ';
f=input(prompt);
%Last image
l=f+99;
ind=[f:l];
[s1 s2]=size(ind);
pathnfile1=[path1 '\' name1 sprintf('%3.3d',ind(1)) '.tiff'];
M1=imread(pathnfile1,'tiff');
M1=imrotate(M1,90);
M2=imshow(M1);
BaseName=name1;
FileName=[path2 '\' BaseName,num2str(f),'.tiff'];
imwrite(M1,FileName,'tiff');
for j=[1:99];
pathnfile1=[path1 '\' name1 sprintf('%3.3d',ind(1+j)) '.tiff'];
M1=imread(pathnfile1,'tiff');
M1=imrotate(M1,90);
M2=imshow(M1);
BaseName=name1;
FileName=[path2 '\' BaseName,num2str(f+j),'.tiff'];
imwrite(M1,FileName,'tiff');
end
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Average Model MATLAB Instructions
Prior to running the MATLAB code for the average model, an excel sheet containing the average
x and y force provided by the system the E11 and E22 calculated by MATLAB code. The
information can be found in the rawdata.xls file exported from MATLAB code Biaxial_3. Note:
the x1 load cell was not functional so the x2 force was used as the average x force.
For example: If the treatment group is control, all control tests for ratio 1:1 must be in one excel
sheet. The columns would be as followed. First sample: column A: x average force; column B: y
average force; column C: E11; column D: E22; column E: empty. Repeat for every sample into
next column i.e. second sample: column F: x average force; etc.
In addition, another excel file containing the thickness of each sample in column A must be
made. For example: If there were 3 samples for the control at 1:1 force, A1 would be the
thickness of the first sample, A2 the second sample, and A3 the third sample.. The thicknesses
must correspond to the information on the previous excel sheet. For example: the thickness in A1
must correspond to the information for that sample in the in columns A-D of the previous excel
sheet. The thickness in A2 must correspond to the information for that sample in the in columns
F-I of the previous excel sheet. The thickness in A3 must correspond to the information for that
sample in the in columns K-N of the previous excel sheet.
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Average_Model.m MATLAB Code
%Average Model
clc
clear all
close all
%%Written by Jessica Perez
%Version January 2019
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code calculates the average stress and strain of n samples for one
%tension ratio.
%Equation:
% Pavg=Tavg/n * sum(1/h)
% Favg=sqrt(2*Eavg+1)
% Savg=Pavg*Favg^(-T)
%Input:
% Excel files:
%
(1)File containing tension and strain data for n# samples for one
%
tension ratio (see notes (1) for order of information)
%
(2)File containing thicknesses (mm) of each sample being averaged in
%
column A in order
%Output:
% Command window:
%
(1) max areal strain and (2) anisotropy index
% Excel files:
%
(1) AveragePlotData.xlsx
%
Contains: Average Green Strain, 2nd P-K stress, 1st P-K stress and
%
areal strain for circumferential and radial direction
%
(2) AverageEandTandStandardError.xlsx
%
Contains: Average Green strain and tension in circumferential and
%
radial direction and the standard error
% Graphs that need to be saved as jpeg or other filetype:
%
(1) Average 2nd P-K stress vs average Green strain of circumferential
%
and radial direction with error bars
%
(2) Average 2nd P-K stress vs average Green strain of circumferential
%
and radial direction without error bars
%
Legend:
%
Circumferential=Black
%
Radial=Red
%Notes:
% (1) To extract the
%
sample numbers
%
n1: Column
%
n2: Column
%
n3: Column

files
there
A=x2;
F=x2;
K=x2;

the data should be as
are being averaged of
Column B=y1y2; Column
Column G=y1y2; Column
Column L=y1y2; Column
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follows for however many
one tension ratio:
C:Exx; Column D:Eyy
H:Exx; Column I:Eyy
M:Exx; Column N:Eyy

%
etc ......
% (2) Figures have no titles, x and y labels, or legends. I put those when
%
I'm compiling figures in a powerpoint. However, the code to do so is
%
commented so you can just uncomment them for whatever you want on
%
the graph.
%Extracting all control thickness from excel file and indexing
disp('Select thickness file ')
[filename,pathname]=uigetfile('*.*', 'Select file');
t=xlsread(filename);
n=size(t,1);
%Extracting all control data from excel file and indexing
disp('Select data file ')
[filename,pathname]=uigetfile('*.*', 'Select file');
data=xlsread(filename);
index=size(data,1);
%Creating matrices for the average x and y force and green strain (Exx and
%Eyy) according to number of samples (n)
for j=1:n
col_x(j)=1+(5.*(j-1));
x(j)={data([1:50],col_x)};
col_y(j)=2+(5.*(j-1));
y(j)={data([1:50],col_y)};
col_Exx(j)=3+(5.*(j-1));
E11(j)={data([1:50],col_Exx)};
col_Eyy(j)=4+(5.*(j-1));
E22(j)={data([1:50],col_Eyy)};
end
x=cell2mat(x(n));
y=cell2mat(y(n));
E11=cell2mat(E11(n));
E22=cell2mat(E22(n));
% x and y
w=10.^-2;
Txx=x./w;
Tyy=y./w;

tension
% (m) assume width 1 cm
%(N/m) force/width
%(N/m) force/width

%average tension (Tavg,ii) and standard deviation
Txx_avg=mean(Txx,2);
Txx_sem=std(Txx,0,2)./sqrt(n);
Tyy_avg=mean(Tyy,2);
Tyy_sem=std(Tyy,0,2)./sqrt(n);
%average green strain (Eave,ii)
E11_avg=mean(E11,2);
E11_sem=std(E11,0,2)./sqrt(n);
E22_avg=mean(E22,2);
E22_sem=std(E22,0,2)./sqrt(n);
%Average P
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% Pavg,ii=Tavg,ii/n * Sum(1/h)
t=t.*(10.^-3); %(m) h in mm and need in m
P11_avg=Txx_avg./n.*(sum(1./t));
P11_avg=P11_avg./1000; %kPa
P22_avg=Tyy_avg./n.*(sum(1./t));
P22_avg=P22_avg./1000; %kPa
%Average F
% Favg,ii=sqrt(2*Eavg,ii+1)
F11_avg=sqrt(2.*E11_avg+1);
F22_avg=sqrt(2.*E22_avg+1);
%Average S
% Savg,ii=Pavg,ii*Favg,ii^(-T)
F11_avg_i=1./(F11_avg);
F22_avg_i=1./(F22_avg);
S11_avg=(F11_avg_i.*P11_avg);
S22_avg=(F22_avg_i.*P22_avg);
%Average areal strain and anisotropy index
ASavg=E11_avg.*E22_avg; %areal strain is Ecirc*Erad
ASavg_max=max(ASavg)
AIavg=max(E11_avg./E22_avg) %anisotropy index is Ecirc/Erad
output=[E11_avg, E22_avg, S11_avg, S22_avg, P11_avg, P22_avg,ASavg];
h={'E11 avg', 'E22 avg', 'S11 avg', 'S22 avg', 'P11 avg', 'P22 avg','AS
avg'};
m=[h;num2cell(output)];
filename='AveragePlotData.xlsx';
xlswrite(filename,m);
output=[E11_avg,E11_sem, E22_avg, E22_sem, Txx_avg, Txx_sem, Tyy_avg,
Tyy_sem];
h={'E11 avg','E11 std', 'E22 avg', 'E22 std', 'Txx avg', 'Txx std', 'Tyy
avg', 'Tyy std'};
m=[h;num2cell(output)];
filename='AverageEandTandStandardError.xlsx';
xlswrite(filename,m);
%Figures
%Standard error graph
E11_sem=std(E11,0,2)./sqrt(n);
S11_std_spot=S11_avg(4:2:end);
S11_std_spot_th=transpose([S11_std_spot S11_std_spot S11_std_spot]);
E11_std_spot=E11_avg(4:2:end);
E11_std_bar=E11_sem(4:2:end);
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E11_std_pos=E11_std_spot+E11_std_bar;
E11_std_neg=E11_std_spot-E11_std_bar;
E11_std_negmidpos=transpose([E11_std_neg, E11_std_spot, E11_std_pos]);
E11_std_pos_neg=E11_std_pos-E11_std_neg;
E22_sem=std(E22,0,2)./sqrt(n);
S22_std_spot=S22_avg(4:2:end);
S22_std_spot_th=transpose([S22_std_spot S22_std_spot S22_std_spot]);
E22_std_spot=E22_avg(4:2:end);
E22_std_bar=E22_sem(4:2:end);
E22_std_pos=E22_std_spot+E22_std_bar;
E22_std_neg=E22_std_spot-E22_std_bar;
E22_std_negmidpos=transpose([E22_std_neg, E22_std_spot, E22_std_pos]);
E22_std_pos_neg=E22_std_pos-E22_std_neg;
%Figure with error bars
figure (1)
sz=15;
plot(E11_avg,S11_avg,'k',E22_avg,S22_avg,'r','LineWidth',2); hold on
scatter (E11_std_spot, S11_std_spot,sz,'k');hold on
plot(E11_std_negmidpos,S11_std_spot_th,'k');hold on
scatter (E22_std_spot, S22_std_spot,sz,'r');hold on
plot(E22_std_negmidpos,S22_std_spot_th,'r');
% legend('Circumferential','Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Savg_max=max(max(max(S11_avg)),(max(max(S22_avg)))); %max S for axis limits
(y limit)
Estd_max=max(max(max(E11_std_negmidpos)),(max(max(E22_std_negmidpos))));
axis([0 Estd_max+0.05 0 Savg_max+10]); % 1 for mas S
set(gca,'Ytick', 0:20:Savg_max+10);
set(gca,'Xtick', 0:0.1:Estd_max+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=350;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
%Figure without error bars
figure(2)
sz=15;
scatter(E11_avg,S11_avg,sz,'k'); hold on;
scatter(E22_avg,S22_avg,sz,'r'); hold on;
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% legend('Circumferential','Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11_avg)),(max(max(E22_avg)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_avg)),(max(max(S22_avg)))); %max S for axis limits (y
limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=350;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
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Plotting_Figures.m MATLAB Code
%Plotting 2nd P-K stress vs Green strain
clc
clear all
close all
%Written by Jessica Perez
%Version April 2019
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code graphs all tension ratios in both circumferential and radial
%direction with S vs E in one graph, E vs S and AS vs S in one direction,
%and S11 vs S22
%Input:
% File containing ratio data
%Output:
% Graphs that need to be saved as jpeg or other filetype:
%
(1) One graph with all ratios in both the circumferential and radial
%
direction for Green Strain (E) vs 2nd P-K stress (S)
%
(2) One figure with 2 subplots. E vs 2nd P-K stress. Left graph is
%
the circumferential direction and the right one is the radial
%
direction
%
(3) One figure with 2 subplots. Areal strain (AS) vs 2nd P-K stress.
%
Left graph is the circumferential direction and the right one is
%
the radial direction
%
(4) One graph with S11 vs S22 for all 5 ratios
% All legends and axis can be uncommented to see appropriate symbols for
% each item graphed.
%Note:
% To extract the files the data should be as follows on the file with
% all the ratio data:
%
1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22
%
1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22
%
0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22
%
1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22
%
0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22
%Extracting all ratio data from excel file
[filename,pathname]=uigetfile('*.*', 'Select file');
data=xlsread(filename);
index=size(data,1);
%Seperating data by ratios 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
E11_1_1=data([1:index],1);
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E22_1_1=data([1:index],2);
S11_1_1=data([1:index],3);
S22_1_1=data([1:index],4);
AS_1_1=data([1:index],7);
E11_1_75=data([1:index],9);
E22_1_75=data([1:index],10);
S11_1_75=data([1:index],11);
S22_1_75=data([1:index],12);
AS_1_75=data([1:index],15);
E11_75_1=data([1:index],17);
E22_75_1=data([1:index],18);
S11_75_1=data([1:index],19);
S22_75_1=data([1:index],20);
AS_75_1=data([1:index],23);
E11_1_50=data([1:index],25);
E22_1_50=data([1:index],26);
S11_1_50=data([1:index],27);
S22_1_50=data([1:index],28);
AS_1_50=data([1:index],31);
E11_50_1=data([1:index],33);
E22_50_1=data([1:index],34);
S11_50_1=data([1:index],35);
S22_50_1=data([1:index],36);
AS_50_1=data([1:index],39);
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1];
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1];
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1];
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1];
AS=[AS_1_1, AS_1_75, AS_75_1, AS_1_50, AS_50_1];
%figure
figure(1)
sz=15;
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E11_1_75,S11_1_75,sz,'r'); hold on;
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
sz=20;
scatter(E22_1_1,S22_1_1,sz,'k','x'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r','x'); hold on;
sz=15;
scatter(E22_75_1,S22_75_1,sz,'g','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
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scatter(E22_1_50,S22_1_50,sz,'y','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;

title('All Ratios')
% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential
0.75:1','Circumferential 1:0.5','Radial 0.5:1','Radial 1:1','Radial
1:0.75','Radial 0.75:1','Radial 1:0.5','Radial 0.5:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11)),(max(max(E22)))); %max E for axis limits (x limit)
Smax=max(max(max(S11)),(max(max(S22)))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]) % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=350;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
figure (2)
subplot(1,2,1)
sz=15;
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E11_1_75,S11_1_75,sz,'r'); hold on;
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
title ('Green Strain vs.'); %title only so easier to save/distinguish
% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential
0.75:1','Circumferential 1:0.5')
% title('Circumferential')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(E11)); %max E for axis limits (x limit)
Smax=max(max(S11)); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
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set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure(2)
subplot (1,2,2);
sz=20;
scatter(E22_1_1,S22_1_1,sz,'k','x'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r','x'); hold on;
sz=15;
scatter(E22_75_1,S22_75_1,sz,'g','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_1_50,S22_1_50,sz,'y','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
title ('2nd P-K stress'); %title only so easier to save/distinguish
% legend('Radial 1:1','Radial 1:0.75','Radial 0.75:1','Radial 1:0.5')
% title('Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(E22)); %max E for axis limits (x limit)
Smax=max(max(S22)); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=800;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
figure (3)
subplot(1,2,1)
sz=15;
scatter(AS_1_1,S11_1_1,sz,'k'); hold on;
scatter(AS_1_75,S11_1_75,sz,'r'); hold on;
scatter(AS_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(AS_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(AS_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
title ('Areal Strain vs.'); %title only so easier to save/distinguish
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% legend('Circumferential 1:1','Circumferential 1:0.75','Circumferential
0.75:1','Circumferential 1:0.5')
% title('Circumferential')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
ASmax=max(max(AS)); %max E for axis limits (x limit)
Smax=max(max(S11)); %max S for axis limits (y limit)
axis([0 ASmax+0.02 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.05:ASmax+0.02);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure(3)
subplot (1,2,2);
sz=20;
scatter(AS_1_1,S22_1_1,sz,'k','x'); hold on;
scatter(AS_1_75,S22_1_75,sz,'r','x'); hold on;
sz=15;
scatter(AS_75_1,S22_75_1,sz,'g','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(AS_1_50,S22_1_50,sz,'y','d','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(AS_50_1,S22_50_1,sz,'b','h','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
title ('2nd P-K stress'); %title only so easier to save/distinguish
% legend('Radial 1:1','Radial 1:0.75','Radial 0.75:1','Radial 1:0.5')
% title('Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
ASmax=max(max(AS)); %max E for axis limits (x limit)
Smax=max(max(S22)); %max S for axis limits (y limit)
axis([0 ASmax+0.02 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.05:ASmax+0.02);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=800;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
figure(4)
scatter(S11_1_1,S22_1_1,sz,'k'); hold on;
scatter(S11_1_75,S22_1_75,sz,'r'); hold on;
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scatter(S11_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(S11_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(S11_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
title ('2nd P-K stress circ vs rad'); %title only so easier to
save/distinguish
% legend('1:1','1:0.75','0.75:1','1:0.5')
% title('Radial')
% xlabel('S22 (kPa)')
% ylabel('S22 (kPa)')
S11max=max(max(S11)); %max S11 for axis limits (x limit)
S22max=max(max(S22)); %max S22 for axis limits (y limit)
axis([0 S11max+10 0 S22max+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:S22max+10);
set(gca,'Xtick', 0:20:S11max+10);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=350;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])

167

Constitutive Models MATLAB Instructions and Codes
For the constitutive models, excel sheets containing the Green strain (E), 1st P-K (P) stress, and
2nd P-K (S) stress in the circumferential and radial direction of all tension loading ratios must be
made. MATLAB code Biaxial_4.m exports an excel sheet (plotdata.xlsx) containing E, S, and P
in both the circumferential and radial direction and the areal strain for each tension loading
ratios. One excel sheet needs to be made containing all 5 ratios (1:1, 1:0.75, 0.75:1, 1:0.50, and
0.50:1).
The columns would be as followed. For the first tension ratio of 1:1: column A: E11; column B:
E22; column C: S11; column D: S22; column E: P11; column F: P22, column G: AS, and
column H: empty. Repeat in the preceding columns for the remaining ratios in the order of 1:1,
1:0.75, 0.75:1, 1:0.50, and 0.50:1 i.e. Tension ratio 1:0.75: column I: E11; column J: E22, etc.
Tension ratio 0.75:1: column Q: E11; column R: E22, etc. Tension ratio 1:0.50: column Y: E11;
column Z: E22, etc. Tension ratio 0.50:1: column AG: E11; column AH: E22, etc. It is important
to create the excel file in this order as MATLAB codes load the data accordingly.
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ModifiedMooneyRivlin_Isotropic.m MATLAB Code
%Isotropic Modified Mooney-Rivlin
clc
clear all
close all
warning off;
%Written by Jessica Perez
%Version January 2019
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code calculates the constants for the Mooney Rivlin computational
%model and graphs the experimental data and model data.
%%Yang Modified Mooney Rivlin-Isotropic Equation
%Strain Energy (W)
%W=c1*(I1-3)+c2*(I2-3)+D1*[exp(D2*(I1-3))-1]
%Cauchy Stress (sigma)
%sigma=-pI+2.*dW/dI1.*B-2.*dW/dI2.*B.^-1
%p=hydrostatic pressure term associated with the incompressibility
%constraint
%I1 and I2 from Kanner to use with Yang
%I1=trB=lam1^2+lam2^2+lam3^2
%I2=1/2*[(trB)^2)-tr(B^2)]=lam1^2*lam2^2+lam2^2*lam3^2+lam3^2*lam1^2
%E vs S
%S11=(2E11+1)^(-1)*[2c2-2(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])+2(2E11+1)
%
(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])-2c2(2E11+1)^(-1)]
%S22=(2E22+1)^(-1)*[2c2-2(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])+2(2E22+1)
%
(c1+D1[D2exp(D2(2E11+2E22+3)-3D2)])-2c2(2E22+1)^(-1)]
%Note:
% To extract the files the data should be as follows on the file with
% all the ratio data.
% 1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22
% 1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22
% 0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22
% 1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22
% 0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22
%Input:
% File containing ratio data
%Output:
% Excel file:Mooney-Rivlin Constants.xlsx
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%
Contains: c1,c2,D1,D2,condition data, r square combined
% Graphs that need to be saved as jpeg or other filetype:
%
(1) Individual ratios of the circumferential and radial together (5
%
figures in subplot)
%
Legend:
%
Experimental Circumferential=black circles
%
Experimental Radial=red circles
%
Model Fit=Red Line
%
Order:
%
left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
%
(2) All ratios with circumferential and radial seperate (2 figures in
%
subplot)
%
Legend:
%
Experimental 1:1=black circles
%
Experimental 1:0.75=red circles
%
Experimental 0.75:1=upside down green triangle
%
Experimental 1:0.50=yello triangle
%
Experimental 0.5:1=blue square
%
Model Fit=Red Line
%
Order:
%
left to right= Circumferential, Radial
%
%
%
%
%
%
%

Note:
(1)Figures are the size that allows the subplots to be saved
properly and not be stretched out.
(2)Figures have no titles, x and y labels, or legends. I put those when
I'm compiling figures in a powerpoint. However, the code to do so is
commented so you can just uncomment them for whatever you want on
the graph.

%Extracting all ratio data from excel file
[filename,pathname]=uigetfile('*.*', 'Select file');
data=xlsread(filename);
index=size(data,1);
%Seperating data by ratios 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
E11_1_1=data([1:index],1);
E22_1_1=data([1:index],2);
S11_1_1=data([1:index],3);
S22_1_1=data([1:index],4);
P11_1_1=data([1:index],5);
P22_1_1=data([1:index],6);
AS_1_1=data([1:index],7);
E11_1_75=data([1:index],9);
E22_1_75=data([1:index],10);
S11_1_75=data([1:index],11);
S22_1_75=data([1:index],12);
P11_1_75=data([1:index],13);
P22_1_75=data([1:index],14);
AS_1_75=data([1:index],15);
E11_75_1=data([1:index],17);
E22_75_1=data([1:index],18);
S11_75_1=data([1:index],19);
S22_75_1=data([1:index],20);
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P11_75_1=data([1:index],21);
P22_75_1=data([1:index],22);
AS_75_1=data([1:index],23);
E11_1_50=data([1:index],25);
E22_1_50=data([1:index],26);
S11_1_50=data([1:index],27);
S22_1_50=data([1:index],28);
P11_1_50=data([1:index],29);
P22_1_50=data([1:index],30);
AS_1_50=data([1:index],31);
E11_50_1=data([1:index],33);
E22_50_1=data([1:index],34);
S11_50_1=data([1:index],35);
S22_50_1=data([1:index],36);
P11_50_1=data([1:index],37);
P22_50_1=data([1:index],38);
AS_50_1=data([1:index],39);
E11_1_1=data([1:index],1);
E22_1_1=data([1:index],2);
S11_1_1=data([1:index],3);
S22_1_1=data([1:index],4);
E11_1_75=data([1:index],9);
E22_1_75=data([1:index],10);
S11_1_75=data([1:index],11);
S22_1_75=data([1:index],12);
E11_75_1=data([1:index],17);
E22_75_1=data([1:index],18);
S11_75_1=data([1:index],19);
S22_75_1=data([1:index],20);
E11_1_50=data([1:index],25);
E22_1_50=data([1:index],26);
S11_1_50=data([1:index],27);
S22_1_50=data([1:index],28);
E11_50_1=data([1:index],33);
E22_50_1=data([1:index],34);
S11_50_1=data([1:index],35);
S22_50_1=data([1:index],36);
% Model formulation
syms c1 c2 D1 D2 E11 E22 real
W=2.*c1.*(E11+E22)+4.*(E11.*E22+E11+E22)+D1.*(exp(2.*D2.*(E11+E22))-1);
fun_11=matlabFunction(diff(W,E11)); %symbolic
fun_22=matlabFunction(diff(W,E22)); %symbolic
clear E11 E22
% Objective function. This is the sum of squares of the residuals. I had to
% write out the complete equations because I'm not sure yet how to
% incorporate function handles fun_11 and fun_22 into this.
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obj_fun = @(x)...
+ sum((((2.*E11_1_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22_1_1+3)3.*x(4))))+2.*(2.*E11_1_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22
_1_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_1+1).^(-1)))S11_1_1).^(2)+(((2.*E22_1_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22_1_1+3)3.*x(4))))+2.*(2.*E22_1_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22
_1_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_1+1).^(-1)))-S22_1_1).^(2))...
+ sum((((2.*E11_1_75+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E22_1_75+3)3.*x(4))))+2.*(2.*E11_1_75+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E
22_1_75+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_75+1).^(-1)))S11_1_75).^(2)+(((2.*E22_1_75+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E22_1_75+3)3.*x(4))))+2.*(2.*E22_1_75+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E
22_1_75+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_75+1).^(-1)))-S22_1_75).^(2))...
+ sum((((2.*E11_75_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E22_75_1+3)3.*x(4))))+2.*(2.*E11_75_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E
22_75_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_75_1+1).^(-1)))S11_75_1).^(2)+(((2.*E22_75_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E22_75_1+3)3.*x(4))))+2.*(2.*E22_75_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E
22_75_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_75_1+1).^(-1)))-S22_75_1).^(2))...
+ sum((((2.*E11_1_50+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E22_1_50+3)3.*x(4))))+2.*(2.*E11_1_50+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E
22_1_50+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_50+1).^(-1)))S11_1_50).^(2)+(((2.*E22_1_50+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E22_1_50+3)3.*x(4))))+2.*(2.*E22_1_50+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E
22_1_50+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_50+1).^(-1)))-S22_1_50).^(2))...
+ sum((((2.*E11_50_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E22_50_1+3)3.*x(4))))+2.*(2.*E11_50_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E
22_50_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_50_1+1).^(-1)))S11_50_1).^(2)+(((2.*E22_50_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E22_50_1+3)3.*x(4))))+2.*(2.*E22_50_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E
22_50_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_50_1+1).^(-1)))-S22_50_1).^(2));
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2));
% Minimization of objective function using fmincon
x0=[1,2,3,4]; % initial guesses
lb=[-inf,-inf,-inf,-inf]; % lower bound for parameters
ub=[inf,inf,inf,inf]; % upper bound for parameters
A=[0,0,0,0;0,0,0,0;0,0,0,0;0,0,0,0]; % Variables to enforce inequality
constraint
b=[0,0,0,0]; % Variables to enforce inequality constraint
options = optimoptions('fmincon','Display','iter','Algorithm','sqp');
%Options to control execution of fmincon
% options =
optimoptions('fmincon','Display','iter','Algorithm','sqp','MaxIterations',100
00,'MaxFunEval',100000,'StepTolerance',1e-20);
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x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options);
% Backed out coeffecients
c1=x(1)
c2=x(2)
D1=x(3)
D2=x(4)
% Matrix form of coeffecients
D=[c1,c2,D1,D2];
% Total R_square
SSres= ...
+ sum((((2.*E11_1_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22_1_1+3)3.*x(4))))+2.*(2.*E11_1_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22
_1_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_1+1).^(-1)))S11_1_1).^(2)+(((2.*E22_1_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22_1_1+3)3.*x(4))))+2.*(2.*E22_1_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1+2.*E22
_1_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_1+1).^(-1)))-S22_1_1).^(2))...
+ sum((((2.*E11_1_75+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E22_1_75+3)3.*x(4))))+2.*(2.*E11_1_75+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E
22_1_75+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_75+1).^(-1)))S11_1_75).^(2)+(((2.*E22_1_75+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E22_1_75+3)3.*x(4))))+2.*(2.*E22_1_75+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75+2.*E
22_1_75+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_75+1).^(-1)))-S22_1_75).^(2))...
+ sum((((2.*E11_75_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E22_75_1+3)3.*x(4))))+2.*(2.*E11_75_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E
22_75_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_75_1+1).^(-1)))S11_75_1).^(2)+(((2.*E22_75_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E22_75_1+3)3.*x(4))))+2.*(2.*E22_75_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1+2.*E
22_75_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_75_1+1).^(-1)))-S22_75_1).^(2))...
+ sum((((2.*E11_1_50+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E22_1_50+3)3.*x(4))))+2.*(2.*E11_1_50+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E
22_1_50+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_50+1).^(-1)))S11_1_50).^(2)+(((2.*E22_1_50+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E22_1_50+3)3.*x(4))))+2.*(2.*E22_1_50+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50+2.*E
22_1_50+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_50+1).^(-1)))-S22_1_50).^(2))...
+ sum((((2.*E11_50_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E22_50_1+3)3.*x(4))))+2.*(2.*E11_50_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E
22_50_1+3)-3.*x(4))))-2.*x(2).*(2.*E11_50_1+1).^(-1)))S11_50_1).^(2)+(((2.*E22_50_1+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E22_50_1+3)3.*x(4))))+2.*(2.*E22_50_1+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1+2.*E
22_50_1+3)-3.*x(4))))-2.*x(2).*(2.*E22_50_1+1).^(-1)))-S22_50_1).^(2));
c_bar1=mean2(S11_1_1);
r_bar1=mean2(S22_1_1);
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c_bar2=mean2(S11_1_75);
r_bar2=mean2(S22_1_75);
c_bar3=mean2(S11_75_1);
r_bar3=mean2(S22_75_1);
c_bar4=mean2(S11_1_50);
r_bar4=mean2(S22_1_50);
c_bar5=mean2(S11_50_1);
r_bar5=mean2(S22_50_1);
SStot= ...
+ sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))...
+ sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))...
+ sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))...
+ sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))...
+ sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2));
R_square_combine=1-(SSres/SStot)
%Export constants into excel sheet
output=[c1,c2,D1,D2, R_square_combine];
h={'c1', 'c2','D1','D2', 'R_square_combine'};
m=[h;num2cell(output)];
filename='Modified M-R (Isotropic) Constants.xlsx';
xlswrite(filename,m);
% Generated values for plotting model fit
E11_1_1_m=linspace(0,max(E11_1_1),1000);
E22_1_1_m=linspace(0,max(E22_1_1),1000);
model11_1_1_m=(2.*E11_1_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1_m+2.*E22_1_1_m+3)3.*x(4))))+2.*(2.*E11_1_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1_m+2.
*E22_1_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_1_m+1).^(-1));
model22_1_1_m=(2.*E22_1_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1_m+2.*E22_1_1_m+3)3.*x(4))))+2.*(2.*E22_1_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_1_m+2.
*E22_1_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_1_m+1).^(-1));
model11_1_1_m=linspace(0,max(model11_1_1_m),1000);
model22_1_1_m=linspace(0,max(model22_1_1_m),1000);
E11_1_75_m=linspace(0,max(E11_1_75),1000);
E22_1_75_m=linspace(0,max(E22_1_75),1000);
model11_1_75_m=(2.*E11_1_75_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75_m+2.*E22_1_75_m+3)3.*x(4))))+2.*(2.*E11_1_75_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75_m+
2.*E22_1_75_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_75_m+1).^(-1));
model22_1_75_m=(2.*E22_1_75_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75_m+2.*E22_1_75_m+3)3.*x(4))))+2.*(2.*E22_1_75_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_75_m+
2.*E22_1_75_m+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_75_m+1).^(-1));
model11_1_75_m=linspace(0,max(model11_1_75_m),1000);
model22_1_75_m=linspace(0,max(model22_1_75_m),1000);
E11_75_1_m=linspace(0,max(E11_75_1),1000);
E22_75_1_m=linspace(0,max(E22_75_1),1000);
model11_75_1_m=(2.*E11_75_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1_m+2.*E22_75_1_m+3)-
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3.*x(4))))+2.*(2.*E11_75_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1_m+
2.*E22_75_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_75_1_m+1).^(-1));
model22_75_1_m=(2.*E22_75_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1_m+2.*E22_75_1_m+3)3.*x(4))))+2.*(2.*E22_75_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_75_1_m+
2.*E22_75_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E22_75_1_m+1).^(-1));
model11_75_1_m=linspace(0,max(model11_75_1_m),1000);
model22_75_1_m=linspace(0,max(model22_75_1_m),1000);
E11_1_50_m=linspace(0,max(E11_1_50),1000);
E22_1_50_m=linspace(0,max(E22_1_50),1000);
model11_1_50_m=(2.*E11_1_50_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50_m+2.*E22_1_50_m+3)3.*x(4))))+2.*(2.*E11_1_50_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50_m+
2.*E22_1_50_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_1_50_m+1).^(-1));
model22_1_50_m=(2.*E22_1_50_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50_m+2.*E22_1_50_m+3)3.*x(4))))+2.*(2.*E22_1_50_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_1_50_m+
2.*E22_1_50_m+3)-3.*x(4))))-2.*x(2).*(2.*E22_1_50_m+1).^(-1));
model11_1_50_m=linspace(0,max(model11_1_50_m),1000);
model22_1_50_m=linspace(0,max(model22_1_50_m),1000);
E11_50_1_m=linspace(0,max(E11_50_1),1000);
E22_50_1_m=linspace(0,max(E22_50_1),1000);
model11_50_1_m=(2.*E11_50_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1_m+2.*E22_50_1_m+3)3.*x(4))))+2.*(2.*E11_50_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1_m+
2.*E22_50_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_50_1_m+1).^(-1));
model22_50_1_m=(2.*E11_50_1_m+1).^(-1).*(2.*x(2)2.*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1_m+2.*E22_50_1_m+3)3.*x(4))))+2.*(2.*E11_50_1_m+1).*(x(1)+x(3).*(x(4).*exp(x(4).*(2.*E11_50_1_m+
2.*E22_50_1_m+3)-3.*x(4))))-2.*x(2).*(2.*E11_50_1_m+1).^(-1));
model11_50_1_m=linspace(0,max(model11_50_1_m),1000);
model22_50_1_m=linspace(0,max(model22_50_1_m),1000);
%Plot:
% Large matrix containg all values
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1];
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1];
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1];
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1];
model11=[model11_1_1_m,model11_1_75_m,model11_75_1_m,model11_1_50_m,model11_5
0_1_m];
model22=[model22_1_1_m,model22_1_75_m,model22_75_1_m,model22_1_50_m,model22_5
0_1_m];
%Figure (1) plots Individual ratios of the circumgerential and radial
%together (5 figures in subplot)Figure is very wide to insure that plots
%are displayed properly. Save figure as jpeg or desired file type.
%Size of markers in scatterplot
sz=15;
figure (1)
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subplot (1,5,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E22_1_1,S22_1_1,sz,'r'); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E22_1_1_m,model22_1_1_m,'r'); hold off;
Emax_1_1=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits
(x limit)
Smax_1_1=max(max(max(S11_1_1)),(max(max(S22_1_1)))); %max S for axis limits
(y limit)
axis([0 Emax_1_1+0.05 0 Smax_1_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_1+10);
set(gca,'Xtick', 0:0.1:Emax_1_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,2)
scatter(E11_1_75,S11_1_75,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
plot(E11_1_75_m,model11_1_75_m,'r',E22_1_75_m,model22_1_75_m,'r'); hold off;
Emax_1_75=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis
limits (x limit)
Smax_1_75=max(max(max(S11_1_75)),(max(max(S22_1_75)))); %max S for axis
limits (y limit)
axis([0 Emax_1_75+0.05 0 Smax_1_75+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.75:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_75+10);
set(gca,'Xtick', 0:0.1:Emax_1_75+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,3)
sz=15;
scatter(E11_75_1,S11_75_1,sz,'k'); hold on;
scatter(E22_75_1,S22_75_1,sz,'r'); hold on;
plot(E11_75_1_m,model11_75_1_m,'r',E22_75_1_m,model22_75_1_m,'r'); hold off;
Emax_75_1=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis
limits (x limit)
Smax_75_1=max(max(max(S11_75_1)),(max(max(S22_75_1)))); %max S for axis
limits (y limit)
axis([0 Emax_75_1+0.05 0 Smax_75_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
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% title('1:0.75')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_75_1+10);
set(gca,'Xtick', 0:0.1:Emax_75_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,4)
scatter(E11_1_50,S11_1_50,sz,'k'); hold on;
scatter(E22_1_50,S22_1_50,sz,'r'); hold on;
plot(E11_1_50_m,model11_1_50_m,'r',E22_1_50_m,model22_1_50_m,'r'); hold off;
Emax_1_50=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis
limits (x limit)
Smax_1_50=max(max(max(S11_1_50)),(max(max(S22_1_50)))); %max S for axis
limits (y limit)
axis([0 Emax_1_50+0.05 0 Smax_1_50+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.5:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_50+10);
set(gca,'Xtick', 0:0.1:Emax_1_50+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,5)
scatter(E11_50_1,S11_50_1,sz,'k'); hold on;
scatter(E22_50_1,S22_50_1,sz,'r'); hold on;
plot(E11_50_1_m,model11_50_1_m,'r',E22_50_1_m,model22_50_1_m,'r'); hold off;
Emax_50_1=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis
limits (x limit)
Smax_50_1=max(max(max(S11_50_1)),(max(max(S22_50_1)))); %max S for axis
limits (y limit)
axis([0 Emax_50_1+0.05 0 Smax_50_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:0.5')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_50_1+10);
set(gca,'Xtick', 0:0.1:Emax_50_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=1600;
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height=200;
set(gcf,'units','points','position',[x0,y0,width,height])
%Figure (2) plots all ratios with circumferential and radial seperate
%(2 figures in subplot). Save figure as jpeg or desired file type.
%Note: label of each ratio-1:1=circle; 1:0.75=astrix
figure (2)
subplot (1,2,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E11_1_75,S11_1_75,sz,'r'); hold on;
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E11_1_75_m,model11_1_75_m,'r',E11_75_1_m,mod
el11_75_1_m,'r',E11_1_50_m,model11_1_50_m,'r',E11_50_1_m,model11_50_1_m,'r');
hold off;
Emax=max(max(E11)); %max E for axis limits (x limit)
Smax=(max(max(max(S11)),(max(model11)))); %max S for axis limits (x limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
%legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Circumferential')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (2)
subplot (1,2,2)
scatter(E22_1_1,S22_1_1,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E22_1_1_m,model22_1_1_m,'r',E22_1_75_m,model22_1_75_m,'r',E22_75_1_m,mod
el22_75_1_m,'r',E22_1_50_m,model22_1_50_m,'r',E22_50_1_m,model22_50_1_m,'r');
hold off;
Emax=max(max(E22)); %max E for axis limits (x limit)
Smax=(max(max(max(S22)),(max(model22)))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
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%legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',12,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=800;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])

179

ModifiedMooneyRivlin_Anisotropic.m MATLAB Code
%Anisotropic Modified Mooney-Rivlin
clc
clear all
close all
warning off;
%Written by Jessica Perez
%Version January 2019
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code calculates the constants for the Mooney Rivlin computational
%model and graphs the experimental data and model data.
%%Rassouli Mooney Rivlin Modified Anisotropic Equation
%Strain Energy (W)
%W=c1(I1-3)+D1[exp(D2(I1-3))-1]+(k1/2k2)[exp[k2(I4-1)^2-1]
%Cauchy Stress (sigma)
%sigma=-pI+2.*dW/dI1.*B-2.*dW/dI2.*B.^-1
%p=hydrostatic pressure term associated with the incompressibility
%constraint
%I1 and I2 from Kanner
%I1=trB=lam1^2+lam2^2+lam3^2
%I2=1/2*[(trB)^2)-tr(B^2)]=lam1^2*lam2^2+lam2^2*lam3^2+lam3^2*lam1^2
%I4=Cij(nc)i(nc)j
%E vs S
%S11=[4E11(c1+D1D2exp(2E11+2E22))+4k1E11(2E11+1)exp(k2(2E11)^2)]÷(2E11+1)
%S22=[4E22(c1+D1D2exp(2E11+2E22))]÷(2E22+1)
%Note:
% To extract the files the data should be as follows on the file with
% all the ratio data.
% 1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22
% 1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22
% 0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22
% 1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22
% 0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22
%Input:
% File containing ratio data
%Output:
% Excel file:Mooney-Rivlin Constants.xlsx
%
Contains: c1,c2,D1,D2,condition data, r square combined
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% Graphs that need to be saved as jpeg or other filetype:
%
(1) Individual ratios of the circumferential and radial together (5
%
figures in subplot)
%
Legend:
%
Experimental Circumferential=black circles
%
Experimental Radial=red circles
%
Model Fit=Red Line
%
Order:
%
left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
%
(2) All ratios with circumferential and radial seperate (2 figures in
%
subplot)
%
Legend:
%
Experimental 1:1=black circles
%
Experimental 1:0.75=red circles
%
Experimental 0.75:1=upside down green triangle
%
Experimental 1:0.50=yello triangle
%
Experimental 0.5:1=blue square
%
Model Fit=Red Line
%
Order:
%
left to right= Circumferential, Radial
%
%
%
%
%
%
%

Note:
(1)Figures are the size that allows the subplots to be saved
properly and not be stretched out.
(2)Figures have no titles, x and y labels, or legends. I put those when
I'm compiling figures in a powerpoint. However, the code to do so is
commented so you can just uncomment them for whatever you want on
the graph.

%Extracting all ratio data from excel file
[filename,pathname]=uigetfile('*.*', 'Select file');
data=xlsread(filename);
index=size(data,1);
%Seperating data by ratios 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
E11_1_1=data([1:index],1);
E22_1_1=data([1:index],2);
S11_1_1=data([1:index],3);
S22_1_1=data([1:index],4);
E11_1_75=data([1:index],9);
E22_1_75=data([1:index],10);
S11_1_75=data([1:index],11);
S22_1_75=data([1:index],12);
E11_75_1=data([1:index],17);
E22_75_1=data([1:index],18);
S11_75_1=data([1:index],19);
S22_75_1=data([1:index],20);
E11_1_50=data([1:index],25);
E22_1_50=data([1:index],26);
S11_1_50=data([1:index],27);
S22_1_50=data([1:index],28);
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E11_50_1=data([1:index],33);
E22_50_1=data([1:index],34);
S11_50_1=data([1:index],35);
S22_50_1=data([1:index],36);
% Objective function. This is the sum of squares of the residuals.
obj_fun = @(x)...
+
sum((((4.*E11_1_1.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1+2.*E22_1_1))+4.*x(4).*E11
_1_1.*(2.*E11_1_1+1).*exp(x(5).*(2.*E11_1_1).^2))./(2.*E11_1_1+1))S11_1_1).^2+(((4.*E22_1_1.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1+2.*E22_1_1)))./(2
.*E22_1_1+1))-S22_1_1).^2)...
+
sum((((4.*E11_1_75.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75+2.*E22_1_75))+4.*x(4).*
E11_1_75.*(2.*E11_1_75+1).*exp(x(5).*(2.*E11_1_75).^2))./(2.*E11_1_75+1))S11_1_75).^2+(((4.*E22_1_75.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75+2.*E22_1_75)))
./(2.*E22_1_75+1))-S22_1_75).^2)...
+
sum((((4.*E11_75_1.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1+2.*E22_75_1))+4.*x(4).*
E11_75_1.*(2.*E11_75_1+1).*exp(x(5).*(2.*E11_75_1).^2))./(2.*E11_75_1+1))S11_75_1).^2+(((4.*E22_75_1.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1+2.*E22_75_1)))
./(2.*E22_75_1+1))-S22_75_1).^2)...
+
sum((((4.*E11_1_50.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50+2.*E22_1_50))+4.*x(4).*
E11_1_50.*(2.*E11_1_50+1).*exp(x(5).*(2.*E11_1_50).^2))./(2.*E11_1_50+1))S11_1_50).^2+(((4.*E22_1_50.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50+2.*E22_1_50)))
./(2.*E22_1_50+1))-S22_1_50).^2)...
+
sum((((4.*E11_50_1.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1+2.*E22_50_1))+4.*x(4).*
E11_50_1.*(2.*E11_50_1+1).*exp(x(5).*(2.*E11_50_1).^2))./(2.*E11_50_1+1))S11_50_1).^2+(((4.*E22_50_1.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1+2.*E22_50_1)))
./(2.*E22_50_1+1))-S22_50_1).^2);
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2));
% Minimization of objective function using fmincon
x0=[1,1,1,1,1]; % initial guesses
lb=[-inf,-inf,2,-inf,-inf]; % lower bound for parameters
ub=[inf,inf,2,inf,inf]; % upper bound for parameters
A=[0,0,0,0,0;0,0,0,0,0;0,0,0,0,0;0,0,0,0,0;0,0,0,0,0]; % Variables to enforce
inequality constraint
b=[0,0,0,0,0]; % Variables to enforce inequality constraint
options = optimoptions('fmincon','Display','iter','Algorithm','sqp');
%Options to control execution of fmincon
% options =
optimoptions('fmincon','Display','iter','Algorithm','sqp','MaxIterations',100
00,'MaxFunEval',100000,'StepTolerance',1e-20);
x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options);
% Backed out coeffecients
c1=x(1)
D1=x(2)
D2=x(3)
k1=x(4)
k2=x(5)
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% Matrix form of coeffecients
D=[c1,D1,D2,k1,k2];
% Total R_square
SSres= ...
+
sum((((4.*E11_1_1.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1+2.*E22_1_1))+4.*x(4).*E11
_1_1.*(2.*E11_1_1+1).*exp(x(5).*(2.*E11_1_1).^2))./(2.*E11_1_1+1))S11_1_1).^2+(((4.*E22_1_1.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1+2.*E22_1_1)))./(2
.*E22_1_1+1))-S22_1_1).^2)...
+
sum((((4.*E11_1_75.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75+2.*E22_1_75))+4.*x(4).*
E11_1_75.*(2.*E11_1_75+1).*exp(x(5).*(2.*E11_1_75).^2))./(2.*E11_1_75+1))S11_1_75).^2+(((4.*E22_1_75.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75+2.*E22_1_75)))
./(2.*E22_1_75+1))-S22_1_75).^2)...
+
sum((((4.*E11_75_1.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1+2.*E22_75_1))+4.*x(4).*
E11_75_1.*(2.*E11_75_1+1).*exp(x(5).*(2.*E11_75_1).^2))./(2.*E11_75_1+1))S11_75_1).^2+(((4.*E22_75_1.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1+2.*E22_75_1)))
./(2.*E22_75_1+1))-S22_75_1).^2)...
+
sum((((4.*E11_1_50.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50+2.*E22_1_50))+4.*x(4).*
E11_1_50.*(2.*E11_1_50+1).*exp(x(5).*(2.*E11_1_50).^2))./(2.*E11_1_50+1))S11_1_50).^2+(((4.*E22_1_50.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50+2.*E22_1_50)))
./(2.*E22_1_50+1))-S22_1_50).^2)...
+
sum((((4.*E11_50_1.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1+2.*E22_50_1))+4.*x(4).*
E11_50_1.*(2.*E11_50_1+1).*exp(x(5).*(2.*E11_50_1).^2))./(2.*E11_50_1+1))S11_50_1).^2+(((4.*E22_50_1.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1+2.*E22_50_1)))
./(2.*E22_50_1+1))-S22_50_1).^2);
c_bar1=mean2(S11_1_1);
r_bar1=mean2(S22_1_1);
c_bar2=mean2(S11_1_75);
r_bar2=mean2(S22_1_75);
c_bar3=mean2(S11_75_1);
r_bar3=mean2(S22_75_1);
c_bar4=mean2(S11_1_50);
r_bar4=mean2(S22_1_50);
c_bar5=mean2(S11_50_1);
r_bar5=mean2(S22_50_1);
SStot= ...
+ sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))...
+ sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))...
+ sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))...
+ sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))...
+ sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2));
R_square_combine=1-(SSres/SStot)
%Export constants into excel sheet
output=[c1,D1,D2,k1,k2, R_square_combine];
h={'c1','D1','D2','k1','k2','R_square_combine'};
m=[h;num2cell(output)];
filename='Modified M-R (Anisotropic) Constants.xlsx';
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xlswrite(filename,m);
% Generated values for plotting model fit
E11_1_1_m=linspace(0,max(E11_1_1),1000);
E22_1_1_m=linspace(0,max(E22_1_1),1000);
model11_1_1_m=(4.*E11_1_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1_m+2.*E22_1_1_m)
)+4.*x(4).*E11_1_1_m.*(2.*E11_1_1_m+1).*exp(x(5).*(2.*E11_1_1_m).^2))./(2.*E1
1_1_1_m+1);
model22_1_1_m=(4.*E22_1_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_1_m+2.*E22_1_1_m)
))./(2.*E22_1_1_m+1);
model11_1_1_m=linspace(0,max(model11_1_1_m),1000);
model22_1_1_m=linspace(0,max(model22_1_1_m),1000);
E11_1_75_m=linspace(0,max(E11_1_75),1000);
E22_1_75_m=linspace(0,max(E22_1_75),1000);
model11_1_75_m=(4.*E11_1_75_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75_m+2.*E22_1_7
5_m))+4.*x(4).*E11_1_75_m.*(2.*E11_1_75_m+1).*exp(x(5).*(2.*E11_1_75_m).^2)).
/(2.*E11_1_75_m+1);
model22_1_75_m=(4.*E22_1_75_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_75_m+2.*E22_1_7
5_m)))./(2.*E22_1_75_m+1);
model11_1_75_m=linspace(0,max(model11_1_75_m),1000);
model22_1_75_m=linspace(0,max(model22_1_75_m),1000);
E11_75_1_m=linspace(0,max(E11_75_1),1000);
E22_75_1_m=linspace(0,max(E22_75_1),1000);
model11_75_1_m=(4.*E11_75_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1_m+2.*E22_75_
1_m))+4.*x(4).*E11_75_1_m.*(2.*E11_75_1_m+1).*exp(x(5).*(2.*E11_75_1_m).^2)).
/(2.*E11_75_1_m+1);
model22_75_1_m=(4.*E22_75_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_75_1_m+2.*E22_75_
1_m)))./(2.*E22_75_1_m+1);
model11_75_1_m=linspace(0,max(model11_75_1_m),1000);
model22_75_1_m=linspace(0,max(model22_75_1_m),1000);
E11_1_50_m=linspace(0,max(E11_1_50),1000);
E22_1_50_m=linspace(0,max(E22_1_50),1000);
model11_1_50_m=(4.*E11_1_50_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50_m+2.*E22_1_5
0_m))+4.*x(4).*E11_1_50_m.*(2.*E11_1_50_m+1).*exp(x(5).*(2.*E11_1_50_m).^2)).
/(2.*E11_1_50_m+1);
model22_1_50_m=(4.*E22_1_50_m.*(x(1)+x(2).*x(3).*exp(2.*E11_1_50_m+2.*E22_1_5
0_m)))./(2.*E22_1_50_m+1);
model11_1_50_m=linspace(0,max(model11_1_50_m),1000);
model22_1_50_m=linspace(0,max(model22_1_50_m),1000);
E11_50_1_m=linspace(0,max(E11_50_1),1000);
E22_50_1_m=linspace(0,max(E22_50_1),1000);
model11_50_1_m=(4.*E11_50_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1_m+2.*E22_50_
1_m))+4.*x(4).*E11_50_1_m.*(2.*E11_50_1_m+1).*exp(x(5).*(2.*E11_50_1_m).^2)).
/(2.*E11_50_1_m+1);
model22_50_1_m=(4.*E22_50_1_m.*(x(1)+x(2).*x(3).*exp(2.*E11_50_1_m+2.*E22_50_
1_m)))./(2.*E22_50_1_m+1);
model11_50_1_m=linspace(0,max(model11_50_1_m),1000);
model22_50_1_m=linspace(0,max(model22_50_1_m),1000);
%Plot:
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% Large matrix containg all values
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1];
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1];
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1];
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1];
model11=[model11_1_1_m,model11_1_75_m,model11_75_1_m,model11_1_50_m,model11_5
0_1_m];
model22=[model22_1_1_m,model22_1_75_m,model22_75_1_m,model22_1_50_m,model22_5
0_1_m];
%Figure (1) plots Individual ratios of the circumgerential and radial
%together (5 figures in subplot)Figure is very wide to insure that plots
%are displayed properly. Save figure as jpeg or desired file type.
%Size of markers in scatterplot
sz=15;
figure (1)
subplot (1,5,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E22_1_1,S22_1_1,sz,'r'); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E22_1_1_m,model22_1_1_m,'r'); hold off;
Emax_1_1=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits
(x limit)
Smax_1_1=max(max(max(S11_1_1)),(max(max(S22_1_1)))); %max S for axis limits
(y limit)
axis([0 Emax_1_1+0.05 0 Smax_1_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_1+10);
set(gca,'Xtick', 0:0.1:Emax_1_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,2)
scatter(E11_1_75,S11_1_75,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
plot(E11_1_75_m,model11_1_75_m,'r',E22_1_75_m,model22_1_75_m,'r'); hold off;
Emax_1_75=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis
limits (x limit)
Smax_1_75=max(max(max(S11_1_75)),(max(max(S22_1_75)))); %max S for axis
limits (y limit)
axis([0 Emax_1_75+0.05 0 Smax_1_75+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.75:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_75+10);
set(gca,'Xtick', 0:0.1:Emax_1_75+0.05);
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set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,3)
sz=15;
scatter(E11_75_1,S11_75_1,sz,'k'); hold on;
scatter(E22_75_1,S22_75_1,sz,'r'); hold on;
plot(E11_75_1_m,model11_75_1_m,'r',E22_75_1_m,model22_75_1_m,'r'); hold off;
Emax_75_1=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis
limits (x limit)
Smax_75_1=max(max(max(S11_75_1)),(max(max(S22_75_1)))); %max S for axis
limits (y limit)
axis([0 Emax_75_1+0.05 0 Smax_75_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:0.75')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_75_1+10);
set(gca,'Xtick', 0:0.1:Emax_75_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,4)
scatter(E11_1_50,S11_1_50,sz,'k'); hold on;
scatter(E22_1_50,S22_1_50,sz,'r'); hold on;
plot(E11_1_50_m,model11_1_50_m,'r',E22_1_50_m,model22_1_50_m,'r'); hold off;
Emax_1_50=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis
limits (x limit)
Smax_1_50=max(max(max(S11_1_50)),(max(max(S22_1_50)))); %max S for axis
limits (y limit)
axis([0 Emax_1_50+0.05 0 Smax_1_50+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.5:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_1_50+10);
set(gca,'Xtick', 0:0.1:Emax_1_50+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,5)
scatter(E11_50_1,S11_50_1,sz,'k'); hold on;
scatter(E22_50_1,S22_50_1,sz,'r'); hold on;
plot(E11_50_1_m,model11_50_1_m,'r',E22_50_1_m,model22_50_1_m,'r'); hold off;
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Emax_50_1=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis
limits (x limit)
Smax_50_1=max(max(max(S11_50_1)),(max(max(S22_50_1)))); %max S for axis
limits (y limit)
axis([0 Emax_50_1+0.05 0 Smax_50_1+10]) % add 0.1 for max E and 10 for mas S
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:0.5')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax_50_1+10);
set(gca,'Xtick', 0:0.1:Emax_50_1+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=1600;
height=200;
set(gcf,'units','points','position',[x0,y0,width,height])
%Figure (2) plots all ratios with circumferential and radial seperate
%(2 figures in subplot). Save figure as jpeg or desired file type.
%Note: label of each ratio-1:1=circle; 1:0.75=astrix
figure (2)
subplot (1,2,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E11_1_75,S11_1_75,sz,'r'); hold on;
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E11_1_75_m,model11_1_75_m,'r',E11_75_1_m,mod
el11_75_1_m,'r',E11_1_50_m,model11_1_50_m,'r',E11_50_1_m,model11_50_1_m,'r');
hold off;
Emax=max(max(max(E11)),(max(max(E22)))); %max E for axis limits (x limit)
Smax=max(max(max(S11)),(max(max(S22)))); %max S for axis limits (y limit)
Emax=max(max(E11)); %max E for axis limits (x limit)
Smax=(max(max(max(S11)),(max(model11)))); %max S for axis limits (x limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.05 for max E and 10 for mas S
% legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Circumferential')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
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figure (2)
subplot (1,2,2)
scatter(E22_1_1,S22_1_1,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E22_1_1_m,model22_1_1_m,'r',E22_1_75_m,model22_1_75_m,'r',E22_75_1_m,mod
el22_75_1_m,'r',E22_1_50_m,model22_1_50_m,'r',E22_50_1_m,model22_50_1_m,'r');
hold off;
Emax=max(max(E22)); %max E for axis limits (x limit)
Smax=(max(max(max(S22)),(max(model22)))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
% legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',12,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=800;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
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FungModelFit_EnergyPlot.m MATLAB Code
clc
clear all
close all
warning off;
%%Edited by Jessica Perez
%Version November 26, 2018
%Written by Alex Khang, October 31, 2018
%University of Arkansas
%Department of Biomedical Engineering
%Mechanobiology and Soft Materials Laboratory (MSML)
%PI: Dr. Kartik Balachandran
%This code calculates the constants for the fung-type computational model
%and graphs the experimental data and model data.
%Fung-type Model:
% x=E11, y=E22
% S11=(c./2).*(exp(c1.*x.^2+c2.*y.^2+2.*c3.*x.*y)).*(2.*c1.*x+2.*c3.*y)
% S22=(c./2).*(exp(c1.*x.^2+c2.*y.^2+2.*c3.*x.*y)).*(2.*c1.*x+2.*c3.*y)
%Note:
% To extract the files the data should be as follows on the file with
% all the ratio data.
% 1:1: Column A=E11; Column B=E22; Column C=S11; Column D=S22
% 1:0.75: Column I=E11; Column J=E22; Column K=S11; Column L=S22
% 0.75:1: Column Q=E11; Column R=E22; Column S=S11; Column T=S22
% 1:0.5: Column Y=E11; Column Z=E22; Column AA=S11; Column AB=S22
% 0.5:1: Column AG=E11; Column AH=E22; Column AI=S11; Column AJ=S22
%Input:
% File containing ratio data
%Output:
% Excel file:Fung-type Constants.xlsx
%
Contains: c,c1,c2,c3,condition data, r square combined, anisotropy
%
index
% Graphs that need to be saved as jpeg or other filetype:
%
(1) Individual ratios of the circumferential and radial together (5
%
figures in subplot)
%
Legend:
%
Experimental Circumferential=black circles
%
Experimental Radial=red circles
%
Model Fit=Red Line
%
Order:
%
left to right= 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
%
(2) All ratios with circumferential and radial seperate (2 figures in
%
subplot)
%
Legend:
%
Experimental 1:1=black circles
%
Experimental 1:0.75=red circles
%
Experimental 0.75:1=upside down green triangle
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%
%
%
%
%
%
%
%
%
%
%
%
%

Experimental 1:0.50=yello triangle
Experimental 0.5:1=blue square
Model Fit=Red Line
Order:
left to right= Circumferential, Radial
(3) Contour plots of the Fung-type model
Note:
(1)Figures are the size that allows the subplots to be saved
properly and not be stretched out.
(2)Figures have no titles, x and y labels, or legends. I put those when
I'm compiling figures in a powerpoint. However, the code to do so is
commented so you can just uncomment them for whatever you want on
the graph.

%Extracting all ratio data from excel file
[filename,pathname]=uigetfile('*.*', 'Select file');
data=xlsread(filename);
index=size(data,1);
%Seperating data by ratios 1:1, 1:0.75, 0.75:1, 1:0.5, 0.5:1
E11_1_1=data([1:index],1);
E22_1_1=data([1:index],2);
S11_1_1=data([1:index],3);
S22_1_1=data([1:index],4);
E11_1_75=data([1:index],9);
E22_1_75=data([1:index],10);
S11_1_75=data([1:index],11);
S22_1_75=data([1:index],12);
E11_75_1=data([1:index],17);
E22_75_1=data([1:index],18);
S11_75_1=data([1:index],19);
S22_75_1=data([1:index],20);
E11_1_50=data([1:index],25);
E22_1_50=data([1:index],26);
S11_1_50=data([1:index],27);
S22_1_50=data([1:index],28);
E11_50_1=data([1:index],33);
E22_50_1=data([1:index],34);
S11_50_1=data([1:index],35);
S22_50_1=data([1:index],36);
% Large matrix containg
E11=[E11_1_1, E11_1_75,
E22=[E22_1_1, E22_1_75,
S11=[S11_1_1, S11_1_75,
S22=[S22_1_1, S22_1_75,

all values
E11_75_1, E11_1_50,
E22_75_1, E22_1_50,
S11_75_1, S11_1_50,
S22_75_1, S22_1_50,

% % Model formulation
% syms c a1 a2 a3 Exx Eyy real
% Q=a1*Exx^2+a2*Eyy^2+2*a3*Exx*Eyy;
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E11_50_1];
E22_50_1];
S11_50_1];
S22_50_1];

%
%
%
%

W=0.5*c*(exp(Q)-1);
fun_11=matlabFunction(diff(W,Exx)); %symbolic
fun_22=matlabFunction(diff(W,Eyy)); %symbolic
clear Exx Eyy

% Objective function. This is the sum of squares of the residuals. I had to
% write out the complete equations because I'm not sure yet how to
% incorporate function handles fun_11 and fun_22 into this.
obj_fun = @(x)...
+
sum(((x(1).*exp(E11_1_1.^2.*x(2)+E22_1_1.^2.*x(3)+E11_1_1.*E22_1_1.*x(4).*2.0
).*(E11_1_1.*x(2).*2.0+E22_1_1.*x(4).*2.0).*(1.0./2.0))S11_1_1).^2+((x(1).*exp(E11_1_1.^2.*x(2)+E22_1_1.^2.*x(3)+E11_1_1.*E22_1_1.*x
(4).*2.0).*(E11_1_1.*x(4).*2.0+E22_1_1.*x(3).*2.0).*(1.0./2.0))-S22_1_1).^2)
...
+
sum(((x(1).*exp(E11_1_75.^2.*x(2)+E22_1_75.^2.*x(3)+E11_1_75.*E22_1_75.*x(4).
*2.0).*(E11_1_75.*x(2).*2.0+E22_1_75.*x(4).*2.0).*(1.0./2.0))S11_1_75).^2+((x(1).*exp(E11_1_75.^2.*x(2)+E22_1_75.^2.*x(3)+E11_1_75.*E22_1_
75.*x(4).*2.0).*(E11_1_75.*x(4).*2.0+E22_1_75.*x(3).*2.0).*(1.0./2.0))S22_1_75).^2) ...
+
sum(((x(1).*exp(E11_75_1.^2.*x(2)+E22_75_1.^2.*x(3)+E11_75_1.*E22_75_1.*x(4).
*2.0).*(E11_75_1.*x(2).*2.0+E22_75_1.*x(4).*2.0).*(1.0./2.0))S11_75_1).^2+((x(1).*exp(E11_75_1.^2.*x(2)+E22_75_1.^2.*x(3)+E11_75_1.*E22_75
_1.*x(4).*2.0).*(E11_75_1.*x(4).*2.0+E22_75_1.*x(3).*2.0).*(1.0./2.0))S22_75_1).^2) ...
+
sum(((x(1).*exp(E11_1_50.^2.*x(2)+E22_1_50.^2.*x(3)+E11_1_50.*E22_1_50.*x(4).
*2.0).*(E11_1_50.*x(2).*2.0+E22_1_50.*x(4).*2.0).*(1.0./2.0))S11_1_50).^2+((x(1).*exp(E11_1_50.^2.*x(2)+E22_1_50.^2.*x(3)+E11_1_50.*E22_1_
50.*x(4).*2.0).*(E11_1_50.*x(4).*2.0+E22_1_50.*x(3).*2.0).*(1.0./2.0))S22_1_50).^2) ...
+
sum(((x(1).*exp(E11_50_1.^2.*x(2)+E22_50_1.^2.*x(3)+E11_50_1.*E22_50_1.*x(4).
*2.0).*(E11_50_1.*x(2).*2.0+E22_50_1.*x(4).*2.0).*(1.0./2.0))S11_50_1).^2+((x(1).*exp(E11_50_1.^2.*x(2)+E22_50_1.^2.*x(3)+E11_50_1.*E22_50
_1.*x(4).*2.0).*(E11_50_1.*x(4).*2.0+E22_50_1.*x(3).*2.0).*(1.0./2.0))S22_50_1).^2);
% obj_fun=matlabFunction(sum((sym(fun_11)-S11).^2+(sym(fun_22)-S22).^2));
% Minimization of objective function using fmincon
x0=[1,4,1,1]; % initial guesses
lb=[0,-inf,-inf,-inf]; % lower bound for parameters
ub=[inf,inf,inf,inf]; % upper bound for parameters
A=[0,-1,0,1;0,0,-1,1]; % Variables to enforce inequality constraint A1>A3
b=[0;0]; % Variables to enforce inequality constraint A2>A3
options = optimoptions('fmincon','Display','iter','Algorithm','sqp');
%Options to control execution of fmincon
% options =
optimoptions('fmincon','Display','iter','Algorithm','sqp','MaxIterations',100
00,'MaxFunEval',100000,'StepTolerance',1e-20);
x = fmincon(obj_fun,x0,A,b,[],[],lb,ub,[],options);
% Backed out coeffecients
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c=x(1)
c1=x(2)
c2=x(3)
c3=x(4)
% Matrix form of coeffecients
D=[c,c1;c2,c3];
% Condition number. This must be less than or equal to 200 for acceptable
% numerical convergence.
Condition_number=norm(D,1)*norm(inv(D),1)
% Total R_square
SSres= ...
+
sum(((x(1).*exp(E11_1_1.^2.*x(2)+E22_1_1.^2.*x(3)+E11_1_1.*E22_1_1.*x(4).*2.0
).*(E11_1_1.*x(2).*2.0+E22_1_1.*x(4).*2.0).*(1.0./2.0))S11_1_1).^2+((x(1).*exp(E11_1_1.^2.*x(2)+E22_1_1.^2.*x(3)+E11_1_1.*E22_1_1.*x
(4).*2.0).*(E11_1_1.*x(4).*2.0+E22_1_1.*x(3).*2.0).*(1.0./2.0))-S22_1_1).^2)
...
+
sum(((x(1).*exp(E11_1_75.^2.*x(2)+E22_1_75.^2.*x(3)+E11_1_75.*E22_1_75.*x(4).
*2.0).*(E11_1_75.*x(2).*2.0+E22_1_75.*x(4).*2.0).*(1.0./2.0))S11_1_75).^2+((x(1).*exp(E11_1_75.^2.*x(2)+E22_1_75.^2.*x(3)+E11_1_75.*E22_1_
75.*x(4).*2.0).*(E11_1_75.*x(4).*2.0+E22_1_75.*x(3).*2.0).*(1.0./2.0))S22_1_75).^2) ...
+
sum(((x(1).*exp(E11_75_1.^2.*x(2)+E22_75_1.^2.*x(3)+E11_75_1.*E22_75_1.*x(4).
*2.0).*(E11_75_1.*x(2).*2.0+E22_75_1.*x(4).*2.0).*(1.0./2.0))S11_75_1).^2+((x(1).*exp(E11_75_1.^2.*x(2)+E22_75_1.^2.*x(3)+E11_75_1.*E22_75
_1.*x(4).*2.0).*(E11_75_1.*x(4).*2.0+E22_75_1.*x(3).*2.0).*(1.0./2.0))S22_75_1).^2) ...
+
sum(((x(1).*exp(E11_1_50.^2.*x(2)+E22_1_50.^2.*x(3)+E11_1_50.*E22_1_50.*x(4).
*2.0).*(E11_1_50.*x(2).*2.0+E22_1_50.*x(4).*2.0).*(1.0./2.0))S11_1_50).^2+((x(1).*exp(E11_1_50.^2.*x(2)+E22_1_50.^2.*x(3)+E11_1_50.*E22_1_
50.*x(4).*2.0).*(E11_1_50.*x(4).*2.0+E22_1_50.*x(3).*2.0).*(1.0./2.0))S22_1_50).^2) ...
+
sum(((x(1).*exp(E11_50_1.^2.*x(2)+E22_50_1.^2.*x(3)+E11_50_1.*E22_50_1.*x(4).
*2.0).*(E11_50_1.*x(2).*2.0+E22_50_1.*x(4).*2.0).*(1.0./2.0))S11_50_1).^2+((x(1).*exp(E11_50_1.^2.*x(2)+E22_50_1.^2.*x(3)+E11_50_1.*E22_50
_1.*x(4).*2.0).*(E11_50_1.*x(4).*2.0+E22_50_1.*x(3).*2.0).*(1.0./2.0))S22_50_1).^2);
c_bar1=mean2(S11_1_1);
r_bar1=mean2(S22_1_1);
c_bar2=mean2(S11_1_75);
r_bar2=mean2(S22_1_75);
c_bar3=mean2(S11_75_1);
r_bar3=mean2(S22_75_1);
c_bar4=mean2(S11_1_50);
r_bar4=mean2(S22_1_50);
c_bar5=mean2(S11_50_1);
r_bar5=mean2(S22_50_1);
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SStot= ...
+ sum(((S11_1_1-c_bar1).^2)+((S22_1_1-r_bar1).^2))...
+ sum(((S11_1_75-c_bar2).^2)+((S22_1_75-r_bar2).^2))...
+ sum(((S11_75_1-c_bar3).^2)+((S22_75_1-r_bar3).^2))...
+ sum(((S11_1_50-c_bar4).^2)+((S22_1_50-r_bar4).^2))...
+ sum(((S11_50_1-c_bar5).^2)+((S22_50_1-r_bar5).^2));
R_square_combine=1-(SSres/SStot)
%Anisotropy Index
AI=min((c1+c3)./(c2+c3),(c2+c3)./(c1+c3))
%Export constants into excel sheet
output=[c, c1, c2, c3, Condition_number, R_square_combine, AI];
h={'c', 'c1', 'c2', 'c3', 'Condition_number', 'R_square_combine', 'AI'};
m=[h;num2cell(output)];
filename='Fung-type Constants.xlsx';
xlswrite(filename,m);
% Generated values for plotting model fit
E11_1_1_m=linspace(0,max(E11_1_1),1000);
E22_1_1_m=linspace(0,max(E22_1_1),1000);
model11_1_1_m=x(1).*exp(E11_1_1_m.^2.*x(2)+E22_1_1_m.^2.*x(3)+E11_1_1_m.*E22_
1_1_m.*x(4).*2.0).*(E11_1_1_m.*x(2).*2.0+E22_1_1_m.*x(4).*2.0).*(1.0./2.0);
model22_1_1_m=x(1).*exp(E11_1_1_m.^2.*x(2)+E22_1_1_m.^2.*x(3)+E11_1_1_m.*E22_
1_1_m.*x(4).*2.0).*(E11_1_1_m.*x(4).*2.0+E22_1_1_m.*x(3).*2.0).*(1.0./2.0);
E11_1_75_m=linspace(0,max(E11_1_75),1000);
E22_1_75_m=linspace(0,max(E22_1_75),1000);
model11_1_75_m=x(1).*exp(E11_1_75_m.^2.*x(2)+E22_1_75_m.^2.*x(3)+E11_1_75_m.*
E22_1_75_m.*x(4).*2.0).*(E11_1_75_m.*x(2).*2.0+E22_1_75_m.*x(4).*2.0).*(1.0./
2.0);
model22_1_75_m=x(1).*exp(E11_1_75_m.^2.*x(2)+E22_1_75_m.^2.*x(3)+E11_1_75_m.*
E22_1_75_m.*x(4).*2.0).*(E11_1_75_m.*x(4).*2.0+E22_1_75_m.*x(3).*2.0).*(1.0./
2.0);
E11_75_1_m=linspace(0,max(E11_75_1),1000);
E22_75_1_m=linspace(0,max(E22_75_1),1000);
model11_75_1_m=x(1).*exp(E11_75_1_m.^2.*x(2)+E22_75_1_m.^2.*x(3)+E11_75_1_m.*
E22_75_1_m.*x(4).*2.0).*(E11_75_1_m.*x(2).*2.0+E22_75_1_m.*x(4).*2.0).*(1.0./
2.0);
model22_75_1_m=x(1).*exp(E11_75_1_m.^2.*x(2)+E22_75_1_m.^2.*x(3)+E11_75_1_m.*
E22_75_1_m.*x(4).*2.0).*(E11_75_1_m.*x(4).*2.0+E22_75_1_m.*x(3).*2.0).*(1.0./
2.0);
E11_1_50_m=linspace(0,max(E11_1_50),1000);
E22_1_50_m=linspace(0,max(E22_1_50),1000);
model11_1_50_m=x(1).*exp(E11_1_50_m.^2.*x(2)+E22_1_50_m.^2.*x(3)+E11_1_50_m.*
E22_1_50_m.*x(4).*2.0).*(E11_1_50_m.*x(2).*2.0+E22_1_50_m.*x(4).*2.0).*(1.0./
2.0);
model22_1_50_m=x(1).*exp(E11_1_50_m.^2.*x(2)+E22_1_50_m.^2.*x(3)+E11_1_50_m.*
E22_1_50_m.*x(4).*2.0).*(E11_1_50_m.*x(4).*2.0+E22_1_50_m.*x(3).*2.0).*(1.0./
2.0);
E11_50_1_m=linspace(0,max(E11_50_1),1000);
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E22_50_1_m=linspace(0,max(E22_50_1),1000);
model11_50_1_m=x(1).*exp(E11_50_1_m.^2.*x(2)+E22_50_1_m.^2.*x(3)+E11_50_1_m.*
E22_50_1_m.*x(4).*2.0).*(E11_50_1_m.*x(2).*2.0+E22_50_1_m.*x(4).*2.0).*(1.0./
2.0);
model22_50_1_m=x(1).*exp(E11_50_1_m.^2.*x(2)+E22_50_1_m.^2.*x(3)+E11_50_1_m.*
E22_50_1_m.*x(4).*2.0).*(E11_50_1_m.*x(4).*2.0+E22_50_1_m.*x(3).*2.0).*(1.0./
2.0);
%Plot fit lines:
%Figure (1) plots Individual ratios of the circumgerential and radial
%together (5 figures in subplot)Figure is very wide to insure that plots
%are displayed properly. Save figure as jpeg or desired file type.
%Size of markers in scatterplot
sz=15;
figure (1)
subplot (1,5,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E22_1_1,S22_1_1,sz,'r'); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E22_1_1_m,model22_1_1_m,'r'); hold off;
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11_1_1)),(max(max(E22_1_1)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_1_1)),(max(max(S22_1_1),max(max(model11_1_1_m),max(max(m
odel22_1_1_m)))))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,2)
scatter(E11_1_75,S11_1_75,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
plot(E11_1_75_m,model11_1_75_m,'r',E22_1_75_m,model22_1_75_m,'r'); hold off;
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.75:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11_1_75)),(max(max(E22_1_75)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_1_75)),(max(max(S22_1_75),max(max(model11_1_75_m),max(ma
x(model22_1_75_m)))))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
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set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,3)
scatter(E11_75_1,S11_75_1,sz,'k'); hold on;
scatter(E22_75_1,S22_75_1,sz,'r'); hold on;
plot(E11_75_1_m,model11_75_1_m,'r',E22_75_1_m,model22_75_1_m,'r'); hold off;
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:0.75')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11_75_1)),(max(max(E22_75_1)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_75_1)),(max(max(S22_75_1),max(max(model11_75_1_m),max(ma
x(model22_75_1_m)))))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,4)
scatter(E11_1_50,S11_1_50,sz,'k'); hold on;
scatter(E22_1_50,S22_1_50,sz,'r'); hold on;
plot(E11_1_50_m,model11_1_50_m,'r',E22_1_50_m,model22_1_50_m,'r'); hold off;
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('0.5:1')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(max(E11_1_50)),(max(max(E22_1_50)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_1_50)),(max(max(S22_1_50),max(max(model11_1_50_m),max(ma
x(model22_1_50_m)))))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (1)
subplot (1,5,5)
scatter(E11_50_1,S11_50_1,sz,'k'); hold on;
scatter(E22_50_1,S22_50_1,sz,'r'); hold on;
plot(E11_50_1_m,model11_50_1_m,'r',E22_50_1_m,model22_50_1_m,'r'); hold off;
% legend('Experimental-Circumferential','S22-Experimental-Radial','Model FitCircumferential','Model Fit-Radial')
% title('1:0.5')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
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Emax=max(max(max(E11_50_1)),(max(max(E22_50_1)))); %max E for axis limits (x
limit)
Smax=max(max(max(S11_50_1)),(max(max(S22_50_1),max(max(model11_50_1_m),max(ma
x(model22_50_1_m)))))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=1800;
height=200;
set(gcf,'units','points','position',[x0,y0,width,height])
%Figure (2) plots all ratios with circumferential and radial seperate
%(2 figures in subplot). Save figure as jpeg or desired file type.
% Large matrix containg all values
E11=[E11_1_1, E11_1_75, E11_75_1, E11_1_50, E11_50_1];
E22=[E22_1_1, E22_1_75, E22_75_1, E22_1_50, E22_50_1];
S11=[S11_1_1, S11_1_75, S11_75_1, S11_1_50, S11_50_1];
S22=[S22_1_1, S22_1_75, S22_75_1, S22_1_50, S22_50_1];
modelxx=[model11_1_1_m,model11_1_75_m,model11_75_1_m,model11_1_50_m,model11_5
0_1_m];
modelyy=[model22_1_1_m,model22_1_75_m,model22_75_1_m,model22_1_50_m,model22_5
0_1_m];
%Note: label of each ratio-1:1=circle; 1:0.75=astrix
figure (2)
subplot (1,2,1)
scatter(E11_1_1,S11_1_1,sz,'k'); hold on;
scatter(E11_1_75,S11_1_75,sz,'r'); hold on;
scatter(E11_75_1,S11_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_1_50,S11_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E11_50_1,S11_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E11_1_1_m,model11_1_1_m,'r',E11_1_75_m,model11_1_75_m,'r',E11_75_1_m,mod
el11_75_1_m,'r',E11_1_50_m,model11_1_50_m,'r',E11_50_1_m,model11_50_1_m,'r');
hold off;
% legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Circumferential')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(E11)); %max E for axis limits (x limit)
Smax=(max(max(max(S11)),(max(modelxx)))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
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set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
figure (2)
subplot (1,2,2)
scatter(E22_1_1,S22_1_1,sz,'k'); hold on;
scatter(E22_1_75,S22_1_75,sz,'r'); hold on;
scatter(E22_75_1,S22_75_1,sz,'g','v','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_1_50,S22_1_50,sz,'y','^','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
scatter(E22_50_1,S22_50_1,sz,'b','s','filled','MarkerEdgeColor',[0 0
0],'LineWidth',0.6); hold on;
plot(E22_1_1_m,model22_1_1_m,'r',E22_1_75_m,model22_1_75_m,'r',E22_75_1_m,mod
el22_75_1_m,'r',E22_1_50_m,model22_1_50_m,'r',E22_50_1_m,model22_50_1_m,'r');
hold off;
% legend('Experimental 1:1','Experimental 1:0.75','Experimental
0.75:1','Experimental 1:0.5','Experimental 0.5:1','Model Fit 1:1','Model Fit
1:0.75','Model Fit 0.75:1','Model Fit 1:0.5','Model Fit 0.5:1')
% title('Radial')
% xlabel('Green Strain')
% ylabel('2nd P-K Stress (kPa)')
Emax=max(max(E22)); %max E for axis limits (x limit)
Smax=(max(max(max(S22)),(max(modelyy)))); %max S for axis limits (y limit)
axis([0 Emax+0.05 0 Smax+10]); % add 0.1 for max E and 10 for mas S
set(gca,'Ytick', 0:20:Smax+10);
set(gca,'Xtick', 0:0.1:Emax+0.05);
set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2);
box on;
x0=10;
y0=10;
width=800;
height=250;
set(gcf,'units','points','position',[x0,y0,width,height])
%Strain Energy Contour Plot:
%E for circ and rad. Note: There aren't the experimental E but a range to
%see how the constants fit
E11cp=[-1.5:0.02:1.5];
E22cp=[-1.5:0.02:1.5];
%Strain Energy Equation for Fung-type model
Q=c1.*E11cp.^2+c2.*E22cp.^2+2.*c3.*E11cp.*E22cp;
W=0.5.*c.*(exp(Q)-1);
%Figure of contour plot
figure (3)
[xx,yy]=meshgrid(E11cp,E22cp);
Q=c1.*xx.^2+c2.*yy.^2+2.*c3.*xx.*yy;
W=0.5.*c.*(exp(Q)-1);
contour(xx,yy,W,[0.01 0.5 3 10 30],'k','ShowText','on','LineWidth', 1.5)
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set(findobj(gcf,'type','axes'),'FontName','Arial','FontSize',18,'FontWeight',
'Bold', 'LineWidth', 2, 'XTick',-1.5:0.5:1.5, 'YTick',-1.5:0.5:1.5);
box on;
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PicrosiriusRedAnlaysis.m MATLAB Code
% Picrosirius Red Analysis
%
% This program reads in picrosirius red image files and calculates
% percentage of red, orange, yellow and green fibers in the
% image.
%
% INSTRUCTIONS: Select PSR image to analyze. Create a polygon surrounding.
% the region of interest then right click and choose create mask. Copy the
% matrix percentage_royg to excel sheet. Matrix numbers correspond to the
% red, orange, yellow, and green percentages respectivley.
%
% INPUT: PSR image
%
% RETURNS: Matrix with red, orange, yellow, and green percentages.
%
% Created by Dr. Kartik Balchandran
%
Mechanobiology and Soft Materials Laboratory
%
University of Arkansas, Fayetteville, AR 72701
%
% Edited by Jessica Perez January 2017
%
Mechanobiology and Soft Materials Laboratory
%
University of Arkansas, Fayetteville, AR 72701
%
% Edited by Ishita tandon November 2018
%
Mechanobiology and Soft Materials Laboratory
%
University of Arkansas, Fayetteville, AR 72701
%
Ranges of hue bins updated.
%
Hue Values adapted from https://www.december.com/html/spec/colorhsltable6.html
%------------------------------------------------------------------------clc;
clear all;
close all;
display('Select image');
[filename pathname]=uigetfile('*.*','Select File...');
stain=imread(filename); %Image file name
% select region of interest by tracing polygon and then mask by right
% clicking and selecting creat mask
display('Select region of interest then double click to create mask');
Mask=roipoly(stain);
% RGB channels of image
red = double(stain(:,:,1)); % Red channel
green = double(stain(:,:,2)); % Green channel
blue = double(stain(:,:,3)); % Blue channel
% Mask of RGB channels
Ir=Mask.*red;
Ig=Mask.*green;
Ib=Mask.*blue;
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% Recombining RGB channels and changing it from double to uint8
stain_cropped=uint8(cat(3,Ir, Ig, Ib));
figure (1);
subplot(3,3,1);
imshow(stain);
title('Original Image');
subplot(3,3,2);
imshow(stain_cropped)
title('Cropped Image');

% Magnifies image to simplify the selection of area of intest
stain_cropped=double(stain_cropped);
stain_cropped_norm = stain_cropped./255;
stain_cropped_thres= stain_cropped_norm > 0.1;
stain_cropped_thres=double(stain_cropped_thres);
stain1=stain_cropped_norm.*stain_cropped_thres;
stain_hsv=rgb2hsv(stain1);
hue_mat=stain_hsv(:,:,1); %h=(:,:,1); s=(:,:,2); v=(:,:,3)
hue_mat1= hue_mat .* 360; % hsv is a 360 degree circle
[height, width]=size(hue_mat1);
% Defines the hue values for a particular color
H1= double(hue_mat1 > 0 & hue_mat1 < 15) + double(hue_mat1 > 345 & hue_mat1 <
360); %red
H2= double(hue_mat1 > 16 & hue_mat1 < 38); %orange
H3= double(hue_mat1 > 39 & hue_mat1 < 63); %yellow
H4= double(hue_mat1 > 64 & hue_mat1 < 150); %green
% Shows the individual red, orange, yellow, green images based on the above
mentioned criteria
figure(1)
subplot(3,3,3);
imshow(stain_cropped)
title('HSV Image');
subplot(3,3,4);
imshow(H1)
title('Red pixels');
subplot(3,3,5)
imshow (H2)
title('Orange pixels');
subplot(3,3,7)
imshow (H3)
title('Yellow pixels');
subplot(3,3,8)
imshow (H4)
title('Green pixels')
num_red=0;
num_orange=0;
num_yellow=0;
num_green=0;
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num_total_pixels = height .* width;
for i=1:height
for j=1:width
if(hue_mat1(i,j) > 0) && (hue_mat1(i,j) < 15) %red pixels
num_red = num_red + 1;
elseif(hue_mat1(i,j) > 345) && (hue_mat1(i,j) <360) %red pixels
num_red = num_red + 1;
elseif(hue_mat1(i,j) > 16) && (hue_mat1(i,j) < 38) %orange pixels
num_orange = num_orange + 1;
elseif(hue_mat1(i,j) > 39) && (hue_mat1(i,j) < 63) %yellow pixels
num_yellow = num_yellow + 1;
elseif(hue_mat1(i,j) > 64) && (hue_mat1(i,j) < 150) %green pixels
num_green = num_green + 1;
end
end
end
% Displays the percentage of fibers that are red, orange, yellow, or green
total= num_red+num_orange+num_yellow+num_green;
red=(num_red./total).*100;
orange=(num_orange./total).*100;
yellow=(num_yellow./total).*100;
green=(num_green./total).*100;
% Matrix with red, orange, yellow, and green percentages
Percentage_royg=[red;orange;yellow;green]
output=[total, num_red,
num_orange,num_yellow,num_green,red,orange,yellow,green];
% h={'total pixels', 'red pixels', 'orange pixels','yello pixels', 'green
pixels','red %', 'orange %','yellow %','green %'};
m=[num2cell(output)];
filename='PSR Data.csv';
csvwrite(filename,m);
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APPENDIX C SUMPLEMENTAL INFORMATION
Reasons why samples were not used in overall analysis:
*Sample ripped in one staple
**Staples were not placed properly causing the load to be placed unevenly
***Sample believed to be mounted backwards (circumferential in y axis and radial in x axis)
****Sample completely tore and all tension ratios were not completed

Figure 0-1. Images of biaxial testing of all samples

202

Figure 0-2. 2nd P-K stress vs Green strain graphs for each individual sample of the 9 treatment
groups
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Table 0-1. Max areal strain (ASmax), anisotropy index (AI), low (TML) and high (TMH) tangent
modulus for the circumferential and radial direction, and extensibility for the circumferential and
radial direction for each individual specimens.
Treatment

Sample

ASmax

AI

Circ
TML

Control

FB 1
FB 2
FB 3**
FB 4
FB 5*
FB 6**
FB 7
FB 8

0.138
0.122
0.061
0.087
0.162
0.088
0.067
0.069

0.477
0.822
0.747
0.575
0.766
0.407
0.417
0.334

49.9
32.4
19.2
38.2
24.3
74.5
88.1
65.6

3375.7
1252.5
2324.5
2940.3
3799.7
2187.5
3532.6
4434.1

9.4
21.5
23.0
16.7
13.8
21.5
44.3
20.5

1048.1
999.1
1566.1
946.1
1539.5
1589.1
1180.0
1340.8

0.216
0.237
0.179
0.190
0.329
0.131
0.120
0.118

0.435
0.293
0.239
0.299
0.408
0.395
0.288
0.376

Ang-I

FB 1
FB 2
FB 3
FB 4
FB 5***
FB 6**
FB 7**
FB 8

0.142
0.114
0.150
0.118
0.038
0.090
0.116
0.053

0.590
0.515
0.342
0.861
0.951
0.386
0.677
0.595

35.6
27.4
25.2
53.9
57.8
58.7
22.3
66.9

2367.2
2868.7
2982.2
1503.8
2238.4
2471.8
1502.6
2888.3

11.9
23.9
7.5
20.6
69.6
25.5
16.3
39.2

1229.4
860.7
962.5
1693.2
2916.4
1041.0
1007.5
1632.0

0.237
0.207
0.188
0.236
0.144
0.134
0.207
0.139

0.407
0.367
0.577
0.309
0.168
0.378
0.322
0.234

Ang-II

FB 1
FB 2***
FB 3
FB 4*
FB 5
FB 6
FB 7
FB 8

0.123
0.085
0.120
0.148
0.125
0.051
0.043
0.034

0.360
0.663
0.844
0.396
0.551
0.321
0.369
0.336

46.8
42.1
32.7
77.8
27.6
77.5
21.5
131.9

3382.1
1850.3
1343.9
2330.5
2278.2
3279.9
4860.2
6480.7

8.9
26.7
15.6
28.0
17.2
29.7
16.6
26.6

815.7
1047.1
1823.0
683.8
1252.3
928.5
1026.3
2222.2

0.172
0.190
0.234
0.180
0.225
0.009
0.104
0.085

0.472
0.268
0.321
0.457
0.410
0.292
0.257
0.270

Ang-I+
Quinaprilat

FB 1
FB 2
FB 3**
FB 4
FB 5
FB 6**
FB 7*

0.072
0.114
0.223
0.088
0.115
0.071
0.065

0.849
0.416
0.524
0.297
0.489
0.836
0.385

62.1
36.8
34.5
51.9
73.4
52.4
73.4

1231.1
2482.0
2232.7
4946.9
3285.5
1474.8
4154.9

34.2
15.3
12.0
17.5
19.0
20.2
23.5

999.1
678.9
1151.9
1371.6
1535.3
1684.7
1285.4

0.174
0.179
0.146
0.130
0.190
0.165
0.130

0.215
0.417
0.561
0.459
0.407
0.224
0.320

Ang-I+
Chymostatin

FB 1
FB 2
FB 3
FB 4**
FB 5
FB 6

0.086
0.127
0.072
0.111
0.049
0.082

0.356
0.573
0.419
0.403
0.378
0.809

96.5
43.8
45.6
74.9
43.6
39.4

2776.6
3321.9
3341.6
2394.1
4232.6
2669.6

33.7
22.6
40.8
18.2
26.1
46.3

1011.4
1185.6
852.3
740.4
1947.3
1482.5

0.132
0.240
0.139
0.164
0.104
0.200

0.394
0.400
0.301
0.411
0.301
0.231
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Circ
TMH

Rad
TML

Rad
TMH

Circ
Ext

Rad
Ext

Table 0-2. (Cont.)
Treatment
Sample

ASmax

AI

Circ
TML

Circ
TMH

Rad
TML

Rad
TMH

Circ
Ext

Rad
Ext

Ang-I+
Losartan

FB 1**
FB 2
FB 3
FB 4****
FB 5
FB 6
FB 7

0.239
0.198
0.083
0.125
0.100
0.122
0.048

0.187
0.367
0.309
0.615
0.315
0.599
0.334

18.7
22.6
60.9
29.8
40.0
29.8
34.9

4232.1
1311.6
2776.5
2028.0
3075.7
1439.8
4850.0

1.9
8.1
10.3
23.6
15.8
10.4
18.3

303.6
512.2
800.3
1001.4
765.3
1325.0
2102.4

0.193
0.208
0.126
0.220
0.146
0.208
0.102

0.964
0.591
0.424
0.342
0.463
0.393
0.330

Ang-II+
Losartan

FB 1**
FB 2*
FB 3
FB 4***
FB 5
FB 6
FB 7**
FB 8

0.096
0.067
0.086
0.052
0.082
0.094
0.042
0.044

0.416
0.568
0.260
0.732
0.308
0.477
0.691
0.238

25.5
46.4
51.4
54.4
30.7
25.6
65.3
60.8

4750.8
4739.9
8038.4
2122.9
3854.4
2857.8
3688.9
5840.3

19.5
23.1
4.8
26.4
17.9
29.2
30.9
14.9

770.8
1241.3
1135.6
2449.3
1040.4
1254.9
1827.1
885.8

0.173
0.173
0.139
0.138
0.131
0.155
0.145
0.080

0.356
0.265
0.504
0.220
0.430
0.328
0.199
0.320

Ang-I+
PD123,319

FB 1
FB 2
FB 3
FB 4****
FB 5*
FB 6
FB 7

0.108
0.133
0.087
0.056
0.056
0.072
0.071

0.509
0.271
0.501
0.436
0.386
0.324
0.200

30.1
78.8
87.1
73.6
77.8
79.4
47.5

4827.1
7081.3
4251.3
3263.3
3693.5
4612.5
5301.3

13.4
17.5
38.5
9.3
31.6
17.6
11.4

1416.3
1070.4
1456.8
1832.1
1127.0
1226.7
821.8

0.212
0.166
0.168
0.114
0.103
0.124
0.100

0.386
0.588
0.315
0.299
0.464
0.385
0.490

Ang-II+
PD123,319

FB 1****
FB 2**
FB 3*
FB 4
FB 5
FB 6
FB 7
FB 7(8)

0.087
0.080
0.193
0.107
0.077
0.073
0.137
0.079

0.840
0.435
0.216
0.397
0.251
0.661
0.571
0.392

37.1
23.7
70.9
59.8
79.0
41.2
55.1
69.6

1935.7
4952.3
5423.2
4543.9
3911.0
2637.4
2001.9
3846.4

34.1
19.3
8.2
24.0
14.6
14.5
13.7
19.5

1190.4
1140.6
689.3
2009.4
1028.8
2344.4
718.0
974.2

0.213
0.165
0.174
0.174
0.108
0.182
0.180
0.144

0.230
0.354
0.777
0.462
0.455
0.292
0.443
0.340
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Table 0-3. Material constants along with the conditional number, R2 of the fit, and anisotropy
index (AI) for individual specimens by fitting the experimental data to the Fung-type model.
Sample
No.
FB 1
FB 2
FB 3**
FB 4
FB 5*
FB 6**
FB 7
FB 8

c(kPa)
0.519
0.828
1.568
0.650
0.650
0.318
1.025
0.768

c1
9.273
13.507
19.149
15.021
15.021
25.621
23.489
36.907

c2
5.750
10.866
11.782
12.657
12.657
10.832
12.816
9.974

c3
3.427
0.143
-2.619
2.263
2.263
4.088
3.983
2.432

R2
0.789
0.929
0.732
0.917
0.917
0.949
0.953
0.968

AI
0.723
0.807
0.554
0.863
0.863
0.502
0.612
0.315

FB 1
FB 2
FB 3
FB 4
FB 5***
FB 6**
FB 7**
FB 8

1.020
0.446
1.252
1.117
N/A
1.422
0.376
0.834

13.428
26.804
22.536
18.514

6.171
8.946
3.497
11.811

0.634
-0.413
-1.407
-2.554

0.797
0.932
0.773
0.878

0.484
0.323
0.099
0.580

22.966
15.552
55.868

7.326
12.556
22.981

1.534
1.909
-9.307

0.884
0.920
0.911

0.362
0.828
0.294

Ang-II

FB 1
FB 2***
FB 3
FB 4*
FB 5
FB 6
FB 7
FB 8

1.016
1.313
0.613
8.594
2.109
1.190
0.303
0.145

19.318
26.269
15.122
9.250
15.167
26.848
19.716
124.516

5.132
14.274
15.580
1.928
7.231
9.286
17.911
31.700

0.958
-6.163
-1.391
0.700
-0.482
4.411
11.475
-4.411

0.897
0.724
0.830
0.797
0.799
0.853
0.847
0.958

0.300
0.403
0.968
0.264
0.460
0.438
0.942
0.227

Ang-I+
Quinaprilat

FB 1
FB 2
FB 3**
FB 4
FB 5
FB 6**
FB 7*

1.295
0.410
3.047
0.266
1.305
0.859
0.906

19.452
31.756
6.880
43.667
19.559
20.159
23.437

15.117
9.752
2.947
10.297
7.445
18.707
11.055

-0.026
-2.171
-0.140
-0.128
-0.453
1.492
2.971

0.867
0.977
0.740
0.920
0.756
0.901
0.837

0.777
0.256
0.417
0.234
0.366
0.933
0.531

Ang-I+
FB 1
Chymostatin FB 2
FB 3
FB 4**
FB 5
FB 6

0.745
0.263
2.687
1.033
0.202
0.569

35.161
24.898
15.398
26.297
47.316
19.440

8.706
12.574
6.111
6.035
19.776
13.074

-0.210
-3.234
0.601
-1.303
8.456
5.374

0.947
0.874
0.661
0.805
0.932
0.898

0.243
0.431
0.419
0.189
0.506
0.743

Treatment
Control

Ang-I
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Table 0-4. (Cont.)
Treatment
Ang-I+
Losartan

Ang-II+
Losartan

Ang-I+
PD123,319

Ang-II+
PD123,319

Sample
No.
FB 1**
FB 2
FB 3
FB 4****
FB 5
FB 6
FB 7

c(kPa)
0.303
1.124
1.616

c1
19.716
11.492
16.468

c2
17.911
3.380
3.648

c3
11.475
0.960
2.534

R2
0.847
0.822
0.802

AI
0.942
0.349
0.325

0.147
0.440
0.054

47.865
29.980
84.662

10.640
13.038
21.148

-2.500
-5.049
7.781

0.944
0.909
0.971

0.179
0.320
0.313

FB 1**
FB 2*
FB 3
FB 4***
FB 5
FB 6
FB 7**
FB 8

0.265
0.707
0.148

36.002
23.508
49.333

8.906
12.543
8.734

0.715
1.736
-0.303

0.839
0.765
0.833

0.262
0.566
0.172

0.373
0.876
0.131
0.247

20.683
34.483
83.916
75.102

8.121
8.960
40.398
15.093

4.874
0.080
-10.652
4.835

0.912
0.903
0.920
0.960

0.508
0.262
0.406
0.249

FB 1
FB 2
FB 3
FB 4****
FB 5*
FB 6
FB 7

0.238
2.177
1.863

25.266
11.520
35.166

10.718
3.095
11.017

0.786
1.361
-4.903

0.875
0.792
0.872

0.442
0.346
0.202

2.286
0.357
0.168

27.291
29.659
53.634

10.018
9.811
8.830

1.653
5.883
2.424

0.864
0.926
0.955

0.403
0.442
0.201

FB 1****
FB 2**
FB 3*
FB 4
FB 5
FB 6
FB 7
FB 7(8)

N/A
0.721
1.797
0.167
0.296
1.163
3.373
1.553

14.299
6.176
46.462
68.502
17.597
14.523
16.063

11.003
2.570
10.402
9.727
8.951
5.380
6.792

2.393
2.024
-2.232
-2.616
3.697
-0.476
1.733

0.809
0.820
0.906
0.943
0.823
0.750
0.747

0.803
0.560
0.185
0.108
0.594
0.349
0.479
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Figure 0-3. 2nd P-K stress vs Green strain for each sample in the control group with fit to Fungtype constative model using constants in Table 0-3
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Figure 0-4. 2nd P-K stress vs Green strain for each sample in the ang-I treated group with fit to
Fung-type constative model using constants in Table 0-3
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Figure 0-5. 2nd P-K stress vs Green strain for each sample in the ang-II treated group with fit to
Fung-type constative model using constants in Table 0-3
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Figure 0-6. 2nd P-K stress vs Green strain for each sample in the ang-I + quinaprilat treated
group with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-7. 2nd P-K stress vs Green strain for each sample in the ang-I + chymostatin treated
group with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-8. 2nd P-K stress vs Green strain for each sample in the ang-I + losartan treated group
with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-9. 2nd P-K stress vs Green strain for each sample in the ang-II + losartan treated group
with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-10. 2nd P-K stress vs Green strain for each sample in the ang-I + PD123,319 treated
group with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-11. 2nd P-K stress vs Green strain for each sample in the ang-II + PD123,319 treated
group with fit to Fung-type constative model using constants in Table 0-3
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Figure 0-12. Constant strain energy contour plot over Green strain field for each individual
sample of the 9 treatment groups with fit to Fung-type constitutive model
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AD.1 Biomechanics
All living organisms experience or produce some type of movement in their system. The
study of biomechanics allows scientists and engineers to analyze the biomechanical function of
biomaterials, biological systems, organs, tissue, cells, and cell organelles. Understanding the
mechanics of the body is important to improve the movements of the body and to understand the
alterations in mechanical function the body may suffer after injury or during a disease. By doing
so, the research community can develop treatments to improve movement, prosthetics for those
that suffered limp loss, medical devices to assist loss of mechanical functions, therapeutic
treatments, and biomaterials to replace injured tissue.
AD.1.1 Mechanical properties
The mechanical properties include material and structural properties. Material properties
are what make up the material, and structural properties characterize the behavior of the material
such as size, shape, or form it undergoes (88). Material properties can be characterized by the
relationship between stress and strain. In a linear material, stress and strain are proportional and
when graphed are a straight line. A non-linear relationship are when the mathematical relation
between stress and strain cannot be characterized by a straight line. A material can be elastic or
plastic. When stress is applied and released, and the material reverts to its undeformed state, it is
considered an elastic material. In a plastic material, there is a permanent change in strain or
deformation when the stress is applied and then released (Figure 0-1) (89). These properties can
be tested through mechanical testing methods using various standard laboratory equipment. The
stiffness or Young’s Modulus of a linear elastic material can be calculated by measuring the
slope of the linear region (Figure 0-1a). The area under the curve is the strain energy, the energy
that is dissipated due to the work that is done during deformation (Figure 0-1b) (88).
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Figure 0-1. Load-displacement curve, adapted from Saunders (88)
The key material properties studied are stress and strain. Stress is the force applied to the
material per area, and strain is the deformation of the material in respect to a line or square.
Stress is calculated by dividing the force by the cross-sectional surface area (A) (Figure 0-2a),
and strain is a ratio of the change in length divided by the initial length. The load-displacement
curve and the stress-strain curve will have an identical in shape, but the x and y scales will be
different (Figure 0-2b,c) (88).

Figure 0-2. (A) A diagram of a material experiencing load (F) and the cross-sectional area of
the material (A). Graphs of a linear (B) load-displacement curve and a (C) stress-strain curve,
adapted from Saunders (88)
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AD.1.2 Stress and strain
Stress can be determined by normalizing the force that is being applied to a crosssectional area. There are three forms of stress: normal stress, shear stress, and bending stresses.
Normal stress is when a material is subject to force under axial loading. Shear stress is when
force is being applied in equal and opposite transverse fields. (90).
Normal stress is when force is being applied perpendicular to the surface area (Figure 0-3a).
There are two kinds of normal stresses, tensile and compressive stress. Tensile stress is when the
material is stretched or lengthened (Figure 0-3b), and compression stress is when the material is
compressed or shortened (Figure 0-3c). Shear stress is force acting parallel to the surface area
(Figure 0-3d).
Strain is the deformation the material undergoes during stress. Normal strain is the
deformation the material undergoes by forces acting perpendicular to the surface in respect to a
line, normal stress. The material is either elongated by the tensile stress or contracted by the
compression stress which act by force being applied to the surface perpendicular to it. Shear
strain is the deformation the material experiences by forces acting parallel to the surface with
respect to a shear stress. Shear strain changes the angle between the corners of the square which
were originally right angles.

Figure 0-3. Diagrams of (A) normal and (D) shear stress and the two types of normal stress,
(B) tensile and (C) compression stress.
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Stress-strain plots allow one to measure various bulk mechanical properties of materials.
The strength of the material correlates with the stress required to deform material. The yield
strength is the amount of stress that a material can undergo before it transitions to plastic
deformation. The largest stress is the ultimate strength that a material can withstand, and the
breaking strength, also known as failure strength, is the strength that the mateiral can endure
before breaking (Figure 0-4a). The toughness can be measured by calculating the area under a
material’s stress-strain curve (Figure 0-4b) (88).

Figure 0-4. Strain-strain curve depicting the (A) yield, ultimate, and breaking stress and (B) the
toughness of the material, adapted from Saunders (88)
Stiffness can be calculated by acquiring the slope of the linear region of a material’s
stress-strain curve, and it allows one to measure the compliance of the material. Materials will
deform less if its stiffness is greater. In linear material, the stiffness is called Young’s modulus
(E). In a non-linear biological material, there are typically two pseudo-linear regimes, the toe
region and the linear region. The stiffness of the material can be assessed via the high and low
tangent modulus (TM), stiffness of the linear and toe region respectively (Figure 0-5) (74).
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Figure 0-5. Stress-strain curve with Young’s Modulus for a linear material and Tangent
Modulus for a non-linear material
In an elastic material, the material will revert to its original state when loaded and
unloaded. In viscous materials, the material will not revert to its original state but instead stay at
the state in which it was when the load was released. Viscoelastic materials are materials that
exhibit both viscous-like and elastic-like properties. The relationship between stress and strain in
viscoelastic material depends on time (91).
AD.1.3 Biaxial testing
There are various forms to test material depending on its properties. For incompressible
materials such as biological tissues, biaxial testing is ideal as it allows for the characterization of
a three-dimensional stress-strain relationship. Biaxial testing is where a material is subjected to
load in both the x and y directions in contrast to uniaxial testing which only subject the material
to load in one direction.
When running biaxial testing in viscoelastic material, such as biological tissues,
hysteresis is present. Hysteresis is the energy lost within the material between successuve
loading and unloading cycles. It is necessary to precondition the material prior to testing so it
reaches an equilibrium state before running biaxial testing (Figure 0-6a), with the loading and
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unloading curve taking the same path as it is being displaced. In other words, the material will
exhibit more “pseudo” elastic-like properties (Figure 0-6b) (88).

Figure 0-6. Preconditioning of material during biaxial testing (A) load vs time and (B) load vs
displacement
There are many modes of biaxial deformation. A material can experience tensile stress in
both axis (Figure 0-7a), tensile stress in one axis and compression stress in the other (Figure
0-7b), and compression stress in both axis (Figure 0-7c) (92). A material can be stretched to
either a particular load or deformation and then allowed to return to 0 load or deformation. The
type of biaxial model used is dependent on the load the material experiences in the body.

Figure 0-7. Models of biaxial testing, (A) tensile load in both axis, (B) tensile load in one axis
and compression in the other, and (C) compression on both axis, adapted from Ozkaya, et. al.
(92)
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In biaxial testing, strain and stress is measured taking into account deformation. The
deformation gradient (F) is the fundamental measurement of deformation of a material that
mathematically explains the changes in length, angles, and area of volume. Figure 0-8
demonstrates a simple illustration of the deformations of a square. β0 is the original position of
the object, or the reference configuration, and βt is the position of the object after deformation, or
its current configuration. x1 and x2 are the axis of β0, and x1’ and x2’ are the axis of βt. A, B, C,
and D are the initial x1 and x2 coordinates, and A’, B’, C’, and D’ are the x1’ and x2’ coordinates
after deformation. u is the displacement vector (x’-x). To calculate deformation, F needs to
express x in terms of x’ by using Eq.(0.1).
x1=ax1’+bx2’

(0.1)

x2=cx1’+dx2’
F=dx/dx’

Figure 0-8. Simple diagram of material deformation/motion
Engineering strain can be calculated by dividing the experimental length by the original
length. However, in biaxial testing, the Green strain (E) tensor is calculated using Eq. (0.2).
C=FTF

(0.2)

E= 0.5(C-I)
As stated previously, stress is the force being applied to a specific area. However, there
are three stresses that consider the orientations, force and area, that give rise by the natural
tensorial nature of stress: Cauchy stress, 1st Piola-Kirchoff (P-K) stress, and 2nd P-K stress.
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Cauchy stress (σ) is the true stress experienced by the material. The 1st P-K stress (P) is a
measurement of stress that is Lagrangian in nature. 1st P-K stress is the most commonly
measured stress with mechanical testing equipment. It measures the force being applied at each
time point divided by the area of the square in the original configuration, β0 and is calculated
with Eq. (0.3). Cauchy stress is calculated with Eq. (0.4) where J is the Jacobian. The Jacobian is
a measure that quantifies the change in volume that is produced during the deformation. If
material is incompressible such as tissue, J=1. The 2nd P-K stress (S) is calculated using Eq.(0.5).
The 2nd P-K stress is not a direct physical measure of stress, but it is useful in many ways. The
2nd P-K stress is the energy conjugate of Green strain (E) and can thus be used to determine
constitutive models (82).
P=f/Ao

(0.3)

σ=J-1PFT

(0.4)

S= F-1P

(0.5)

The maximum Green strain is used to calculate the areal strain and the strain anisotropy
(Figure 0-9a). Areal strain is calculated by multiplying the maximum Green strain in the
circumferential and radial directions (ECIRC * ERAD). The higher the areal strain, the more strain
the material can undergo. Strain anisotropy index is calculated by dividing the maximum Green
strain in the circumferential and radial direction (ECIRC ÷ ERAD). A strain anisotropy index close
to 1 indicates a more isotropic material, while less or greater than 1 indicates a more anisotropic
material. As mentioned previously, the stiffness of a non-linear material can be measured by the
low and high tangent moduli, the stiffness of the toe region and the elastic region respectively
(Figure 0-9b). The low tangent modulus (TML) is the stiffness in the toe region (pre-transitional)
where the fibers are “un-crimping”. The high tangent modulus (TMH) is the stiffness in the
elastic region (post-transitional) where the fibers have been “uncrimpled” and are now being
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stretched (74). Extensibility is calculated by the x-intercept of the high tangent modulus (Figure
0-9c). The higher the extensibility, the more the material can stretch. The TM L, TMH, and
extensibility are measured in both the circumferential and radial directions. The material is stiffer
and hence less extensible in the circumferential direction than in the radial direction (74).

Figure 0-9. 2nd P-K stress vs Green strain graph indicating (A) maximum Green strain used to
calculate areal strain and strain anisotropy, (B) high and low tangent modulus, and (C)
extensibility.
AD.1.4 Constitutive models
As shown previously, strain energy can be calculated by measuring the area under the
curve. Strain energy can also be related to provide phenomenological constitutive models for
materials. Constitutive models can also provide additional information on the mechanical
responses of materials. One important property to note when deciding an appropriate constitutive
model is if the material is anisotropic or isotropic. An anisotropic material has different material
properties with respect to the direction the load is applied. An isotropic material has the same
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material properties regardless of the direction the load is applied. Another property is if the
sample is homogenous or non-homogenous. In a homogenous sample, it is made up of the same
material throughout its body. In a non-homogenous sample, it is made up of different materials
throughout its body (89). In addition, one chooses a model specific to either elastic or
viscoelastic materials. In this thesis, we have focused on the development of constitutive models
to characterize homogeneous pseudo-elastic materials.
In an isotropic elastic material, there are two common models: Neo-Hookean and
Mooney Rivlin. In these models, strain energy (W) is a function of strain variants (I) which can
be calculated using Eq. (0.6).
I1=tr (B)=λ12+ λ22+ λ32 (78)

(0.6)

I2=0.5 [ (trB)2-tr(B2)]= λ12 λ22+ λ22 λ32+ λ32 λ12 (78)
I3=det (B)=λ12 λ22 λ32
I4=Cij(nc)i(nc)j
λ1, λ2, and λ3 are the principal stretches and the left Cauchy-Green tensor (B) can be
calculated by B=FFT. nc refers to the principle direction of the material fibers. The standard
constitutive model for an incompressible, isotropic, elastic material can be determined with Eq
(0.7).

𝜎 = −𝑝1 + 2

𝑑𝑊
𝑑𝑊 −1
𝐵−2
𝐵
𝑑𝐼1
𝑑𝐼2

(0.7)

p is a hydrostatic pressure term associated with the incompressibility constraints and σ is
Cauchy stress. The Neo-Hookean strain energy can be obtained with Eq. (0.8), and the MooneyRivlin (M-R) strain energy can be obtained with Eq. (0.9).
W=0.5µ (I1-3)
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(0.8)

W= 0.5µ[ (I1-3) + (1-α) (I2-3)]

(0.9)

µ is the shear modulus constant for infinitesimal deformations, and α is a dimensionless
constant. µ must be greater than 0, and α must be greater than 0 or less than 1 (78).
In addition to the M-R strain energy seen in Eq. (0.9), there are various modified forms.
Two modified Mooney-Rivlin strain energy equations are the isotropic and anisotropic M-R
models. The isotropic modified M-R strain energy can be given by Eq. (0.10). The anisotropic
M-R model has an additional anisotropic term and can be given by Eq. (0.11) (80).
W=c1 (I1-3) + c2 (I2-3) + D1 [exp (D2 (I1 - 3)) - 1]

(0.10)

W=c1(I1-3) + D1 [exp (D2 (I1 - 3)) - 1] + (k1/2k2) [exp [k2 (I4 - 1)2 - 1]

(0.11)

There are various models used for viscoelastic anisotropic material including the Fungtype model and the Choi-Vito model. The strain energy for the Fung-type model can be obtain
with Eq. (0.12), and the strain energy from the Choi-Vito model is given by Eq. (0.13).
W=0.5c (eQ-1),

(0.12)

W=0.5c (eQ1- eQ2- eQ3 - 3),

(0.13)

where Q=c1E112+ c2E222+2 c3E11E22.

where Q1=c1E112, Q2=c2E222, Q3=c3E11E22. c*c1 and c*c2 are metrics for nonlinear stiffness in
the circumferential and radial direction respectively, and c3 is the interaction between the
circumferential and radial direction (82).
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